Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N2/156Sponsor Name [CONTACT_108163]:Affiliates of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013]
For all countries, except the US, Canada, and 
Japan:
[COMPANY_006] Healthcare KGaA, Darmstadt, [LOCATION_013]an affiliate of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013]
Frankfurter Str. 250
Darmstadt, [LOCATION_013]
In the US and Canada:
EMD Serono Research & Development Institute, 
Inc.
an affiliate of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013]45A Middlesex Turnpi[INVESTIGATOR_107898], MA, [ZIP_CODE], [LOCATION_003]
Local Sponsor for Sites in Japan:
[COMPANY_006] Biopharma Co., Ltd.: Japanan affiliate of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013]Arco Tower, 1-8-1 ShimomeguroMeguro-ku, Tokyo 153-8926, Japan
Regulatory Agency Identifying 
Numbers:, EudraCT: 2019-003583-40
Protocol Version: 22 June 2021/Version 3.0
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N3/156Protocol Amendment Summary of Changes
Protocol History
Version Number Type Version Date
1.[ADDRESS_119962]-2019
2.0 Global Amendment 1.0 23-Jun-2020
3.0 Global Amendment 2.0 22-Jun-2021
Protocol Version 3.0 (22-June-2021)
This amendment is substantial based on the criteria in Article 10(a) of Directive 2001/20/EC of 
the European Parliament and the Council of the European Union.
Overall Rationale for the Amendment
The primary purpose of this amendment is to update the risk classification. In addition, the primary 
analysis time point has been moved from [ADDRESS_119963] global
participant.
Section # and Name [CONTACT_108164] “Medical Responsible” field
Removed “Amendment number”,
“Replaces Version” and “Approval Date” rows To be consistent with current Sponsor 
protocol template (Version 15)
2.3 Benefit/Risk AssessmentText updated to address risk 
reclassificationThe risk reclassification was based on in-
depth analysis of a pooled safety dataset of N = 765 participants who received 
bintrafusp alfa monotherapy at 1200 mg 
Q2W.
5. Study Population
Appendix 2Edits related to informed consent 
procedureTo be consistent with current Sponsor 
protocol template (Version 15)
6.[ADDRESS_119964] of events has been 
updated accordingly
6.9.1 Infusion-related 
Reactions Including Immediate HypersensitivityInfusion-related reactions are 
reclassified from “important identified risk” to “identified risk” for bintrafusp alfa
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N4/156Section # and Name [CONTACT_23688]
6.9.3. TGF- βInhibition 
Mediated Skin ReactionsSkin Adverse Events have been 
renamed as TGF- βInhibition 
Mediated Skin ReactionsThe risk reclassification was based on in-
depth analysis of a pooled safety dataset of N = 765 participants who received bintrafusp alfa monotherapy at 1200 mg 
Q2W as reflected in Investigator’s 
Brochure, v7.[IP_ADDRESS] Anemia Term “treatment-related anemia 
events” has been revised to “anemia” and reclassified from “important potential risk” to “important identified risk” for bintrafusp alfa
6.9.5 Bleeding Events Bleeding events are reclassified from 
“potential risk” to “important identified 
risk” for bintrafusp alfa
[IP_ADDRESS] Impaired Wound 
HealingThe risk name “Alte rations in Wound 
Healing or Repair of Tissue Damage” has been changed to “Impaired Wound Healing”
7.[ADDRESS_119965] to 
Follow-up informationTo be consistent with current Sponsor 
protocol template (Version 15)
8.1.[ADDRESS_119966] 12 months of follow up for all 
participancts and allowing a longer follow up of potential late responders.
Note: Minor changes have been performed throughout the protocol to address consistency pertaining to major changes made in the protocol or to add further clarity and precision.
- Confidential -
This document is the property of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or one of its subsidiaries. It is intended for 
restricted use only and may not – in full or part – be passed on, reproduced, published or used without express 
permission of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or its subsidiary. Copyright © 2021 by [CONTACT_28794], Darmstadt, 
[LOCATION_013], or its subsidiary. All rights reserved.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N5/156Table of Contents
Title Page ..............................................................................................................1
Table of Contents .............................................................................................................. 5
Table of In-Text Tables .......................................................................................................9Table of In-Text Figures ......................................................................................................9
1 Protocol Summary ..............................................................................10
1.1 Synopsis..............................................................................................101.2 Schema................................................................................................131.3 Schedule of Activities.........................................................................142 Introduction.........................................................................................242.1 Study R ationale...................................................................................24
2.2 Background.........................................................................................252.3 Benefit/Risk Assessment ....................................................................273 Objectives and Endpoints ...................................................................284 Study Design.......................................................................................294.1 Overall Design ....................................................................................294.2 Scientific Rationale for Study Design ................................................304.3 Justification for Dose..........................................................................324.4 End of Study Definition......................................................................325 Study Population.................................................................................325.1 Inclusion Criteria ................................................................................335.2 Exclusion Criteria ...............................................................................365.3 Lifestyle Considerations .....................................................................385.4 Screen Failures....................................................................................386 Study Intervention(s) ..........................................................................396.1 Study Interventi on(s) Administration.................................................39
6.2 Study Intervention(s) Preparation, Handling, Storage, and 
Accountability.....................................................................................39
6.3 Measures to Minimize Bias: Study Intervention Assignment and 
Blinding ..............................................................................................40
6.3.1 Study Intervention Assignment ..........................................................406.3.2 Blinding ..............................................................................................406.4 Study Intervention Compliance ..........................................................41
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N6/1566.[ADDRESS_119967]...........................466.9.1 Infusion-related Reactions Including Immediate Hypersensitivity ....46
6.9.3 TGF- β Inhibition Mediated Skin Reactions .......................................50
6.9.4 Anemia................................................................................................516.9.5 Bleeding Events..................................................................................[IP_ADDRESS] Mucosal/Non-Tumor Bleeding...........................................................[IP_ADDRESS] Tumor Bleeding..................................................................................536.9.6 Other Potential Risks ..........................................................................[IP_ADDRESS] Impaired Wound Healing ...................................................................[IP_ADDRESS] Embryofetal Toxicity..........................................................................53
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal...............................................................54
7.1 Discontinuation of Study Intervention................................................547.1.1 Temporary Discontinuation................................................................557.1.2 Rechallenge.........................................................................................[IP_ADDRESS] Reinitiation .........................................................................................557.1.3 Treatment Beyond Progression...........................................................[IP_ADDRESS] Treatment Beyond Initial Progression................................................[IP_ADDRESS] Treatment Beyond Confirmed Progression ........................................[IP_ADDRESS] Continuation of Study Intervention After Local Treatment of 
Disease Progression............................................................................56
7.2 Participant Discontinuation/Withdrawal from the Study ...................577.[ADDRESS_119968] to Follow-Up...............................................................................578 Study Assessments and Procedures....................................................598.1 Efficacy Assessments and Procedures................................................59
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N7/1568.2 Safety Assessments and Procedures ...................................................64
8.2.1 Physical Examinations........................................................................648.2.2 Vital Signs ..........................................................................................658.2.3 Electrocardiograms .............................................................................658.2.4 Clinical Safety Laboratory Assessments ............................................658.3 Adverse Events and Serious Adverse Events .....................................668.3.1 Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information....................................................66
8.3.2 Method of Detecting Adverse Events and Serious Adverse Events...668.3.3 Follow-up of Adverse Events and Serious Adverse Events ...............668.3.4 Regulatory Reporting Requirements for Serious Adverse Events .....678.3.5 Pregnancy ...........................................................................................688.4 Treatment of Overdose .......................................................................68
8.7 Pharmacogenetics ...............................................................................70
8.9 Health Economics...............................................................................73
8.10 Immunogenicity Assessments ............................................................739 Statistical Considerations....................................................................739.1 Statistical Hypotheses.........................................................................73
9.3 Populations for Analyses ....................................................................75
9.4 Statistical Analyses.............................................................................769.4.1 Efficacy Analyses ...............................................................................769.4.2 Safety Analyses ..................................................................................789.4.3 Other Analyses....................................................................................799.4.4 Sequence of Analyses .........................................................................8010 References...........................................................................................8111 Appendices .........................................................................................83
CC
I
CCI
CCICCI
CC
I
CC
I
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N8/156Appendix 1 Abbreviations......................................................................................84
Appendix 2 Study  Governance...............................................................................88
Appendix 3 Contraception......................................................................................95Appendix 4 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting................................................97
Appendix 5 The Recommendations for irAE Management ................................101Appendix 6 Clinical Laboratory Tests .................................................................139
Appendix 7 Prohibited Traditional Chinese Medicines .......................................140
Appendix 9 Response Evaluation Criteria in Solid Tumors (RECIST) Version 
1.1 .....................................................................................................142
Appendix 10 Protocol Amendment History...........................................................151Appendix 11 Sponsor Signature [CONTACT_3490] ....................................................................154Appendix 12 Coordinating Investigator [INVESTIGATOR_24026]........................................155Appendix 13 Principal Investigator [INVESTIGATOR_24026]...............................................156
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N9/156Table of In-Text Tables
Table 1 Schedule of Assessments....................................................................14
Table 2 Bintrafusp alfa Pharmacokinetic, Immunogenicity Sampling............23Table 3 Study Objectiv es and Endpoints.........................................................28
Table 4 Study Intervention ..............................................................................39
Table 5 Treatment Modification of Bintrafusp alfa for Symptoms of 
Infusion-related Reactions Including Immediate Hypersensitivity ....47
Table 6 Evaluation Guidance of Suspected Anemia Adverse Events .............52Table 7 Pharmacokinetic Parameters...............................................................69
Table 9 Confidence Intervals for Different Objective Response Rates at 
the Interim Analysis............................................................................74
Table 10 Confidence Intervals for Different Objective Response Rates at 
the Primary Analysis...........................................................................74
Table 11 Analysis Populations ..........................................................................76Table 12 Statistical Analysis Methods for Efficacy Analysis ...........................77Table 13 Safety Endpoints and Statistical Analysis Methods ...........................78
Table of In-Text Figures
Figure 1 Study Design Diagram........................................................................13CCI
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N10/1561 Protocol Summary
1.1 Synopsis
Protocol Title:
A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in 
Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-containing Chemotherapy
Short Title:
Phase II Bintrafusp alfa Monotherapy in Platinum-Experienced Cervical Cancer
Rationale: 
Globally, cervical cancer is one of the most common and lethal gynecologic cancers. 
Advanced/metastatic disease is typi[INVESTIGATOR_70039], often with poor response ratesand short durations of response (DOR). Improved treatment options are needed for patients with advanced cervical cancer. For patients with advanced, unresectable and/or metastatic cervical cancer with disease progression during or after platinum-based chemotherapy there is no established consensus for second-line treatment options due to low response rates that are typi[INVESTIGATOR_107899]-lived with variable toxicities. The majority of studies of systemic anticancer treatments (including chemotherapy and targeted agents) in platinum-experienced cervical cancer patients have resulted in meager clinical response with reported objective response rates (ORR) ranging from 3% to 10%.  
Pembrolizumab is the first checkpoint inhibitor that received accelerated approval from the Food 
and Drug Administration (FDA) in 2018 for use as monotherapy for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose 
tumors express programmed death-ligand 1 (PD-L1) (Combined Positive Score (CPS) ≥ 1) as 
determined by [CONTACT_13247]-approved test. While the overall response rates with pembrolizumab (12.2% to 14.3%) are comparable to other treatment options for platinum-experienced cervical cancer patients, the durability of responses with pembrolizumab are noteworthy and have 
presented immunotherapy as a promising treatment for this disease. Notably, the limited response rates leave significant room for improvement.  
A novel agent such as bintrafusp alfa, which targets the tumor microenvironment where it blocks 
both the cell intrinsic PD-L1/programmed death-1 (PD-1) interaction and the immunosuppressive transforming growth factor- β (TGF-β), is hypothesized to be more effective than agents that target 
only a single pathway.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N11/156Objectives and Endpoints:
Objectives Endpoints
Primary
!To evaluate clinical efficacy of bintrafusp alfa
based on ORR!Confirmed objective response according to 
RECIST 1.1 assessed by [CONTACT_108073]
!To evaluate clinical efficacy of bintrafusp alfa
based on DOR!DOR according to RECIST 1.1 assessed by [CONTACT_26708]
!To evaluate clinical efficacy of bintrafusp alfa
based on DRR!Durable response of at least [ADDRESS_119969] 1.1 assessed by [CONTACT_26708]
!To evaluate clinical safety of bintrafusp alfa !Occurrence of TEAEs and treatment-related AEs 
including AEs of special interest
!To evaluate clinical efficacy based on PFS !PFS according to RECIST 1.1 assessed by [CONTACT_26708]
!To evaluate ORR, DOR, DRR and PFS by 
[CONTACT_108074]!Confirmed objective response, DOR, DRR, and PFS 
according to RECIST 1.1 assessed by [CONTACT_10670] 
!To evaluate clinical efficacy based on OS !OS
!To characterize the PK profile of bintrafusp alfa !The concentration observed immediately at the end 
of infusion (C EOI) of bintrafusp alfa
!The concentration observed immediately before next 
dosing (corresponding to pre-dose or trough concentration [C
trough] for multiple dosing) of 
bintrafusp alfa
!To characterize the immunogenicity of bintrafusp 
alfa!Immunogenicity of bintrafusp alfa as measured by 
[CONTACT_108075]-upvisit (up to [ADDRESS_119970] treatment)
!To evaluate clinical efficacy of bintrafusp alfa 
according to PD-L1 expression!Efficacy endpoints by [CONTACT_4002]-L1 expression in tumor
ADA=antidrug antibody, AE=adverse event, DOR=duration of response, DRR=durable response rate, 
IRC=Independent Review Committee, NCI-CTCAE v5.0=National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0, OS =overall survival, PD-L1=programmed death-ligand 1, ORR=objective response rates, PFS=progression-free survival, PK=pharmacokinet ic,  RECIST 1.1=Response Evaluation Criteria in Solid 
Tumors Version 1.1, TEAE=Treatment-emergent adverse event.
Overall Design : This Phase II, multicenter, international, single-arm study is to evaluate 
bintrafusp alfa monotherapy in participants with advanced unresectable and/or metastatic cervical cancer with disease progression during or after platinum-based chemotherapy.
The study plans to enroll approximately [ADDRESS_119971] 15% of participants from China. After reaching the completion of the global study enrollment, if the number of participants enrolled in China does not meet the 15% target, enrollment may continue in China to meet local requirement until the target (at least 15%) participants from China is met.
Participants will receive an intravenous (IV) infusion of bintrafusp alfa at a dose of 1200 mg over 
1 hour (-10 minutes/+ 20 minutes, i.e., over 50 to 80 minutes) once every 2 weeks.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647-0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N20/156
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N24/1562 Introduction
Bintrafusp alfa (M7824) is a first-in-class, intravenously (IV) administered bifunctional fusion 
protein that combines an anti-programmed death-lig and 1 (anti-PD-L1) antibody and the soluble 
extracellular domain of the human transforming growth factor- β (TGF-β) receptor as a TGF- β 
neutralizing “trap” into a single molecule. Bintrafusp alfa is the recommended international 
nonproprietary name [INVESTIGATOR_8178] M7824.
Complete information on the chemistry, pharmacology, efficacy, and safety of bintrafusp alfa is 
in the Investigator’s Brochure (IB).
2.1 Study Rationale
This is a Phase II, mu lticenter, international, single-arm, open label study to evaluate bintrafusp 
alfa monotherapy in participants with advanced unresectable cervical cancer with disease progression during or after prior platinum-based chemotherapy. 
The majority of studies of systemic anticancer treatments (including chemotherapy and targeted 
agents) in platinum-experienced cervical cancer p atients have resulted in meager clinical response 
with a reported objective response rates (ORR) ranging from 3% to 10% (Monk 2009) . A literature 
review of studies including almost 2000 patients (see Section  2.2) similarly resulted in a median 
ORR across studies of 10% and weighted average median progression-free survival (PFS) and overall survival (OS) of only 3.[ADDRESS_119972] checkpoint inhibitor that received accelerated approval from the Food 
and Drug Administration (FDA) in 2018 for use as  a monotherapy for the treatment of patients 
with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (Combined Positive Score [CPS] ≥ 1) as determined by [CONTACT_108076]-approved test. While the overall response rates with pembrolizumab (12.2% to 14.3%) are 
comparable to other treatment options for platinum-experienced cervical cancer patients, the durability of responses for pembrolizumab are noteworthy and have presented immunotherapy as a promising treatment for this disease (see Section  2.2). Notably, the limited response rates leave 
room for improvement.  
A novel agent such as bintrafusp alfa, which targets the tumor microenvironment where it blocks 
both the cell intrinsic PD-L1/programmed death-1 (PD-1) interaction and the immunosuppressive TGF-β, is hypothesized to be more effective than agents that target only a single pathway (see 
Section  2.2).
The promising clinical activity of bintrafusp alfa observed in cervical cancer patients of the Phase I 
Study EMR200647-001 (see Section 2.2) and its manageable safety profile in close to 
700 participants with various cancer types (refer to IB) support further investigation of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or 
after prior platinum-containing chemotherapy; see Section  4.2for more details.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N25/1562.[ADDRESS_119973] common and lethal gynecologic cancers. 
Advanced/metastatic disease is typi[INVESTIGATOR_70039], often with poor response ratesand durations of response (DOR).
Improved treatment options are needed for patients with advanced cervical cancer:
!Currently, platinum-containing chemotherapy regimen with or without bevacizumab is the 
standard first-line therapy for patients w ith metastatic cervical cancer. In patients with 
locoregionally advanced cervical cancer, concurrent platinum-containing chemotherapy in combination with radiation therapy is recommended (Monk 2007) .
!Despi[INVESTIGATOR_040] a large series of tested treatment options for patients following standard of care first-line 
treatment, there is no established consensus for second-line treatment. Treatment options are limited due to low response rates that are typ ically short-lived  and associated with variable 
toxicities (McLachlan 2017; Monk 2007) .
A literature review of clinical studies reporting efficacy outcomes for systemic anticancer 
treatments in platinum-experienced patients with locally advanced or metastatic cervical cancer led to the identification of 59 relevant publications reporting results on 1,943 patients withplatinum-experienced cervical cancer. The majority of  studies reported meager response rates with 
a median reported ORR of 10%. A random-effect model to account for heterogeneity between studies estimated the ORR across all selected publications at 15% (95% CI: 12.4%, 18.2%). In addition to this limited response the weighted average median OS and PFS times were 8.3 and 3.3 months respectively. 
In addition to the low response rates, responses were short in duration when they were reported 
(15 studies): median DORs ranged from 1.6 to 13.9 months (13.9 months duration was reported in a study of temsirolimus with a single partial responder among 33 patients evaluable for response), and 12 studies (80%) reported median durations of responses of 6.2 months or less (Tinker 2013) . 
Nivolumab was the first PD-1 inhibitor with reported efficacy data in cervical cancer. In 
Checkmate-358, 19 patients with recurrent and/or metastatic cervical cancer were treated, and an ORR of 26.3% (95% CI: 9.1, 51.2) was observed (Hollebecque 2017) . Neither DOR, nor 
proportion of treated cervical cancer patients naïve to systemic chemotherapy were reported.
Pembrolizumab is the first checkpoint inhib itor that received approval (accelerated) from the FDA
in 2018 for use as monotherapy treatment of patients with recurrent or metastatic cervical cancerwith disease progression on or after chemotherapy whose tumors express PD-L1. This approval was based on the interim results from the Phase II KEYNOTE-158 study (Chung 2019) :
!Among the 98 patients with previously treated advanced cervical cancer, the ORR was 12.2% 
(95% CI: 6.5%, 20.4%), median PFS was 2.1 months (95% CI: 2.0, 2.2 months), and median OS was 9.4 months (95% CI: 7.7, 13.1 months).
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N26/156!Among the 77 patients with PD-L1 positive (CPS ≥1), chemotherapy refractory cervical cancer, 
the ORR was 14.3% (95% CI: 7.4, 24.1). At the time of the publication, median DOR was not 
reached (range 4.1 to 18.6+ months), and median OS was 11 months (95% CI: 9.1, 14.1).
!In KEYNOTE-158, no responses were observed among the PD-L1 negative patients (CPS < 1, 
n=15), and [ADDRESS_119974] overall response as stable disease. 
While the overall response rates with pembrolizumab are only comparable to other treatment 
options for cervical cancer patients (12.2% to 14.3%), the durability of responses are noteworthyand have presented immunotherapy as a promising treatment for this disease.
Recently, molecular characterization of cervical cancer by [CONTACT_108077]-L1 and TGF- β signaling as frequently dysregulated in this disease (The Cancer Genome 
Atlas Research Network 2017,  Roszik 2018) . TGF-β is historically known to be expressed in a 
majority of cervical cancer tissues, and its e xpression correlates with the extent of tumor stroma 
infiltrate (Hazelbag 2002) . Furthermore, the role of TGF- β in cervical cancer pathogenesis is 
supported by [CONTACT_108078] 1) TGF- β1 upregulation by [CONTACT_108079][INVESTIGATOR_27509] (HPV) oncoprotein 
E6 and E7 (Peralta-Zaragoza 2006) , and 2) the correlation of poor prognosis in cervical cancer and 
the expression of plasminogen activator inhibitor-1, a molecule strongly and dose-dependently induced by [CONTACT_4722]- β(Hazelbag 2004) .
Bintrafusp alfa has shown promising clinical activity with durable responses in patients with 
chemotherapy refractory cervical cancer in Phas e I study EMR200647-001. In the Phase I study, 
a total of [ADDRESS_119975] of care treatment were treated for advanced disease. The median treatment duration was 9.6 (range 2.0 to 72.0) weeks. The results are summarized:
!ORR of 24.0% (95% CI: 9.4, 45.1) with 6 confirmed responses per Response Evaluation 
Criteria in Solid Tumors Version 1.1 (RECIST 1.1); 5/6 responses were ongoing at data cutoff (median DOR not reached; range 2.3+ to 24.9+ months). 
!One additional participant developed a partial response (PR) after initial confirmed disease 
progression, bringing the total clinical response rate to 28.0% (95% CI: 12.1, 49.4). This additional participant’s PR was ongoing for 8.7 months at data cutoff, with 73.3% disease shrinkage after initial progressive disease (PD). 
!No clear relationship between PD-L1 protein expression and clinical response was observed. 
One patient with negative tumor PD-L1 expression (via 73-10 assay) had a confirmed PR.
Based on the biological rationale and promising clinical activity of bintrafusp alfa in cervical 
cancer and manageable safety profile in close to 700 participants with various cancer types (refer to IB), this study is designed to further investigate bintrafusp alfa in participants with advanced, unresectable, cervical cancer with disease progression during or after platinum-containing chemotherapy.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N27/1562.3 Benefit/Risk Assessment
At the time of study initiation, bintrafusp alfa dem onstrated promising clinical efficacy in a cohort 
of participants with second-line (2L)+ cervical cancer in the Phase I study EMR200647-001, with a confirmed ORR of 24.0% and total clinical response rate of 28.0% (95% CI: 12.1, 49.4). The median DOR had not been reached by [CONTACT_108080] - 5 of 6 responses were ongoing, with 1 ongoing 
response already lasting for > [ADDRESS_119976]-line 
therapy for patients with metastatic cervical cancer. For patients with advanced unresectable and/or metastatic cervical cancer with disease progression duri ng or after platinum-based chemotherapy 
there is no established consensus for second-line treatment options due to low response rates, typi[INVESTIGATOR_107899]-lived and variable toxicities (Bookman 2000;  Muderspach 2001;  Schilder 2005;  
Alberts 2012) . Based upon the poor clinical prognosis new treatment options for this patient 
population are needed, and these patients are included in the eligibility for this study (further rationale included in Section  4.2).
The identified and potential risks with bintra fusp alfa monotherapy were overall manageable and 
no new safety signals emerged in the Phase I studies (EMR200647-001, MS200647-0008)compared with therapi[INVESTIGATOR_107900]-L1 or TGF- β. The following have been identified as 
important identified risks for M7824: Immune-related adverse events (immune-related pneumonitis, immune-related hepatitis, immune-related  colitis, immune-related nephritis and renal 
dysfunction, immune-related endocrinopathies [thyroid disorders, adrenal insufficiency, Type 1 Diabetes mellitus, pi[INVESTIGATOR_74276]], immune-related rash and other immune-related adverse events (irAEs)  [myositis, myocarditis, encephalitis]), TGF- β inhibition mediated skin reactions, 
anemia and bleeding adverse events. The overall incidence and severity for irAEs is found to be consistent across bintrafusp alfa studies and similar  to the known safety profile of approved anti-
PD-L1 agents (Brahmer 2018) .
Infusion-related reactions (IRRs) are classified as identified risk for the treatment with bintrafusp 
alfa. Infusion-related reactions observed with bintrafusp alfa were similar to those seen with monoclonal antibodies. At the time of study initiation, the overall bintrafusp alfa related IRRs wereobserved to be < 5%, of low-grade (Grade 1/2) severity and not requiring permanent treatment discontinuation.
Dermatologic AEs related to TGF- β-inhibition (including keratoacanthomas [KA] and cutaneous 
squamous cell cancers) are an important identified risk with bintrafusp alfa not seen with other PD-1/PD-L1 antibodies. These lesions were previously observed in participants with genetic mutations in the TGF- βreceptor (i.e., Ferguson-Smith syndrome), and participants treated with 
the TGF- β-targeting agent fresolimumab (Goudie 2011;  Morris 2014) . At the time of study 
initiation, in the Phase I studies, treatment-emergent TGF- β inhibition mediated skin reactions 
were observed in approximately 11% of participan ts, and were well-managed with simple excision 
(or spontaneous resolution) and did not require any participant to discontinue treatment (refer to 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N28/156IB). The risk of these lesions with bintrafusp alfa was considered manageable, especially in the 
context of encouraging clinical activity in several tumor types.
3 Objectives and Endpoints
Table 3 Study Objectives and Endpoints
Objectives Endpoints
Primary
!To evaluate clinical efficacy of bintrafusp alfa
based on ORR!Confirmed objective response according to 
RECIST 1.1 assessed by [CONTACT_108073]
!To evaluate clinical efficacy of bintrafusp alfa
based on DOR!DOR according to RECIST 1.1 assessed by [CONTACT_26708]
!To evaluate clinical efficacy of bintrafusp alfa
based on DRR!Durable response of at least [ADDRESS_119977] 1.1 assessed by [CONTACT_26708]
!To evaluate clinical safety of bintrafusp alfa !Occurrence of TEAEs and treatment-related AEs 
including AEs of special interest
!To evaluate clinical efficacy based on PFS !PFS according to RECIST 1.1 assessed by [CONTACT_26708]
!To evaluate ORR, DOR, DRR, and PFS by 
[CONTACT_108074]!Confirmed objective response, DOR, DRR, and PFS 
according to RECIST 1.1 assessed by [CONTACT_10670] 
!To evaluate clinical efficacy based on OS !OS
!To characterize the PK profile of bintrafusp alfa !The concentration observed immediately at the end 
of infusion (C EOI) of bintrafusp alfa
!The concentration observed immediately before next 
dosing (corresponding to pre-dose or trough concentration [C
trough] for multiple dosing) of 
bintrafusp alfa
!To characterize the immunogenicity of bintrafusp 
alfa!Immunogenicity of bintrafusp alfa as measured by 
[CONTACT_108075]-upvisit (up to [ADDRESS_119978] treatment)
!To evaluate clinical efficacy of bintrafusp alfa 
according to PD-L1 expression!Efficacy endpoints by [CONTACT_4002]-L1 expression in tumor
CCI
CCICCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N31/156Single-Arm Design
This is a single-arm study for patients who have progressed on prior platinum-containing therapy.
Available treatments for this patient population have shown limited activity with low response rates and short DOR with most studies reporting median PFS results < 6 months (Monk 2009) .  
The primary objective of this study is the confirmed overall response rate assessed by [CONTACT_108081] (IRC) according to RECIST 1.1, and the key secondary endpoints include DOR, PFS and OS.
Data from a similar patient population with cervical cancer in the Phase I study EMR200647-001 
demonstrated that bintrafusp alfa is an active drug with encouraging and durable (> 6 months) clinical responses for these patients. Therefore, this single-arm Phase II study will allow an adequate and more robust assessment of clinical activity in platinum-experienced cervical cancer. 
Prior Platinum-Based Therapy
Platinum-containing chemotherapy regimen with or without bevacizumab is the standard first-line 
therapy for patients with metastatic cervical cancer. For patients with advanced unresectable and/or metastatic cervical cancer with disease progression duri ng or after platinum-based chemotherapy 
there is no established consensus for second-line treatment options due to low response rates that are typi[INVESTIGATOR_107899]-lived with variable toxicities (Marth 2017) . To be documented with the 
informed consent, all patients enrolled in the study must have all available treatment options discussed with them during the Screening period.
Inclusion of Human Immunodeficiency Virus Positive Patients
In the typi[INVESTIGATOR_107901], standard Screening and early treatment are
effective for detecting and treating pre-cancerous lesi ons as well as early cancerous growth. Given 
the natural history of the disease with a long developmental timeline, patients who develop metastatic disease are frequently those who had prolonged periods with limited access to standard medical care. In addition, these patients are also at higher risk for comorbid illnesses, including human immunodeficiency virus (HIV) infection.  
Research has suggested that HIV+ cancer patients are more likely to die due to their cancer than 
HIV-related complications. In addition, though with limited data, PD-1/PD-L1 inhibitors used in cancer patients with HIV were shown to be safe and with noted activity (Spano 2019) .T h i s  i s  
consistent with an analysis of literature reports, including PD-1/PD-L1 inhibitors as well as cytotoxic T-cell lymphocyte-associated antigen-4 (CTLA-4) blocking agents, from 73 patients showing a manageable safety profile consistent with  the agents; activity in multiple tumor types. 
In addition, 93% of patients with undetectable viral loads maintained undetectable levels during treatment (Cook 2019) .
The inclusion criteria in this study incorporate recommendations from recent  FDA Guidance on
Cancer Clinical Trial Eligibility Criteria (March 2019) that specifies patients with stable, 
well-controlled HIV should be included in clinical studies. Human immunodeficiency virus testing is not mandatory for study inclusion; a known history of HIV infection should be reported for 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N32/156verification of HIV-specific inclusion criteria and appropriate safety monitoring. Any patient 
undergoing HIV testing for the purpose of this study must be appropriately consented as per local regulations.
4.3 Justification for Dose
The recommended Phase II dose (RP2D) for bintrafusp alfa is 1200 mg administered as an IV 
infusion once every 2 weeks. The selection of RP2D is based on the available clinical data from 
the Phase I Studies EMR200647-001 and MS200647-0008, including safety/tolerability, pharmacokinetic (PK), and pharmacodynamics (PD-L1 target occupancy in peripheral blood mononuclear cell and TGF- β plasma concentrations), as well as efficacy in 2L non-small cell lung 
cancer cohorts from the EMR200647-001 study. The selection of RP2D is also supported by [CONTACT_102431] (PopPK) and exposure-response modeling and simulation. 
Refer to the IB for the completed and detailed data and analysis for dose justification. 
4.[ADDRESS_119979] scheduled procedure shown in Section  1.3. 
The end of the study is defined as the date when 67% of all study participants and 67% of the
participants from China have died (in case of a dditional China enrollment after global enrollment 
completion) whichever occurs last. However, the study ends when each participant was followed 
up for at least [ADDRESS_119980], or another mechanism of access as appropriate.
5 Study Population
The criteria in Sections 5.1and 5.2are designed to enroll only participants, who are appropriate 
for the study; thereby, ensuring the study fulfills its objectives. All relevant medical and nonmedical conditions should be taken into consid eration when deciding whether a participant is 
suitable for this study.
Prospective approval of protocol deviations to inclusion and exclusion criteria, also known as 
protocol waivers or exemptions, is not permitted.
Before performing any study assessments that are not part of the participant’s routine medical care, 
the Investigator will confirm that the participant or the participant’s legal representative (where allowed by [CONTACT_10976]) has provided written informed consent, as indicated inAppendix 2.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N34/156b. Adequate hepatic function defined by a total bilirubin level ≤ the upper limit of normal 
(ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤1.5 × ULN. For participants with liver involvement in their tumor, AST ≤ 5.0 × ULN, 
ALT ≤ 5.0 × ULN, and bilirubin ≤3.0 × ULN are acceptable.
c. Adequate renal function defined by [INVESTIGATOR_10426] ≤ 1.5 × ULN or calculated creatinine 
clearance (CrCL) ≥ 30 mL/min for participant with creatinine > 1.5× ULN (glomerular 
filtration rate can also be used).
Note: CrCL should be calculated per institutional standard. If no local guideline is 
available, CrCL should be calculated using the Cockcroft-Gault Method:
CrCL = ([140-age] × weight [kg] × [0.85 for females only]) / (72 × creatinine).
d. Adequate coagulation function defined as international normalized ratio (INR) or 
prothrombin time (PT) ≤ 1.5× ULN unless the participant is receiving anticoagulant 
therapy and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless the 
participant is receiving anticoagulant therapy.
8. Participants with known HIV infections are in general eligible if the following criteria are 
met (FDA Guidance on Cancer Clinical Trial Eligibility, March 2019) :
a. If clinically indicated patients must be stable  on antiretroviral therapy (ART) for at least 
[ADDRESS_119981] an HIV viral load of < 400 copi[INVESTIGATOR_014]/mL at Screening.
d. Have CD4+ T-cell (CD4+) counts ≥ 350 cells/ μL.
e. For patients with a history of an AIDS-defining opportunistic infection within the last 
12 months, patients may be eligible only after consultation and agreement with the study Medical Monitor.  
f. If prophylactic antimicrobial drugs are indicated, patient may still be considered eligible 
upon agreement with the study Medical Monitor.   
9. Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections are in 
general eligible if the following criteria are met (FDA Guidance on Cancer Clinical Trial 
Eligibility, March 2019) :
a. Patients with serologic evidence of chronic HBV infection must have an HBV viral load 
below the limit of quantification. If medically indicated, participants infected with HBV must be treated and on a stable dose of antivirals (e.g., entecavir, tenofovir, or lamivudine; adefovir or interferon are not allowed) at study entry and with planned monitoring and management according to appropriate labeling guidance.
b. Patients with a history of HCV infection should have completed curative antiviral 
treatment and require HCV viral load below the limit of quantification.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N35/156c. Patients on concurrent HCV treatment should have HCV below the limit of 
quantification.
Sex
10. A female is eligible if she is notpregnant or breastfeeding, and at least one of the following 
conditions applies:
!Nota Woman of childbearing potential (WOCBP)
OR
!If a WOCBP, uses a highly effective contraceptive method (i.e., with a failure rate of 
< 1% per year), preferably with low user dependency, as described in Appendix 3 for 
the following time periods: 
!Before the first dose of the study intervention(s), if using hormonal contraception: 
!Has completed at least one 4-week cycle of an oral contraception pi[INVESTIGATOR_107902].
OR
!Has used a depot contraceptive or extended-cycle oral contraceptive for least 
[ADDRESS_119982] using a highly sensitive assay.
!During the intervention period
!After the study intervention period (i.e., after the last dose of study intervention is 
administered) for at least [ADDRESS_119983] cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required.
Additional requirements for pregnancy testing during and after study intervention are in Section 
8.2.4.
The Investigator reviews the medical history, menst rual history, and recent sexual activity to 
decrease the risk for inclusion of a female with an early undetected pregnancy.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N36/156Informed Consent
11. Capable of giving signed informed consent, as indicated in Appendix 2,  which includes 
compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
5.2 Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. Participants with active CNS metastases causing clinical symptoms or metastases that 
require therapeutic intervention are excluded. Participants with a history of treated CNS 
metastases (by [CONTACT_108082]) ar e not eligible unless they have fully recovered 
from treatment, demonstrated no progression for at least [ADDRESS_119984] 7 days prior to the start of study treatment. Note: Lesions in the CNS at baseline must be assessed as non-target lesions only.
2. Has interstitial lung disease OR has had a history of pneumonitis that has required oral or 
IV steroids
3. Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but 
with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
4. Previous malignant disease (other than the target malignancy to be investigated in this study) 
within the last 3 years, except:
a. Participants with a history of superficial/noninvasive bladder cancer, or basal or 
squamous cell carcinoma in situ previously treated with curative intent are NOT excluded. 
b. Endoscopi[INVESTIGATOR_107903] (GI) cancers limited to mucosal layer 
(esophageal, gastric, and colorectal) that are without recurrence in > 1 year are allowed. 
c. Participants with other localized malignancies (e.g., noninvasive breast cancer [ductal 
carcinoma in situ]) treated with curative intent should be discussed with the Medical Monitor. Further biopsy/evaluations may be required prior to allowing enrollment if there are any concerns of a non-cervical cancer recurrence.
Any questions regarding these criteria should be discussed with Medical Monitor.
5. Significant acute or chronic infections including but not limited to: 
a. Participants with active tuberculosis (history of exposure or history of positive 
tuberculosis test; plus presence of clinical symptoms, physical, or radiographic findings).
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N37/156b. Active bacterial or fungal infection requiring systemic therapy (except as indicated, 
discuss alternative scenarios with the Medical Monitor).
6. Active autoimmune disease that might deteriorate when receiving an immunostimulatory 
agent, except:
a. Participants with diabetes Type 1, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid 
disease not requiring immunosuppressive treatment are eligible.
b. Participants requiring hormone replacement with corticosteroids are eligible if the 
steroids are administered only for the purpose of hormonal replacement and at doses ≤10 
mg of prednisone or equivalent per day.
c. Administration of steroids for other conditions through a route known to result in a 
minimal systemic exposure (topi[INVESTIGATOR_2855], intranasal, intro-ocular, or inhalation) is acceptable.
7. Known severe hypersensitivity (Grade ≥ 3 National Cancer Institute-Common Terminology 
Criteria for Adverse Events v5.0 [NCI-CTCAE v5.0]) to investigational product (bintrafusp alfa) or any components in its formulation, any history of anaphylaxis, or recent, within 5 months, history of uncontrollable asthma.
8. Persisting Grade > 1 NCI-CTCAE v5.0 toxicity (except alopecia and vitiligo) related to 
prior therapy; however, sensory neuropathy Grade ≤ 2 is acceptable.
9. Clinically significant cardiovascular/cerebrovascular disease including: cerebral vascular 
accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to 
enrollment), unstable angina, congestive heart failure ( ≥ [LOCATION_001] Heart Association 
Classification Class II), or serious cardiac arrhythmia. Participants with history of bleeding diathesis or recent major bleeding events considered by [CONTACT_108083].
10. Severe and/or clinically relevant acute or chronic diseases which, in the opi[INVESTIGATOR_684], might impair the participant’s tolerance for the study or ability to consistently participate in study procedures.
Prior/Concomitant Therapy
11. Has received prior cancer treatment with any other immunotherapy or checkpoint inhibitors, 
such as anti-PD-1, anti-PD- L1, anti-PD-L2, anti-CTLA-4, or any other immune-modulating 
mAb (e.g. any other antibody or drug specifically targeting T-cell co-stimulation, checkpoint pathways or immune-suppressive pathways [e.g. TGF- β]).
12. Concurrent treatment with prohibited drugs (see Section 6.5.2) .
13. Systemic therapy with immunosuppressive agents within 7 days before the start of study 
intervention; or use of any investigational drug within 28 days before the start of study intervention. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N38/[ZIP_CODE]. Has received or will receive a live vaccine within [ADDRESS_119985] administration 
of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. 
Prior/Concurrent Clinical Study Experience
15. Participants, who received chemotherapy, radiation therapy (with the exception of palliative 
radiotherapy delivered in a normal organ-sparing technique), or biological therapy (e.g.,antibodies) within [ADDRESS_119986] not recovered from the side effects of such therapy (except for alopecia or potentially neuropathy).
Other Exclusions
16. Major surgery within 28 days before the start of study intervention (diagnostic biopsy, for 
example, is not considered major surgery).
17. Pregnancy or breast feeding. 18. Known active alcohol or drug abuse.
5.3 Lifestyle Considerations
Not applicable.
5.4 Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. Rescreened participants will be assigned a new participant number.
For participants who have abnormal laboratory value at Screening that may correct or are using a 
prohibited concomitant medication that will be discontinued, or undergoing a prohibited procedure that will be completed, the Screening period may be extended up to [ADDRESS_119987] the Medical Monitor to discuss whether the participant may be rescreened.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N39/1566 Study Intervention(s)
Study intervention is any investigational inter vention(s), marketed product(s), placebo, or medical 
device(s) intended to be administered to a study participant per the study protocol.
6.1 Study Intervention(s) Administration
Table 4 Study Intervention
Study Intervention Name: [CONTACT_108165] (M7824)
Dose Formulation: Sterile concentrate solution for infusion
Unit Dose Strength(s)/Dosage Level(s): 10 mg/mL in single-use glass vials
Route of Administration: Intravenous infusion
Dosing Instructions: Flat dose of 1200 mg over 1 hour 
(- 10 minutes/+ 20 minutes, i.e., over 50 to 80 minutes) once every 2 weeks.
Sourcing: Provided centrally by [CONTACT_108084]: Each vial will be packaged and labeled per all 
applicable regulatory requirements and Good Manufacturing Practice Guidelines.
6.2 Study Intervention(s) Preparation, Handling, , and 
Accountability
The Investigator, institution, or the head of the medical institution (where applicable) is responsible 
for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).
!Upon receipt of the study intervention(s), the Investigator or designee must confirm appropriate 
temperature conditions have been maintained during transit and any discrepancies are reported and resolved before use. Also, the responsible person will check for accurate delivery. Further guidance and information for study intervention accountability are provided in the Pharmacy Manual.
!Only participants enrolled in the study may r eceive study intervention(s) and only authorized 
site staff may supply it. All study intervention(s) must be stored in a secure, environmentally controlled, and monitored (manual or automated) area, in accordance with the labeled storageconditions, and with access limited to the Investigator and authorized site staff.
!Dispensing will be recorded on the appropriate accountability forms so that accurate records 
will be available for verification at each monitoring visit.
!Study intervention(s) accountability records at the study site will include the following:
!Confirmation of receipt, in good condition, and in the defined temperature range.
!The inventory provided for the clinical study and prepared at the site.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N40/156!The dose(s) each participant used during the study.
!The disposition (including return, if applicable) of any unused study intervention(s).
!Dates, quantities, batch numbers, vial numbers, expi[INVESTIGATOR_31637], formulations, and the 
participant numbers.
!The Investigator site will maintain records, which adequately document that participants were 
provided the doses specified in this protocol, and that all study intervention(s) provided were fully reconciled.
!Unused study intervention(s) must not be discarded or used for any purpose other than the 
present study. No study intervention that is dispensed to a participant may be re-dispensed to a different participant.
!A Study Monitor will periodically collect the study intervention(s) accountability forms.
!Destruction of used and unused study intervention(s) should be performed at the site if allowed 
by [CONTACT_108085]. If that is not possible, the Sponsor/designee will 
be responsible.
!Further guidance and information for the final disposition of unused study intervention(s) is 
provided in the Operations Manual.
Bintrafusp alfa should be stored in a refrigerator  until use. Bintrafusp alfa must not 
be frozen and should be stored in the original packaging.
Additional instructions for the preparation, handling, storage, and disposal of bintrafusp alfa will 
be provided in the Pharmacy Manual.
6.3 Measures to Minimize Bias: Study Intervention Assignment 
and Blinding
6.3.1 Study Intervention Assignment
The Sponsor or delegate will assign a unique participant identifier number to participants in 
chronological order at the time of informed consent signature. Participant identifiers will be comprised of digits representing the study number, the site number, and the participant number, which is allocated sequentially. Enrollment w ill utilize an Interac tive Voice/Web Response 
System.
6.3.2 Blinding
Not applicable.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N41/1566.4 Study Intervention Compliance
In this study, participants will receive study intervention at the study site. Well trained medical 
staff will monitor and perform the study intervention administration. The information of each study intervention administration, including the date, time, and dose of study intervention, will be recorded on the electronic case report forms (eCRFs). The Investigator will make sure that the 
information entered into the eCRF regarding st udy intervention administration is accurate for each 
participant. Any reason for noncompliance should be documented.
Noncompliance is defined as a participant missing > [ADDRESS_119988] in the eCRF all concomitant therapi[INVESTIGATOR_014] (e.g., medicines or nondrug interventions) used from 
the time the participant signs the informed consent form until completion of the study, including any changes. For prescription and over-the-coun ter medicines, vaccines, vitamins, and herbal 
supplements, record the name, reason for use, dates administered, and dosing information.
Any additional concomitant therapy that becomes n ecessary during the study and any change to 
concomitant drugs must be recorded in the corresponding section of the eCRF, noting the name, 
dose, duration, and indication of each drug.
Contact [CONTACT_108086].
6.5.1 Permitted Medicines
The only permitted medications are the following:
1. Any medications (other than prohibited in Section 6.5.2)  that are considered necessary for 
the participants’ welfare and will not interfere with the study intervention may be given at the Investigator’s discretion.
2. Other drugs to be used for non-steroid premedication (antihistamine and acetaminophen)
for the treatment of anaphylactic reactions, IRRs, and severe hypersensitivity reactions/flu-like symptoms and irAEs (see Section  6.9).
3. Blood transfusions and erythroid growth factors are permitted as clinically indicated.
Any medicines that are considered necessary to protect the participant’s welfare in emergencies
may be given at the Investigator’s discretion, regardless if it results in a protocol deviation.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N42/1566.5.[ADDRESS_119989] not be administered during the 28-day Screening period and for the 
duration of study intervention. If the administration of a nonpermitted concomitant drug becomes necessary during the study, the participant will be withdrawn from study intervention (the Sponsor may be contact[CONTACT_108087]).
!Immunotherapy, immunosuppressive drugs (e.g., chemotherapy or systemic corticosteroids), or 
other experimental pharmaceutical products are prohibited. Exceptions are allowed for short-term treatment of allergic reactions or for the treatment of irAEs, specifically:
!Short-term administration of systemic steroid (i.e., for allergic reactions or the 
management of irAEs) is allowed. 
!Steroids with no or minimal systemic effect (topi[INVESTIGATOR_2855], intranasal, intro-ocular, inhalation) 
are allowed.
!Hormone replacement with corticosteroids for adrenal insufficiency is allowed if the 
steroids are administered only for the purpose of hormonal replacement and at doses ≤10 mg or equivalent prednisone per day.
!Prophylactic use of corticosteroids for IRRs is prohibited.
!Concomitant local or regional treatment (radio/chemo-embolization) is prohibited.
!Other systemic anticancer therapy.
!Live vaccines are prohibited. Administration of inactivated vaccines is allowed (e.g., 
inactivated influenza vaccines).
!Any traditional Chinese medication used as anticancer treatment (regardless of the type of 
cancer) is prohibited. Traditional Chinese medication for indications other than anticancer treatment, such as supportive care, may be administered at the discretion of the Investigator. List of prohibited Chinese medications is provided in the Appendix 7.
!Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to 
potentially interfere with major organ function (e.g., hypericin). 
Medications other than those specifically excluded in this study (see above) may be administered 
for the management of symptoms associated with the administration of bintrafusp alfa as required. These might include analgesics, anti-nausea medications, antihistamines, diuretics, antianxiety medications, and medication for pain management, including narcotic agents.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N43/1566.5.3 Other Interventions
Permitted Procedures
!Palliative organ-sparing radiotherapy may be administered only for specific clinical indications 
during the study. The assessment of PD will be made according to RECIST 1.1 and not based on the necessity for palliative radiotherapy.
Prohibited Procedures
!Major surgery within 4 weeks before the start of the study. Discuss with the Medical Monitor 
if unplanned major surgery is required on study to plan for timing of re-treatment. Any diagnostic biopsies collected for clinical reasons during the study should be documented as a concomitant procedure including the outcome of available pathology reports.
6.6 Dose Selection and Modification
Participants will receive an IV infusion of bintrafusp alfa at a dos e of 1200 mg over 1 hour 
once every 2 weeks as detailed in the SoA
(see Table 1) .
Dose modification of bintrafusp alfa is not allowed.
6.7 Study Intervention after the End of the Study
After a participant has completed the study, has withdrawn consent, or has been withdrawn early, 
symptom guided appropriate treatment will be administered, if required, in accordance with the study site’s standard of care and generally accepted medical practice and depending on the participant’s individual medical needs.
On withdrawal from the study, participants may receive whatever care they and their physicians 
agree upon.
6.8 Special Precautions
Any treatment-emergent adverse event (TEAE) that is assessed as potentially related to bintrafusp 
alfa, may require permanent or transient discontinuation of bintrafusp alfa treatment. 
Single laboratory values out of the normal range  that do not have any clinical correlation do not 
necessarily need treatment interruption. Questions or concerns with regard to management and/or follow-up of TEAEs should be discussed with the Medical Monitor.
Immune-related AEs, IRRs including hypersensitivity, anemia, TGF- βinhibition mediated skin 
reactions, and bleeding events are managed and followed up in their respective sections as indicated below. Permanent study intervention discontinuation may be recommended, so the relevant section must be reviewed:
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N44/156!For suspected irAEs, general management by [CONTACT_12134]-CTCAE v5.0 toxicity grading is listed in 
Section 6.9.2.  Recommended guidance and management for specific irAEs as per published 
guidelines is provided in  Appendix 5.  
!Infusion-related reaction (IRR) and hypersensitivity reaction guidance are presented in 
Section 6.9.1.
!Anemia guidance is presented in Section 6.9.4.
!Potential TGF- β-mediated skin AEs guidance and management are provided in Section 6.9.3.  
!For guidance and management of bleeding events, see Section 6.9.5.
General guidance:
!In any case, if ≥ 2 doses are missed due to AE, the Medical Monitor should be consulted
!Inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day
within 12 weeks is an indication for permanent treatment discontinuation (except for use of
steroids as hormone substitution)
!Persistent Grade 2 or 3 adverse reactions (ex cluding endocrinopathies controlled with hormone 
replacement therapy) that do not recover to Grade [ADDRESS_119990] dose of study intervention is an indication for permanent treatment discontinuation.
In general, the following applies for TEAEs related to bintrafusp alfa that are not covered by [CONTACT_108088] 5:
Grade 4 treatment-related TEAEs
Any Grade 4 treatment-related TEAEs require permanent treatment discontinuation, except:
!Endocrinopathies that have been controlled by [CONTACT_108089] 
!Isolated laboratory values out of normal range that do not have any clinical correlation. 
Discuss with Medical Monitor regarding work-up, management, and treatment continuation versus hold versus discontinuation for isolated Grade 4 laboratory abnormalities
!If alternative explanation is identified for Grade [ADDRESS_119991] require permanent treatment 
discontinuation.
Grade 3 treatment-related TEAE
1. Participants with any severe or Grade 3 treatment-related adverse reactions that recur 
should be permanently discontinued. Exceptions  may be considered for the following after 
discussion with Medical Monitor:
!Transient Grade 3 flu-like symptoms or fever that is controlled with medical 
management
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N45/156!Transient Grade 3 fatigue, local reactions, headache, nausea, emesis that resolves to 
≤Grade 1 or baseline
!Tumor flare phenomenon defined as local pain, irritation, or rash localized at sites of 
known or suspected tumors
!Any Grade ≥ 3 drug-related amylase or lipase abnormality that is not associated with 
symptoms or clinical manifestations of pancreatitis
!Grade 3 Hgb decrease (< 8.0 g/dL) that is clinically manageable with blood transfusions 
or erythroid growth factor use
!Increases in ECOG PS ≥3 that resolves to ≤2 by [CONTACT_2006] 1 of the next infusion (i.e., 
infusions should not be given if the ECOG PS is ≥3 on the day of treatment and should 
be delayed until ECOG PS ≤2)
!Keratoacanthoma (KA) and cutaneous squamous cell carcinoma (cSCC)
!Grade 3 non-tumor bleeding requiring intervention or hospi[INVESTIGATOR_107904] (such as concomitant use of antithrombotic agents, traumatic event, etc.).
2. See Appendix 5 for guidance on specific Grade 3 irAEs as many require permanent 
treatment discontinuation, including pneumonitis and nephritis.
!AST or ALT > [ADDRESS_119992] be 
permanently discontinued, except for participants with liver metastases (for example) 
who begin treatment with Grade [ADDRESS_119993] or ALT increases by ≥50% relative to baseline and lasts for at 
least 1 week.
3. Persistent Grade 3 adverse reactions (excluding endocrinopathies controlled with hormone 
replacement therapy) that do not recover to Grade 0 to 1 within 12 weeks after dose of treatment.
Grade 2 treatment-related TEAE
1. If a Grade 2 treatment-related TEAE resolves to Grade ≤ 1 by [CONTACT_108090], study intervention may be continued.
2. If a Grade 2 treatment-related TEAE does not resolve to Grade ≤ 1 by [CONTACT_108091], but it is manageable and/or not clinically relevant, the Medical Monitor should be consulted to assess if it is clinically reasonable to administer the following 
infusion.
Note that treatment recommendations regarding continuation, hold, or discontinuation by [CONTACT_108092] (refer to  Appendix 5) . Toxicity grading is assigned 
based on NCI-CTCAE v5.0. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N46/1566.[ADDRESS_119994] (AESI) are serious or nonserious AEs specific to the known 
mechanism of action of the study intervention that are of clinical interest.
For this study, AESIs include the following:
!Infusion-related reactions including immediate hypersensitivity
!Immune-related AEs
!TGF-β inhibition mediated skin reactions
!Anemia
!Bleeding AEs
6.9.[ADDRESS_119995] of Medical Dictionary for Regulatory Activities (MedDRA) preferred terms and criteria on the timely relationship to an infusion. Events are divided into reactions versus signs and symptoms:
!Reactions are considered when onset is on the day of infusion (during or after the infusion) or 
the day after the infusion (irrespective of resolution date) for IRR, drug hypersensitivity, anaphylactic reaction, hypersensitivity, and type 1 hypersensitivity.
!Signs and symptoms of IRR and hypersensitivity/allergic reactions are considered when onset 
is on the day of infusion (during or after the infusion) and resolved completely with the end date within 2 days after onset of (but not limited to) pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria.
Management of Infusion-related Reactions
Premedication prior to bintrafusp alfa administration for the first 2 infusions is optional and at the 
discretion of the Investigator. If an Investigator chooses to administer premedications, premedication with an antihistamine and with paracetamol (acetaminophen) (e.g., 25 to 50 mg diphenhydramine and 500 to 650 mg paracetamol [acetaminophen] IV or oral equivalent) approximately 30 to 60 minutes prior to each dose of bintrafusp alfa is recommended. 
If Grade ≥ 2 infusion reaction(s) are seen during the first 2 infusions, premedication should be 
continued/implemented for future infusions.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N47/156An assessment for possible IRR should be triggered based upon the development of specific 
symptoms within 24 hours of an infusion. 
Management of symptoms should follow the guidelines shown in Error! Reference source not 
found. .
Table 5 Treatment Modification of Bintrafusp alfa for Symptoms of 
Infusion-related Reactions Including Immediate Hypersensitivity
NCI-CTCAE v5.0 Grade Treatment Modification 
Grade 1 – mild
!Mild transient reaction; infusion interruption not 
indicated; intervention not indicated.!Increase monitoring of vital signs as medically 
indicated as participants are deemed medically 
stable by [CONTACT_108093].
Grade 2 – moderate
!Therapy or infusion interruption indicated but if 
responds promptly to symptomatic treatment (e.g., 
antihistamines, NSAIDs, narcotics, IV fluids); 
prophylactic medications indicated for ∀24 hours.!Stop the infusion of the study intervention-caused 
IRR.
!Increase monitoring of vital signs as medically 
indicated as participants are deemed medically stable by [CONTACT_108093]. 
!If symptoms resolve quickly or decreased to 
Grade 1, resume infusion at 50% of original rate 
with close monitoring of any worsening otherwise 
dosing held until resolution of symptoms with mandated premedication for the next scheduled visit. If worsens to Grade 3 or 4, follow treatment 
modification guidelines accordingly.
Grade 3 or Grade 4 – severe or life-threatening
!Grade 3: Prolonged (e.g., not rapi[INVESTIGATOR_86025]/or brief interruption of 
infusion); recurrence of symptoms following initial 
improvement; hospi[INVESTIGATOR_79806].
!Grade 4: Life-threatening consequences; urgent 
intervention indicated.!Stop the infusion of study intervention-caused IRR 
immediately and disconnect infusion tubing from the 
participant with additional appropriate medical 
measures and closely monitor until deemed medically stable by [CONTACT_108093]. Hospi[INVESTIGATOR_5478]/or close monitoring is 
recommended.
!Administration of glucocorticoids may be required
!Restart the medication taking out the drug that is the 
cause of IRRs from the next scheduled visit 
IRR=infusion-related reactions, IV=intravenous, NCI-CTCAE=National Cancer Institute-Common Terminology Criteria for Adverse Event, NSAIDs=nonsteroidal anti-inflammatory drugs. 
Once the bintrafusp alfa infusion is interrupted or rate reduced to 50% of previous infusion rate, it must remain 
decreased for all subsequent infusions. For Grade [ADDRESS_119996] be recorded.
In the event of a Grade 2 IRR that does not improve or worsens after implementation of the 
treatment modifications indicated in Table 5 (including reducing the infusion rate by 50%), the 
Investigator may consider treatment with corticosteroids and the infusion should be stopped for that day. At the next infusion, the Investigator may consider the addition of H2 blocker antihistamines (e.g., famotidine or ranitidine), in addition to the above provided recommended optional premedication regimen, for selected participan ts. However, prophylactic steroids are not 
permitted. At the next dose, if the participant has a second IRR Grade ≥2 on the slower infusion 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N48/156rate, with the addition of further medication to premedication, the infusion should be stopped, and 
the Investigator may consider withdrawal of this participant from the study.
Hypersensitivity Reaction
If a hypersensitivity reaction occurs, the participant must be treated according to the best available 
medical practice. A complete guideline for the emergency treatment of anaphylactic reactions according to the Working Group of the Resus citation Council [LOCATION_008] and can be found 
at https://www.resus.org.uk/pages/reaction.pdf. Participants should be instructed to report any delayed reactions to the Investigator immediately.
Symptoms may include, but are not limited to: 
!Impaired airway
!Decreased oxygen saturation (< 92%)
!Confusion
!Lethargy
!Hypotension
!Pale/clammy skin
!Cyanosis.
Management of hypersensitivity includes: 
!Epi[INVESTIGATOR_107905]
!Participant should be placed on cardiac, blood pressure, heart rate, and oxygen saturation 
monitoring immediately
!Alert intensive care unit for possible transfer if required.
Prophylaxis of Flu-like Symptoms:
For prophylaxis of flu-like symptoms, a nonsteroidal anti-inflammatory drug (NSAID), e.g., 
ibuprofen 400 mg or comparable NSAID dose, may be administered 2 hours before and 8 hours after the start of each IV infusion.
6.9.2 Immune-related Adverse Events
Immune-related AEs are specific to immunotherapi[INVESTIGATOR_107906]. Immune-related 
AEs are considered AESIs. 
In general, the spectrum of irAEs is similar for bintrafusp alfa compared with other checkpoint 
inhibitors. Effective risk management of these tox icities (irAEs) primarily caused due to inhibition 
of PD-L1 and PD-1 pathways, is based on key recommendations (Champi[INVESTIGATOR_136] 2016) . Participant 
education for on-time reporting of symptoms of potential irAEs and prompt clinical assessment is critical for effective management and quicker resolution of immune-mediated toxicities, thus 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N49/156preventing progression into severe forms of toxic ity that otherwise may become life-threatening 
and difficult to manage or warrant permanent discontinuation from the study.
The following irAEs are important identified risks for bintrafusp alfa:
!Immune-related hepatitis
!Immune-related pneumonitis
!Immune-related colitis
!Immune-related nephritis and renal dysfunction
!Immune-related endocrinopathies (thyroid disorders, adrenal insufficiency, type 1 diabetes 
mellitus, pi[INVESTIGATOR_74276])
!Immune-related rash
!Other immune-related events (myositis, myocarditis, encephalitis)
The following irAEs are important potential risks for bintrafusp alfa:
!Guillain-Barré syndrome
!Uveitis
!Pancreatitis
!Myasthenia gravis/myasthenic syndrome
The Medical Monitor may be involved as needed for follow-up. Details of the diagnostic work-up 
will be requested by [CONTACT_3476]. 
Recommended guidance and management for specific irAEs as per published guidelines as 
provided in Appendix 5. These recommendations are in accordance with the joint American 
Society of Clinical Oncology (ASCO) Clinical Practice Guidelines (Brahmer 2018) and National 
Comprehensive Cancer Network (NCCN 2018) guidelines.
Treatment of irAEs is mainly dependent upon sever ity as defined by [CONTACT_12134]-CTCAE v5.0. In general, 
management by [CONTACT_12134]-CTCAE v5.0 grading is listed below:
!Grade 1: study intervention should be continued with close monitoring, with the exception of 
some neurologic, hematologic, and cardiac toxicities. 
!Grade 2: study intervention may be suspended for most Grade 2 toxicities, with consideration 
of resuming when symptoms revert to Grade 1 or less. Corticosteroids may be administered (initial dose of 0.5 to 1 mg/kg/day of prednisone or equivalent). 
!Grade 3: study intervention is generally su spended and the high-dose corticosteroids 
(prednisone 1 to 2 mg/kg/day or methylprednisolone 1 to 2 mg/kg/day) treatment should be 
initiated. Corticosteroids should be tapered over the course of at least 4 to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N50/156!Grade 4: in general, permanent discontinuation of study intervention is recommended, with the 
exception of endocrinopathies that have been controlled by [CONTACT_108089].
Permanent treatment discontinuation is required in case of immune-related Grade 4 
rash/inflammatory dermatitis, nephritis, autoimmune hemolytic anemia, hemolytic uremic syndrome, aplastic anemia, immune thrombocytopenia, acquired thrombotic thrombocytopenic purpura, inflammatory arthritis, myositis, and polymyalgia-like syndrome. 
For Grade [ADDRESS_119997] by a single laboratory value out of normal 
range without any clinical correlates. In this case, treatment should be held until the etiology is determined. If the event is not considered immune related and resolves to Grade ≤1 restarting 
treatment may be considered.
!For Grade 1 immune-related pneumonitis: continue treatment. If clinically indicated, monitor 
participants weekly or more frequently as needed with history, physical examination, and pulse 
oximetry. If symptoms appear and/or changes in the physical examination are noted, treat as Grade 2.
!For myositis: in case of management with rituximab, treatment should be discontinued.
For organ/system specific management guidelines, see the guideline tables in Appendix 5.
Recommended guidance and management for specific irAEs are provided in the current NCCN 
guideline available at http://www.nccn.org.
6.9.3 TGF- β Inhibition Mediated Skin Reactions
TGF-β inhibition mediated skin reactions, including hyperkeratosis, KA, and/or cSCCs, are 
important identified risks and AESI for bintrafusp alfa.
Skin assessments are performed at Screening period and every 6 weeks for all participants per SoA
(see Table 1) . Baseline skin assessments include a detailed medical history of genetic or iatrogenic 
skin conditions, skin type, significant UV exposure/sun damage of skin, geographical location, and occupational or environmental exposure to radiation or chemicals.  
Skin AEs appear to be related to both mechanisms of bintrafusp alfa; anti-PD-L1 and anti-TGF- β:
1. Immune-related skin AEs possibly mediated by [CONTACT_4002]-L1 inhibition (e.g. rash or maculo-papular 
rash, distributed typi[INVESTIGATOR_107907]). Just as immune-related AEs to other organs (see Section  6.9.2) , immune related AEs affecting the skin are important identified 
risks for bintrafusp alfa and AESI.
Immune-related skin AEs should be managed according to the recommended guidance and 
management for specific irAEs as per published guidelines (refer to Appendix 5) . Treatment 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N51/156typi[INVESTIGATOR_107908], non-sedating antihistamines for pruritus, targeted use of 
potent topi[INVESTIGATOR_107909]; oral corticosteroids in highly symptomatic case.
2. Skin AEs, possibly due to TGF- β inhibition, including hyperkeratosis, KA and/or cSCC, are 
important identified risks and AESI for bintrafusp alfa. The distribution of lesions tends to be in sun-exposed areas. These AEs are AESIs for bintrafusp alfa.
Management guidelines for potential TGF- βinhibition mediated skin reactions are:
1. Discontinuation or interruption is not required in most cases. Continuation of treatment should 
be evaluated by [CONTACT_737]. 
2. Emollients may continue to be used.3. Diagnostic and treatment plan should be developed in collaboration between Investigator and 
dermatologist. In general, treatment of TGF- β inhibition mediated skin lesions such as 
hyperkeratosis, KA and cSCC should be based on local guidelines/standard of care. Lesion evaluation should include excision biopsy of one representative lesion to confirm diagnosis.
4. Treatment and follow-up for KA and cSCC will depend on number and localization of lesions. 
!For single lesions: Full excision may be recommended. 
!In case of multiple lesions or location not suitable for full excision, other treatment options 
may be offered by [CONTACT_108094], such as: 
!Mohs surgery, cryotherapy, or other standard treatment options depending on the 
pathology 
!Use of retinoids, if recommended by [CONTACT_108095], may be considered after discussion 
with Medical Monitor
5. Close clinical follow-up for re-evaluation, resolution, or potential recurrence should be 
implemented.
6. Spontaneous resolution of KA lesions without surgical intervention has been observed, 
typi[INVESTIGATOR_107910].
7. The number and localization of lesions, diagnosis (including histopathological diagnosis), 
treatment, and outcome should be appropriately documented in the eCRF.
Consult with study Medical Monitor, as needed, for management of TGF- βinhibition mediated 
skin reactions.
6.9.4 Anemia
Anemia is an AESI (refer to IB) and important identified risk for bintrafusp alfa. Notably, there are many reasons for anemia in patients with advanced cancer, therefore a thorough investigation of new anemia cases of unspecified etiology is requested.
For new anemia events, items queried may include, but are not limited to, detailed relevant past 
medical and treatment history, bruising tendency, history of blood transfusions and/or dependency, 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N52/156and a request for an updated eCRF including details such as concomitant medications, all 
laboratory data, updated dosing information and, recent tumor evaluation scans. 
General guidance for anemia management and evaluation:
1. Participants must enter the study with Hgb v alues at least 9 g/dL; routine blood test parameters 
are required in the SoA (see  Table 1)
2. All relevant hematologic testing for anemias should be done prior to a blood transfusion, if 
clinically feasible.
3. Transfusion should be performed at the discretion of the Investigator based on clinical 
assessment and considered when the participant experiences significant anemia. An attempt should be made to initiate work-up (as specified below) for the cause of anemia prior to transfusion, if clinically feasible, to not confound this work-up. In general, blood transfusions and erythroid growth factors are permitted as clinically indicated.
Guidance for evaluation of suspected anemias is provided in  Table 6.
Table 6 Evaluation Guidance of Suspected Anemia Adverse Events
Baseline Anemia Evaluation (Prior to Transfusion, if feasible)
CBC with differential (e.g., Hgb, hematocrit, MCV, reticulocytes counts, ANC).
Peripheral blood smear for cell morphological assessment.
Complete metabolic panel including liver panel-LFTs, bilirubin, LDH, renal function, and other chemistries if indicated:
1. Coagulation factors (PT, PTT, INR)
2. Urinalysis including culture
3. Iron panel (TIBC, ferritin, Fe)
4. Serum folate, B12 values
5. TSH/hormonal panel
6. Fecal-occult blood testing
7. Erythropoietin.
Further Recommendation Based on Suspected Etiology (in Addition to Baseline Anemia Testing)
Unknown etiology, suspect 
possible hemolysisCoombs test, fibrinogen, haptoglobin, d-dimer.
Consider hematology consultation.Consider blood transfusion at clinical discretion.
Unknown etiology, suspect 
possible bleedingConsider blood transfusion at clinical discretion.
Consider surgical/interventional radiology consultation.
Consider imaging, as clinically indicated (e.g., FAST scan, CT scan, MRI, angiography).Consider endoscopy (upper/lower). 
Unknown etiology despi[INVESTIGATOR_107911]-upHematology consultation.
Consider bone marrow aspi[INVESTIGATOR_1516]/morphologic evaluation.
ANC=absolute neutrophil count, CBC=complete blood count, CT=computed tomography, FAST=Focused assessment 
with sonography for trauma, Hgb=hemoglobin, INR=international normalized ratio, LDH=lactate dehydrogenase, 
LFT=liver function test, MCV=mean corpuscular volume, MRI=magnetic resonance imaging, PT=prothrombin time, 
PTT=partial thromboplastin time, TIBC=total iron binding capacity, TSH=thyroid-stimulating hormone.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N53/1566.9.5 Bleeding Events
Bleeding events are AESIs and considered an important identified risk for bintrafusp alfa (refer to 
the IB).
[IP_ADDRESS] Mucosal/Non-Tumor Bleeding
Participants treated with bintrafusp alfa were co mmonly reported with mild to moderate mucosal 
AEs such as epi[INVESTIGATOR_3940], hemoptysis, gingival bleeding and hematuria. In general, these reactions resolve without discontinuation of treatment. 
For Grade [ADDRESS_119998] be permanently discontinued unless an 
alternative explanation can be identified (such as concomitant use of antithrombotic agents, traumatic event, etc.). In case of alternative explanations for the Grade 3 bleeding event, study treatment should be held until the event recovers to Grade ≤1.
For Grade [ADDRESS_119999] be permanently discontinued if no alternative 
explanation is identified.  
[IP_ADDRESS] Tumor Bleeding
Participants treated with bintrafusp alfa were reported in lower frequencies, with Grade ≥3 
hemorrhages including tumor bleeding. For Grade ≥ [ADDRESS_120000] be 
held until the event recovers to Grade ≤ 1. Treatment should be permanently discontinued if the 
Investigator considers the participant to be at risk for additional severe bleeding.
6.9.6 Other Potential Risks
[IP_ADDRESS] Impaired Wound Healing
Impaired wound healing is considered an important potential risk (a theoretical risk-based on 
literature findings) for bintrafusp alfa, given the role of TGF- βin wound healing. Management 
should be discussed with the Medical Monitor for participants requiring surgery on study. It is recommended to hold study intervention for approximately [ADDRESS_120001] major surgery for observation. Postoperative wound healing will be closely monitored.
[IP_ADDRESS] Embryofetal Toxicity
Embryofetal toxicities are a known risk of the PD-1/PD-L1 targeting class and are consideredimportant potential risks for bintrafusp alfa. Animal models link the PD-1/PD-L1 signaling pathway with maintenance of pregnancy through induction of maternal immune tolerance to fetal tissue. Embryofetal toxicity is an important potential risk of bintrafusp alfa. An appropriate contraception warning is provided as part of the inclusion criteria. Pregnant and breastfeeding 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N54/156women are not allowed in the bintrafusp alfa study, and adequate contraceptive measures are 
recommended during the study to minimize or eliminate the potential risk to the developi[INVESTIGATOR_16103].
Respective safety measures comprise inclusion/exclusion criteria for participation in clinical 
studies with bintrafusp alfa, guidance for prevention, monitoring, and medical management of potential risks, as well as guidance on study intervention interruption or discontinuation.
7 Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal
7.1 Discontinuation of Study Intervention
Participants may be discontinued from study intervention for any of the following reasons, one 
reinitiating course of treatment may be allowed (see Section  [IP_ADDRESS]) .
!A participant may discontinue from the study intervention at any time at his/her own request 
(i.e., withdrawal of consent), and without giving a reason.
!Occurrence of an exclusion criterion, which is clinically relevant and affects the participant’s 
safety, if discontinuation is considered necessary by [CONTACT_11219]/or Sponsor.
!A participant may be discontinued at any time at the discretion of the Investigator for safety, 
behavioral, compliance, or administrative reasons (See Section 6.8and 6.9for TEAEs and 
AESIs that require treatment discontinuation).
!Confirmed PD per RECIST 1.1, with the exception that participants receiving treatment may 
continue past PD if the participant’s ECOG PS has remained at least stable, and if in the opi[INVESTIGATOR_689], the participant will benefit from continued treatment (See Section  7.1.3) .
!Unacceptable toxicity.
!Some TEAEs and AESIs require withdrawal from treatment. See Section 6.8and 6.9for 
additional details.
!Drug must not be given to a known pregnant participant (refer to  Appendix 3) .
!Use of a prohibited concomitant drug, as defined in Section 6.5.2,  where the predefined 
consequence is withdrawal from the study intervention.
The SoA specifies the data to collect at study intervention discontinuation and follow-up and any 
additional evaluations that need to be completed.
In case of discontinuation from the study intervention:
!The day of End-of-Treatment will correspond to the day of withdrawal (or within 7 days).  
!An attempt should be made to perform all assessments scheduled for the End-of-Treatment visit 
if possible. If not possible, the most clinically relevant assessments and appropriate eCRFs for the End-of-Treatment visit should be prioritized as feasible. 
!Participants will be asked to continue Safety and Survival Follow-up, which includes the 
collection of data on survival, patient-reported outcome (PRO) questionnaires, and subsequent 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N55/156anticancer therapy. After completion of the follow-up period or after the End-of-Treatment 
visit, whichever is applicable, the appropriate eCRF section for Study Termination must be completed. 
!If the participant is enrolled into a new study or any new therapy post-withdrawal from study 
intervention, the Safety Follow-up visit should be scheduled prior to the start of the new 
treatment irrespective of the 28-day Safety Follow-up period.
7.1.1 Temporary Discontinuation
See Sections 6.8and 6.9for guidance on temporary discontinuation from study intervention.
7.1.2 Rechallenge
[IP_ADDRESS] Reinitiation
One reinitiating course of treatment at the same dose and schedule and treatment duration up to 
24 months is allowed at the discretion of the Investigator and agreement of the Medical Responsible for: 
!Participants who are experiencing SD, a PR, or CR at the time of discontinuation, and then 
subsequently develop disease progression after stoppi[INVESTIGATOR_7374], but prior to the End of the Study.
OR
!Participants who are discontinued due to an AE that is subsequently well managed or resolved 
after stoppi[INVESTIGATOR_7374], but prior to the End of the Study.
The participant should reinitiate treatment at the treatment phase visit where they left off according 
to the SoA (see  Table 1) . Participants who reinitiate treatment should stay on study and should be 
treated and monitored according the SoA for the rest of the study.
Prior to reinitiation, the Investigator will need to confirm that the benefit of reinitiating treatment 
outweighs any risk involved, such as that which led to initial treatment discontinuation. For participants with only stable disease at the time of discontinuation, the Investigator should confirm that no other reasonable treatment options are available. In addition, to be eligible for reinitiation, the participant must not have previously withdrawn consent for this trial and should have been followed up with regular eCRF documented evaluation scans up to reinitiation of treatment.
A rebaseline scan must be performed prior to reinitiation of study treatment. Additionally, relevant 
safety laboratory assessments, including both full hematology and full chemistry results within [ADDRESS_120002] be available and verified. The clinical Investigator will determine whether additional evaluation and work-up are required on a case-by-case basis. A discussion with the study team is warranted to determine whether PK/ testing is indicated upon restarting treatment.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N56/1567.1.3 Treatment Beyond Progression
[IP_ADDRESS] Treatment Beyond Initial Progression
Participants will receive bintrafusp alfa as outlined in the SoA until disease progression. Bintrafusp 
alfa may continue past the initial determination of disease progression according to RECIST 1.1 as long as the following criteria are met:
!Treatment with bintrafusp alfa is ongoing
!No new unacceptable treatment or disease-related toxicity
!Tolerance of study interventions
!At least stable ECOG PS
!Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (e.g., CNS metastases).
A radiographic assessment should be performed within 4 to 6 weeks of original PD to determine 
whether there has been a decrease in the tumor size, or continued PD. The assessment of clinical benefit should be balanced by [CONTACT_108096].
[IP_ADDRESS] Treatment Beyond Confirmed Progression
After confirmed PD, if the Investigator feels that the participant continues to achieve clinical benefit by [CONTACT_43893], the participant should remain on the study and continue to receive monitoring according to the SoA. The decision to continue treatment beyond confirmed PD should be discussed with the Medical Monitor and documented in the study records.
Participants who continue beyond progression will be evaluated for further tumor response as per 
the protocol schedule. Treatment should be discontinued permanently upon documentation of further, unequivocal, disease progression unless there are no alternative therapeutic options and the benefit-risk assessment is favorable in consultation between the Investigator and the Medical Monitor. In case of continuation of treatment beyond PD, treatment will be discontinued once any other criteria for withdrawal are met.
[IP_ADDRESS] Continuation of Study Intervention After Local Treatment of 
Disease Progression
If disease progression is due to brain metastasis, pa rticipants may continue study interventions 
after the local treatment of the brain lesions provided that the above criteria are met in addition to the following:
!Tumor assessment showing disease progression has been performed and was documented 
according to RECIST 1.1 prior to the procedure.
!Brain metastases have been treated locally and are clinically stable for at least 2 weeks prior to 
reinitiation of study interventions. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N57/156!There are no ongoing neurological symptoms that are related to the brain localization of the 
disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable).
!Participants must be either off steroids or on a stable or decreasing dose of ≤ 10 mg daily 
prednisone (or equivalent).  
!Benefit-risk assessment to continue study intervention is favorable under consideration of any 
alternative treatment options as assessed by [CONTACT_737].
In addition, if disease progression is mainly due to a metastatic lesion which in the opi[INVESTIGATOR_107912], participants may continue study interventions after the local treatment of such a lesion provided that:
!Tumor assessment showing disease progression has been performed and was documented 
according to RECIST 1.1. prior to the procedure.
!It has been at least 2 weeks and the participant has fully recovered from the surgery.
!Benefit-risk assessment to continue study intervention is favorable under consideration of any 
alternative treatment options as assessed by [CONTACT_737].
7.2 Participant Discontinuation/Withdrawal from the Study
!A participant may withdraw from the study at any time, at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, 
or administrative reasons.
!At the time of discontinuing from the study, if possible, a discontinuation visit will be 
conducted, as listed in the SoA. The SoA specifies the data to collect at study discontinuation and follow-up, and any additional evaluations that need to be completed.
!If the participant withdraws consent for future involvement in the study, any data collected up 
to that point may still be used, but no future data can be generated, and any biological samples collected will be destroyed (refer to the ICF).
!A participant has the right at any time to request destruction of any biological samples taken. 
The Investigator must document this in the site study records.
7.[ADDRESS_120003] to follow-up if she repeatedly fails to return for scheduled visits and is unable to be contact[CONTACT_9298].
The following actions will be taken if a participant fails to return to the study site for a required 
study visit:
!The site will attempt to contact [CONTACT_46342], counsel the participant on the importance of maintaining the assigned visit schedule and ascertain if the participant wants to or should continue in the study.
!Before a participant is deemed “lost to follow- up”, the Investigator or designee will make every 
effort to regain contact [CONTACT_6635]: 1) where possible, make 3 telephone calls; 2) if 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N58/156necessary, send a certified letter (or an equivalent local method) to the participant’s last known 
mailing address, and 3) where applicable locally and if a participant has given the appropriate consent, contact [CONTACT_2299]’s general practitioner or caretaker (where allowed by [CONTACT_427]) for information. These contact [CONTACT_13140]’s medical record.
!If the participant continues to be unreachable, she will be considered to have withdrawn from 
the study.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N59/1568 Study Assessments and Procedures
!Study assessments and procedures and their timing are summarized in the SoA.
!No protocol waivers or exemptions are allowed.
!Immediate safety concerns are discussed with the Sponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention.
!Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
!All Screening evaluations will be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The Investigator will maintain a Screening log to record details of all participants screened, to confirm eligibility, and if applicable, record reasons for Screening failure.
!Prior to performing any study assessments that are not part of the participant’s routine medical 
care, the Investigator will obtain written informed consent as specified in Appendix 2.
!Procedures conducted as part of the participant’s routine medical care (e.g., blood count) and 
obtained before signing of the ICF may be used for Screening or baseline purposes provided 
the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA.
!A maximum of 119 mL of blood will be collected in any 1-month (first month) period from 
each participant in the study, including all sample types.
8.1 Efficacy Assessments and Procedures
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N60/156 CCI
CCICCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N61/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N62/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N63/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N64/1568.2 Safety Assessments and Procedures
The safety profile of the study intervention will be assessed through the recording, reporting, and 
analysis of baseline medical conditions, AEs, physical examination findings, vital signs, electrocardiograms (ECGs), and laboratory tests.
Comprehensive assessment of any potential toxicity experienced by [CONTACT_108097]. The 
Investigator will report any AEs, whether observed by [CONTACT_108098]; the reporting period is specified in Section 8.3.1 (Time Period and Frequency for 
Collecting Adverse Event and Serious Adverse Event Information).
The safety assessments will be performed according to the SoA (Table 1) . Periodic evaluations of 
the study data will be conducted by [CONTACT_108099] (see Section  8.2.4) . 
Ongoing events at the 12-week Safety Follow-up visit should continue to be monitored and 
documented until resolution or resolution with sequelae. All serious adverse events (SAEs)ongoing at the End-of-Treatment visit must be monitored and followed up by [CONTACT_108100], unless the participant is documented as “lost to follow-up”. Reasonable attempts to obtain this information must be made and documented. It is also the responsibility of the Investigator to ensure that any necessary additional therapeutic measures and follow-up procedures are performed.
If a liver function test (LFT) is elevated in an HBV- or HCV-positive participant, HBV 
deoxyribonucleic acid (DNA) or HCV ribonucleic acid (RNA) must be monitored to exclude the possibility of reactivation of viral hepatitis. In case of viral reactivation, follow the HBV and HCV management guidelines.
8.2.1 Physical Examinations
!Vital signs, physical examinations, and ECOG PS will be conducted at Screening and at 
subsequent visits as indicated in the SoA (Table 1) . These should be documented in the eCRF. 
!A complete physical examination at Screening will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurological systems. 
!A brief physical examination (at all other scheduled visits other than Screening) will include, 
at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).
!Investigators should pay special attention to clinical signs related to previous serious illnesses.
!General status, such as asthenia or appetite, should be evaluated at Baseline. Pre-existing 
symptoms of underlying conditions and/or signs of infection should be investigated as clinically indicated. 
!Abnormal findings are to be reassessed at subsequent visits.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N65/1568.2.2 Vital Signs
!Height (at Screening visit only) and weight will be measured and recorded.
!Vital signs including body temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be 
assessed and recorded in the eCRF.
!Vital signs will be measured in a seated or semi-supi[INVESTIGATOR_55848] [ADDRESS_120004] and will 
include temperature, systolic and diastolic blood pressure, pulse and respi[INVESTIGATOR_697].
!Blood pressure and pulse measurements will be assessed with a completely automated device. 
Manual techniques will be used only if an automated device is not available.
!Blood pressure and pulse measurements should be pr eceded by [CONTACT_2669] [ADDRESS_120005] for the 
participant in a quiet setting without distractions (e.g., television, cell phones).
!Blood oxygen saturation will be measured with a pulse oximeter and recorded in the eCRF.
8.2.3 Electrocardiograms
Single 12-lead ECGs will be obtained as outlined in the SoA (Table 1)  using an ECG machine that 
automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
8.2.4 Clinical Safety Laboratory Assessments
Blood and urine samples will be collected for the clinical laboratory tests listed in  Appendix 6 at 
the time points listed in the SoA (Table 1) . All samples should be clearly identified. 
Additional tests may be performed at any time during the study, as determined necessary by [CONTACT_56861].
The tests will be performed by [CONTACT_12082].The Sponsor must receive a list of the local laboratory normal ranges before shipment of study 
intervention(s). Any changes to the ranges during the study must be forwarded to the Sponsor or designated organization.
The Investigator must review each laboratory report, document their review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The laboratory reports must be filed with the source documents.
If a participant has a clinically significant abnormal laboratory test value that is not present at 
baseline, the test should be closely monitored until the test value has returned to the normal range or the Investigator has determined that the abnormality is chronic or stable. 
The report of the results must be retained as a part of the participant’s medical record or source 
documents. Pregnancy testing (serum or highly sensitive urine test, as required by [CONTACT_427]) will be conducted at monthly intervals during study intervention administration and at the time points specified in the SoA (Table 1) , including at the end of relevant systemic exposure 
of the study intervention. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N66/156HIV testing is not mandatory. History of HIV infection will be collected, if known, as part of the 
medical history. If a test is performed at any point in Screening or while on study, a site must 
consent the participant for HIV testing as per local standard guidance.
8.3 Adverse Events and Serious Adverse Events
The definitions of an AE and a SAE are in  Appendix 4.
8.3.1 Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information
The AE reporting period for safety surveillance begins when the participant is initially included in 
the study (date of first signature [CONTACT_43998]/date of first signature [CONTACT_108166]) and continues until the 28-day Safety Follow-up visit, defined as 28 days (± 5 days) after the last study intervention administration. After this visit, all SAEs and nonserious treatment-related AEs should be documented until the last Safety Follow-up visit, defined as 12 weeks (± 2 weeks) after the last study inter vention. Ongoing events at the 12-week Safety 
Follow-up visit should continue to be monitored and documented until resolution or resolution with sequelae, unless the participant is documented as “lost to follow-up”.
Any SAE assessed as related to study intervention must be recorded and reported, as indicated in 
Appendix 4,  whenever it occurs, irrespective of the time elapsed since the last administration of 
study intervention.
The method of recording, evaluating, and assessing causality of AEs (including SAEs) and the 
procedures for completing and transmitting SAE reports are in  Appendix 4.
8.3.2 Method of Detecting Adverse Events and Serious Adverse 
Events
At each study visit, the participant will be quer ied on changes in his or her condition. During the 
reporting period, any unfavorable changes in the pa rticipant’s condition will be recorded as AEs, 
regardless if reported by [CONTACT_108101].
Complete, accurate, and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the eCRF. All SAEs must be additionally documented and reported using the appropriate SAE Report Form as specified in  Appendix 4.
8.3.3 Follow-up of Adverse Events and Serious Adverse Events
Adverse events are recorded and assessed continuously throughout the study, as specified in 
Section 8.3.1 (Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information) and are assessed for their outcome at the 28-day Safety Follow-up visit. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N67/156All SAEs ongoing at the 28-day Safety Follow-up visit must be monitored and followed up by [CONTACT_108102], unless the participant is documented as “lost to follow-up”. Reasonable attempts to obtain this information must be made and documented. It is also the responsibility of the Investigator to ensure that any necessary additional therapeutic measures and follow-up procedures are performed. Further information on follow-up procedures is given in Appendix 4 (Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reports).
Monitoring of Specific Adverse EventsIf monitoring is warranted for certain treatment-related TEAEs for safety issues, the treating 
physician or Investigator is requested to follo w the participant during the post-treatment long-term 
follow-up phase until the end of study period or the participant is “lost to follow-up” and report the management and outcome of AEs to the Sponsor. 
8.3.[ADDRESS_120006] report SAEs (particularly deaths) in accordance with applicable site-specific 
requirements to the IRB that approved the study.
In accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
and the Japanese ministerial ordinance on GCP, the Sponsor/designee will immediately inform all the study Investigators and the Heads of the study sites of findings that could adversely affect the safety of participants, impact the conduct of th e study, or alter the IRB’s approval/favorable 
opi[INVESTIGATOR_43932]. In line with respective applicable regulations, the Sponsor/designee 
will immediately inform all the study Investigators and the Heads of the study sites of AEs that are both serious and unexpected and considered to be related to the administered product (“suspected unexpected serious adverse reactions” or S[LOCATION_003]Rs). In addition, per applicable regulations, the Sponsor/designee will inform the study Investigators and the Heads of the study sites of all SAEs that were reported to the Health Authorities. In accordance with the Japanese regulatory requirements concerning safety reporting, the Investigator should place copi[INVESTIGATOR_107913]. The Head of the study site should also maintain copi[INVESTIGATOR_107914]. National regulations regarding Safety Report notifications to Investigators will be considered.
When specifically required by [CONTACT_43973], the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IRB/IEC and will maintain records of these notifications. When direct reporting is not clearly defined by [CONTACT_108103]-specific regulations, the Investigator will be responsible for promptly notifying the concerned IRB/IEC of any Safety Reports provided by [CONTACT_1034]/designee and of filing copi[INVESTIGATOR_43934].
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N68/156For studies covered by [CONTACT_43975] 2001/20/EC, the Sponsor’s responsibilities 
regarding the reporting of SAEs/S[LOCATION_003]Rs/Safety Issu es will be carried out in accordance with that 
Directive and with the related Detailed Guidance documents.
8.3.5 Pregnancy
Only pregnancies the Investigator considers to be  related to the study intervention (e.g., resulting 
from a drug interaction with a contraceptive method) are AEs. However, all pregnancies with an 
estimated conception date during the period defined in Section 8.3.1 (Time Period and Frequency 
for Collecting Adverse Event and Serious Adverse Event Information) must be recorded in the AE page/section of the eCRF for pregnancies in female participants. The Investigator must notify the Sponsor/designee in an expedited manner of any pregnancy using the Pregnancy Report Form, which must be transmitted by [CONTACT_108104] 4,  section 
on Reporting Serious Adverse Events.
Investigators must actively follow-up, document, and report on the outcome of all these 
pregnancies, even if the participants are withdrawn from the study.
The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy Report 
Form. If an abnormal outcome occurs, the SAE Report Form will be used if the participant sustains an event and the Parent-Child/Fetus AE Report Form if the child/fetus sustains an event. Any abnormal outcome (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) must be reported in an expedited manner, as specified in Section 8.3.1,  while normal 
outcomes must be reported within [ADDRESS_120007] be 
discontinued from study intervention. The Sponsor/designee must be notified without delay and the participant must be followed as indicated above.
8.4 Treatment of Overdose
For this study, any dose of bintrafusp alfa greater than 2 times (i.e., > 2400 mg) of the planned dose administered within a 24-hour time period will be considered an overdose.
Of note: In the dose-escalation study (EMR200647-001), participants safely received up to 
30 mg/kg bintrafusp alfa every 2 weeks (including those with doses > 2400 mg) with no observed maximum tolerated dose (refer to the IB). Safety at significantly higher doses has not been clinically evaluated. 
!In case of overdose with clinical correlation, symptomatic treatment must be used; there are no 
known antidotes for the compound.
!In the event of an overdose, the study intervention infusion should be discontinued, and 
participants should be observed closely for any signs of toxicity. Supportive treatment should be provided if clinically indicated. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N69/156Even if it not associated with an AE or a SAE, an y overdose is recorded in the CRF and reported 
to drug safety in an expedited manner. Overdoses are reported on a SAE Report Form, following the procedure in  Appendix 4,  section on Reporting Serious Adverse Events.
If an AE occurs resulting from an overdose, it should follow SAE reporting criteria as indicated in 
Appendix 4.
8.5 Pharmacokinetics
!Whole blood samples of approximately 3.5 mL will be collected for measurement of serum 
concentrations of bintrafusp alfa. Collection times are specified in the SoA. The actual date and 
time (24-hour clock time) of each sample will be recorded to calculate actual time elapsed since the prior dose administration. 
!The quantification of bintrafusp alfa in serum will be performed using a validated immunoassay 
assay method. Concentrations will be used to evaluate the PK of bintrafusp alfa. 
!Remaining samples collected for analyses of bintrafusp alfa concentration may also be used to 
evaluate immunogenicity and safety or efficacy aspects related to concerns arising during or after the study. 
Details on processes for collection and shipment of these samples are in the Laboratory Manual. 
Retention time and possible analyses of samples after the end of study are specified in the respective ICF.
Pharmacokinetic (PK) and antidrug antibody (ADA) samples will be collected according to the 
bintrafusp alfa PK, Immunogenicity Sampling (Table 2) . Pharmacokinetic and ADA samples 
collected at the same time points may be used interchangeably if the dedicated sample has 
insufficient quantity as the participants will have consented to all collections and tests.
The PK parameters will be summarized using descriptive statistics (Table 7) . Individual as well as 
mean concentration-time plots will be depi[INVESTIGATOR_1230].
The following PK parameters will be calculated, when appropriate.
Table 7 Pharmacokinetic Parameters
Symbol Definition
CEOI The concentration observed immediately at the end of infusion.
Ctrough The concentration observed immediately before next dosing (corresponding to pre-dose or 
trough concentration for multiple dosing).
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N70/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N71/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N72/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N74/156 CCI
CCICCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N75/1569.3 Populations for Analyses
The analyses populations are specified below. The final decision to exclude participants from any 
analysis population will be made and documented during a data review meeting prior to database lock.
The analysis will be performed on approximately 135 patients globally. China participants 
(whether enrolled before or after the completion of the global enrollment) may be analyzed separately per local regulatory requirements, and follow the same definition as Section  4.1.
For purposes of analysis, the analysis populations are defined in Table 11.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N76/156Table 11 Analysis Populations
Screening (SCR) All participants, who provided informed consent, regardless of the participant’s study 
intervention status in the study.
Safety (SAF)/
Full Analysis Set 
(FAS)All participants, who were administered at least 1 infusion of bintrafusp alfa.
The primary analysis population for efficacy and  analyses is the Full Analysis 
Set. The primary analysis population for all analyses of safety and health-related quality of 
life is the Safety population.
Pharmacokinetic 
(PK)All participants who complete at least [ADDRESS_120008] 
1 sample with a measurable concentration of bintrafusp alfa.
Immunogenicity
Analysis Set (IMM)All participants who were administered at least [ADDRESS_120009] one valid ADA result. All ADA analyses will be based on this analysis set.
9.4 Statistical Analyses
Full details of all planned analyses will be described in the study integrated analysis plan (IAP). 
Major modifications of planned analyses will be reflected in a protocol amendment or in the CSR.
In general, continuous variables will be summarized using number (n), mean, median, standard 
deviation, minimum, and maximum. Categorical variables will be summarized using frequency counts and percentages. Proportions are calculated based on the number of participants in the analysis set of interest, unless otherwise specified in the IAP. 
Data collected after reinitiation of treatment will be summarized according to the specifications in 
the IAP.
9.4.[ADDRESS_120010] as listed in  Table 3,  
including but not restricted to PD-L1 expression.
Statistical analysis methods for primary and key secondary efficacy endpoints are summarized in
Table 12. Further details will be specified in the IAP.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N77/156Table [ADDRESS_120011] 
1.1 will be required no sooner than 4 weeks after the initial documentation of CR or 
PR.
The response at each scheduled tumor assessment and the overall response will be 
listed for each participant. The number and proportion of overall response (defined asCR + PR) will be tabulated
The 95% CI for the ORR will be calculated using the Clopper-Pearson method.
Key Secondary
DOR assessed by [CONTACT_108105] a confirmed objective 
response (CR or PR) according to RECIST 1.[ADDRESS_120012] documentation of objective response of disease progression (PD) or death due to any cause, whichever occurs first. The censoring rules for DOR are as described below for PFS.
Kaplan-Meier estimates will be provided;Median DOR and the 95% confidence interval for the median will be calculated 
according to Brookmeyer and Crowley (Brookmeyer 1982) ;
Swimmer plots will be provided.
Durable response 
assessed by [CONTACT_108106] (CR or PR) according to 
RECIST 1.1, determined by [CONTACT_55543], with a duration of at least 6 months. Participants for whom the DOR is censored will be treated as failures (successes) in the analysis of 
durable response if the censored DOR is below (at least) 6 and 12 months. 
The DRR is defined as the percentage of participants with durable response. The 
95% CI for the DRR will be calculated using the Clopper-Pearson method.
PFS according to RECIST 1.[ADDRESS_120013] an event (PD or death), for participants who start new anticancer treatment prior to an event, or for participants with an event after [ADDRESS_120014] administration of study intervention unless death occurred on or before the time of the second planned tumor assessment, in which 
case the death will be considered an event.
Kaplan-Meier estimates will be provided;Median PFS and the 95% confidence interval for the median will be calculated 
according to Brookmeyer and Crowley (Brookmeyer 1982)
Overall survival Overall survival is defined as the time from first administration of study intervention to 
the date of death due to any cause. Participants last known to be alive will be censored at date of last contact.
Kaplan-Meier estimates will be provided;Median OS and the 95% confidence interval for the median will be calculated 
according to Brookmeyer and Crowley (Brookmeyer 1982)
Confirmed Objective 
response, DOR, DRR, and PFS according to 
RECIST 1.1 assessed by 
[CONTACT_108107], see above
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N78/156Endpoint Statistical Analysis Methods
CR= complete response, DOR= duration of response, DRR= durable response rate, IRC= Independent Review 
Committee, ORR= objective response rates, PFS= progression-free survival, PR= partial response, RECIST 1.1= Response Evaluation Criteria in Solid Tumors Version 1.1.
9.4.[ADDRESS_120015] study intervention administration date + [ADDRESS_120016], unless otherwise stated.
Safety endpoints include AEs, AESIs, clinical laboratory assessments, vital signs, physical 
examination, and ECOG PS as described in Section 8.2.
The definitions, procedures for recording, evaluating, follow-up, and reporting of AEs are 
described in  Appendix 4.
Treatment-emergent adverse events are those events with onset dates occurring during the on-
treatment period or if the worsening of an even t is during the on-treatment period. The incidence 
of TEAEs, regardless of attribution, and TEAEs defined as possibly related to bintrafusp alfa will be summarized by [CONTACT_108108] (SOC) and described in terms of intensity and relationship to bintrafusp alfa. Any AEs with an onset or worsening date after the on-treatment period will be reported separately.
See Table [ADDRESS_120017] one dose of 
study intervention and will be based on all safety analysis reporting outcomes like AEs, clinically relevant bioscience (AESIs) and laboratory tests outcomes.
The safety endpoints will be tabulated using descriptive statistics.
!Participants will be analyzed according to the actual treatment they receive.
!The safety endpoints will be analyzed using descriptive statistics.
!The incidence of TEAEs, SAEs, treatment-related AEs, and AESIs, irAEs will be 
summarized by [CONTACT_108109],and described in terms of severity and relationship to treatment.
!The worst on-treatment grades for chemistry and hematology laboratory results 
will be summarized.
!Shifts in toxicity grading from Baseline to highest grade during the on-treatment 
period will be displayed. 
!For laboratory tests without an NCI-CTCAE grade definition results will be 
presented categorically (e.g., below, within, or above normal limits). 
Further details of safety analyses (including AEs, clinical laboratory assessments, 
vital signs, physical examination, ECG parameters, and ECOG PS) will be provided in the IAP.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N79/156Endpoint Statistical Analysis Methods
AE=adverse event; AESI=adverse event of special interest; ECG=electrocardiogram; IAP=Integrated Analysis 
Plan; irAE=immune-related adverse event; NCI-CTCAE=National Cancer Institute-Common Terminology Criteria for Adverse Events; SAE=serious adverse event; TEAE=treatment-emergent adverse event.
9.4.[ADDRESS_120018] as needed. The detailed 
subgroups will be outlined in the IAP. 
Serum concentrations of bintrafusp alfa will be determined by a validated method at the times 
listed in the SoA (see  Table 1) .
!Details on the PK, immunogenicity,  will be 
specified in the IAP finalized before databas e lock. The PopPK analysis and exposure-response 
may be performed using combined data from several bintrafusp alfa clinical studies and will be specified in a separate IAP. PopPK, exposure response and  analyses will be presented separately from the main CSR. 
!Details on the PK analyses (C
EOIand C trough) will be specified in the IAP finalized before 
database lock.
ADA/Immunogenicity
Samples for ADA assessments will be collected as per the SoA. 
The immunogenicity testing strategy is in accordance with current regulatory guidance documents 
and industry best practices.
A validated method to detect ADAs in the presence of drug in human serum will be applied. The 
ADA titers of positive samples will be determined. Positive samples may be further evaluated for neutralizing capability. Individual participants will be categorized across all valid ADA results as ever-positive versus never-positive. ADA ever-pos itive participants will be further categorized as 
pre-existing, including treatment boosted, versus treatment emergent. ADA treatment-emergent participants will be further subdivided into transient positive and persistent positive.
Individual participants may be categorized across all valid neutralizing antibody results as 
ever-positive versus never-positive. Neutralizing antibody ever-positive participants may be 
further categorized as pre-existing versus treatment-emergent. Neutralizing antibody treatment-emergent participants may be further subdivided into transient positive and persistent positive.
Listings of drug concentration, TEAEs, and efficacy measures may be prepared for ADA 
ever-positive participants. 
CCI
CCICCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N81/[ZIP_CODE] References
Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of 
recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec;127(3):451-5.
Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: 
A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Ma nagement of Imm une-Related Advers e Events in 
Patients Treated With Immune Checkpoint Inhi bitor Therapy: American Society of Clinical 
Oncology Clinical Practice Guideline. J Oncol Pract. 2018 Apr;14(4):247-249.
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 
1982;38:29-41.
Champi[INVESTIGATOR_136] S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade 
dysimmune toxicities: A collaborative position paper. Ann Oncol. 2016;27(4):559-74.
Chung HC, Ros W, Delord JP, at al. Efficacy and Safety of Pembrolizumab in Previously Treated 
Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.[ZIP_CODE]. Epub 2019 Apr 3.
Cook MR, Kim C1. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With 
HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019 Jul 1;5(7):1049-1054. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
FDA Guidance on Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, 
or Hepatitis C Virus Infections, Mar 2019.
Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, et al. The European Organization for Research 
and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. [ADDRESS_120019] 15;107(8):1812-22.
Goudie DR, D’Alessandro M, Merriman B, et al. Multiple self-healing squamous epi[INVESTIGATOR_107915] a disease-specific spectrum of mutations in TGFBR1. Nat Genet. 2011;43(4):365-9.
Hazelbag S, Gorter A, Kenter GG, et al. Transforming growth factor-beta1 induces tumor stroma 
and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002;33(12):1193-9.
Hazelbag S, Kenter GG, Gorter A, et al. Prognostic relevance of TGF-beta1 and PAI-1 in cervical 
cancer. Int J Cancer 2004;112(6):1020-8.
Hollebecque A. An open-label, multicohort, Phase I/ II study of nivolumab in patients with virus-
associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. ASCO 2017. Abstract 5504.  
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO 
Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N82/156McLachlan J, Boussios S, Okines A, et al. The Impact of Systemic Therapy Beyond First-line 
Treatment for Advanced Cervical Cancer. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):153-160. doi: 10.1016/j.clon.2016.10.002. Epub 2016 Nov 9.
Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: 
state of the art and future directions. J Clin Oncol. 2007 Jul 10;25(20):2952-65.
Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent 
or recurrent squamous cell carcinoma of the cervi x: a gynecologic oncology group study. J Clin 
Oncol. 2009 Mar 1;27(7):1069-74. 
Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-
transforming growth factor-beta (TGF β) monoclonal antibody in patients with advanced malignant 
melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353.
Muderspach LI, Blessing JA, Levenback C, Moore JL  Jr. A Phase II study of topotecan in patients 
with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001 May;81(2):213-5.
National Comprehensive Cancer Network® guidelines. Version 3.2018. Available at: 
http://www.nccn.org.
Peralta-Zaragoza O, Bermúdez-Morales V, Gutiérrez-Xicotencatl L, et al. E6 and E7 oncoproteins 
from human papi[INVESTIGATOR_61382] 16 induce activation of human transforming growth factor beta1 promoter throughout Sp1 recognition sequence. Viral Immunol. 2006 Summer;19(3):468-80.
Roszik J, Ring KL, Wani KM, et al. Gene Expression Analysis Identifies Novel Targets for 
Cervical Cancer Therapy. Front Immunol. 2018 Sep 19;9:2102. 
Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with 
non-squamous cell carcinoma of the cervix: a phase  II study of the Gynecologic Oncology Group.
Gynecol Oncol. 2005 Jan;96(1):103-7.
Spano JP, Veyri M, Gobert A, et al. Immunotherapy for cancer in people living with HIV: safety 
with an efficacy signal from the series in real life experience. AIDS. 2019 Sep 1;33(11):F13-F19. 
The Cancer Genome Atlas Research Network*. Integrated genomic and molecular characterization 
of cervical cancer. Nature. 2017 Mar 16; 543(7645): 378–384.
Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with 
recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013 Aug;130(2):269-74. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N83/[ZIP_CODE] Appendices
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N84/156Appendix [ADDRESS_120020] computed tomography            
CTLA-4 cytotoxic T-cell lymphocyte-associated antigen-4
Ctrough concentration observed immediately before next dosing 
(corresponding to pre-dose or trough concentration for multiple dosing)
D day             
DNA deoxyribonucleic acid            
DOR duration of response           
DRR durable response rate           
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N85/156ECG electrocardiogram             
ECOG Eastern Cooperative Oncology Group          
eCRF electronic case report forms          
EORTC European Organisation for Research and Treatment of Cancer      
EQ    EuroQol        
EQ-5D-5L EuroQol 5-dimension
FAS Full Analysis Set
FDA Food and Drug Administration            
FT4 free thyroxine            
GCP Good Clinical Practice           
GI gastrointestinal             
HBV hepatitis B virus           
HCV hepatitis C virus           
Hgb hemoglobin             
HIV human immunodeficiency virus             
HPV human papi[INVESTIGATOR_107916]’s Brochure            
ICF informed consent form           
ICH International Council for Harmonisation          
IEC Independent Ethics Committee           
INR international normalized ratio
ir immune-related             
irAEs immune-related adverse events           
IRB Independent Review Board
IRC Independent Review Committee           
IRR infusion-related reactions            
IV intravenous             
KA keratoacanthoma             
LDH lactate dehydrogenase            
LFT liver function test           
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N86/156MedDRA Medical Dictionary for Regulatory Activities         
  
N number of participants          
NCCN National Comprehensive Cancer Network           
NCI-CTCAE National Cancer Institute-Common Terminology Criteria for 
Adverse Events      
NSAID nonsteroidal anti-inflammatory drug           
ORR objective response rates           
OS overall survival            
PAI-[ADDRESS_120021] 1.1 Response Evaluation Criteria in Solid Tumors Version 1.1      
RNA ribonucleic acid
RP2D recommended Phase II dose          
SAE serious adverse event           
SD stable disease
CCI
CCICCI
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N87/156SoA summary of activities            
S[LOCATION_003]Rs suspected unexpected serious adverse reactions         
TEAEs treatment-emergent adverse event            
TGF-β transforming growth factor- β           
           
TSH thyroid-stimulating hormone           
TTP thrombotic thrombocytopenic purpura           
ULN upper limit of normal          
V visit             
VAS visual analog scale           
W week             
W1D1 Week 1 Day 1          
W3 week 3            
WOCBP woman of childbearing potential             
β-HCG β-human chorionic gonadotropin           
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N88/156Appendix 2 Study Governance
Financial Disclosure
Investigators and Sub-Investigators will provide the Sponsor with enough, accurate financial 
information, as requested, for the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. This information is required 
during the study and for 1 year after completion of the study.
Informed Consent Process
!The Investigator or his/her representative will explain the nature of the study to the participant 
or his/her legally-authorized representative (w here allowed by [CONTACT_10976]) and 
answer all questions on the study.
!Participants must be informed that their participation is voluntary.
!Participants or their legally-authorized representative (where allowed by [CONTACT_83344]) will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50; the Japanese ministerial ordinance on GCP; local regulations; ICH guidelines; Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable; and the IRB/IEC or study center.
!The medical record will include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
!If the ICF is updated during their participation in the study, participants will be re-consented to 
the most current, approved version.
!Participants who are rescreened are required to sign a new ICF.
Data Protection
!The Sponsor will assign a unique identifier to participants after obtaining their informed 
consent. All participant records or datasets transferred to the Sponsor will contain the identifier 
only; participant names or any identifiable information will not be transferred.
!The Sponsor must inform participants that thei r personal study-related data will be used per 
local data protection and privacy laws. The level of disclosure will also be explained to the participant, who will be required to give consent for their data to be used, as specified in the informed consent.
!The participant must be informed that his/her medical records may be examined by [CONTACT_108110]-appointed, authorized personnel, by [CONTACT_6667]/IEC members, and by [CONTACT_108111]. All such persons will strictly maintain participants’ confidentiality.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N89/156Study Administrative
The Coordinating Investigator [INVESTIGATOR_107917], per ICH GCP. The Coordinating Investigator [INVESTIGATOR_107918].
The study will appear in the following clinical studies registries: ClinicalTrials.gov and EudraCT.This study requires a significant logistic and administrative structure for its efficient execution. 
Details of structures and associated procedures will be defined in a separate Investigator Site File.
This will be prepared under the supervision of the Clinical Trial Leader in close collaboration with 
the responsible units at the Sponsor.
The Sponsor will coordinate the study and will provide the support for a Contract Research 
Organization (CRO) for some activities of the study. Sponsor Global Clinical Operations will perform oversight of the activities performed by [CONTACT_2024].
The Clinical Trial Supplies department of the Sponsor will supply the study medication of 
bintrafusp alfa, which will be distributed to the sites by [CONTACT_108112].
Participant enrollment will be managed by [CONTACT_108113].
Safety laboratory assessments will be performed locally by [CONTACT_108114]. Pharmacokinetic 
(PK),  will be performed under the responsibility and/or supervision of the Sponsor. 
The Global Drug Safety Department, [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or its designated 
representatives will supervise drug safety and the timely reporting of adverse events (AEs) and serious adverse events (SAEs).
Quality assurance of the study conduct will be performed by [CONTACT_108115], [COMPANY_006] KGaA, Darmstadt, [LOCATION_013].
The department of Global Biostatistics will supervise the statistical analyses (with the exception 
of the PK data analyses that will be outsourced to a CRO).
Details of structures and associated procedures will be defined in a separate Integrated Project 
Management Plan.
CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N90/156Regulatory and Ethical Considerations
This study will be conducted in accordance with the protocol and the following:
!Consensus ethical principles derived from international guidelines, including the Declaration
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines
!Applicable ICH Good Clinical Practice (GCP) Guidelines
!The Japanese ministerial ordinance on GCP 
!Applicable laws and regulations.
The Investigator must submit the protocol, protocol amendments (if applicable), ICF, Investigator 
Brochure, and other relevant documents (e.g., advertisements) to an IRB/IEC and the IRB/IEC will review and approve them before the study is initiated.
For sites in Japan, the Sponsor initiates the study at a site after obtaining written approval from the 
Head of the study site, based on favorable opi[INVESTIGATOR_1649]/approval from the concerned IRB.
Any protocol amendments (i.e., changes to the protocol) will be documented in writing and require 
IRB/IEC approval before implementation of changes, except for changes necessary to eliminate an immediate hazard to study participants. When applicable, amendments will be submitted to the appropriate Health Authorities.
The Investigator will be responsible for the following:
!Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently per the IRB’s/IEC’s requirements, policies, and procedures.
!Notifying the IRB/IEC of SAEs or other significant safety findings, as required by [CONTACT_1744]/IEC 
procedures.
!Providing oversight of the study conduct at the site and adherence to requirements of 21 CFR, 
ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.
The protocol and any applicable documentation will be submitted or notified to the Health 
Authorities in accordance with all local and national regulations for each site.
Review Committees
The following committees will be involved in the study: IRC
Independent Radiology (Review) Committee (IRC)
The IRC will be composed of a minimum of [ADDRESS_120022] overall response (objective response) and date of disease progression for each participant. In addition, the IRC will review radiographic imaging findings for each patient to confirm presence of measurable disease per RECIST 1.1 prior 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N91/156to inclusion in the study. The full membership, mandate, and processes of the IRC will be detailed 
in the IRC charter.
Emergency Medical Support
The Sponsor or designee will provide Emergency Medical Support cards to participants for use 
during the study. These provide the means for participan ts to identify themselves as participating 
in a clinical study. Also, these give health care providers access to any information about this participation that may be needed to determine the course of medical treatment for the participant. The information on the Emergency Medical Support card may include the process for emergency unblinding (if applicable).
The first point of contact [CONTACT_108116]. Consequently, the Investigator agrees to provide his or her emergency contact [CONTACT_108117]. If the Investigator is available when an event occurs, they will answer any 
questions. Any subsequent action (e.g., unblinding) will follow the standard process established for Investigators.
When the Investigator is not available, the Sponsor provides the appropriate means to contact a 
Sponsor (or designee) physician. This includes provision of a 24-hour contact [CONTACT_108118] a call center, whereby [CONTACT_108119] (or designee) physician to assist with the medical emergency.
Clinical Study Insurance and Compensation to Participants
The Sponsor is entirely responsible for AEs that are associated with this study and cause damage 
to the health of the participants, except for AEs caused by [CONTACT_108120]/or significant deviation on the part of the Investigator, the study site, and/or the participant. The Sponsor takes out insurance to fulfill the responsibility. Insurance coverage will be provided for each country participating in the study. Insurance conditions shall meet good local standards, as applicable.
Clinical Study Report
After study completion, the Sponsor will write a CSR in consultation with the Coordinating 
Investigator.
Publication
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows [COMPANY_006] to protect proprietary information and to provide comments. 
The Sponsor will comply with the requirements for publication of study results. Per standard 
editorial and ethical practice, the Sponsor will gene rally support publication of multicenter studies 
only in their entirety and not as individual site  data. In this case, a Coordinating Investigator [INVESTIGATOR_107919].
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N92/156Authorship will be determined by [CONTACT_108121].
Dissemination of Clinical Study Data
After completion of the study, a CSR will be written by [CONTACT_108122] [INVESTIGATOR_107920] E3 and will be submitted in accordance with local regulations.
Any and all scientific, commercial, and technical information disclosed by [CONTACT_108123]. The Investigator shall hold such information in confidence and shall not disclose the information to any third party except to such of the Investigator’s employees and staff who had been made aware that the information is confidential and who are bound to treat it as such and to whom disclosure is necessary to evaluate that information. The Investigator shall not use such information for any purpose other than for determining mutual interest in performing the study and, if the parties decide to proceed with the study, for the purpose of conducting the study.
The Investigator understands that the information de veloped from this clinical study will be used 
by [CONTACT_108124], to the [LOCATION_003] Food and Drug Administration, and to other government agencies. The Investigator also understands that, to allow for the use of the information derived from the clinical study, the Investigator has the obligation to provide the Sponsor with complete test results and all data developed in the study.
No publication or disclosure of study results will be permitted except under the terms and 
conditions of a separate written agreement.
Data Quality Assurance
All participant study data will be recorded on printed or electronic eCRFs or transmitted to the
Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying that data entries are complete, accurate,  legible, and timely by [CONTACT_108125]. Details for managing eCRFs are in the Operations Manual.
For PRO data (e.g., quality of life and pain assessments), ePRO will be used. Paper collection can 
be used only when electronic collection is not readily available. Phone interview of PRO data collection will also be utilized at 12-week  Safety Follow-up visit. 
The Investigator will maintain accurate documentation (source data) that supports the information 
in the eCRF.
The Investigator will permit study-related monitoring, quality assurance audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to the study file and source data.
Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N93/156responsibilities and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on-site monitoring) are in the Monitoring Plan or contracts.
The Sponsor or designee is responsible for data management of this study, including quality 
checking of the data and maintaining a validated d atabase. Database lock will occur once quality 
control and quality assurance procedures have been completed. PDF files of the eCRFs will be downloaded from the system by [CONTACT_108126]. Details will be outlined in 
Data Management documents and procedures.
Study monitors will perform ongoing source data verifi cation to confirm that data in the eCRF are 
accurate, complete, and verifiable; that the safe ty and rights of participants are being protected; 
and that the study is being conducted per the currently approved protocol and any other study agreements, ICH GCP, the Japanese ministerial ordinance on GCP, and all applicable regulatory requirements.
The Investigator will retain records and documents, including signed ICFs, pertaining to the 
conduct of this study for 15 years after study completion, unless local regulations, institutional policies, or the Sponsor requires a longer retention. No records may be destroyed during the retention period without the Sponsor’s written approval. No records may be transferred to another location or party without the Sponsor’s written notification.
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected.
The Investigator will keep a paper or electronic file (medical file and original medical records) at 
the site for each study participant. The file will identify each participant, contain the following demographic and medical information for the participant, and will be as complete as possible:
!Participant’s full name, date of birth, sex, height, and weight
!Medical history and concomitant diseases
!Prior and concomitant therapi[INVESTIGATOR_014] (including changes during the study)
!Study identifier (i.e., the Sponsor’s study number) and participant’s study number
!Dates of entry into the study (i.e., signature [CONTACT_108167]) and each visit to the 
site
!Any medical examinations and clinical findings predefined in the protocol
!All AEs
!Date that the participant left the study, including any reason for early withdrawal from the study 
or study intervention, if applicable.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N94/156Data recorded on printed or electronic eCRFs that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Source documents are stored at the site for the longest possible time permitted by [CONTACT_108127], and/or as per ICH GCP guidelines, whichever is longer. The Investigator or in Japan: a record retainer designated by [CONTACT_108128]’s written approval.
Definition of what constitutes source data is found in the SIV training materials and online study 
modules.
Study and Site Start and Closure
Study Start 
!The study start date is the date when the clinical study will be open for recruitment.
!The first act of recruitment is the first date that the first ICF is signed. This will be the study
start date.
Study Closure and Site Termination
!The Sponsor reserves the right to close the study site or terminate the study at any time and for 
any reason. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have  been collected and a site closure visit has 
been completed.
!The Investigator may initiate site closure at any time, provided there is reasonable cause and 
enough notice is given in advance of the intended termination.
!Reasons for the early closure of a study site by [CONTACT_108129]:
oFailure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local Health Authorities, the Sponsor’s procedures, or GCP guidelines
oInadequate recruitment of participants by [CONTACT_108130]’s compound.
!If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator will promptly inform the participants and assure appropriate participant therapy and/or follow-up.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N95/156Appendix 3 Contraception
Contraceptive use by [CONTACT_108131]. 
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile, as specified below. 
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before the first dose of study intervention, consider additional evaluation. 
A WOCBP is not: 
1. Premenarchal 2. A premenopausal female with 1 of the following: 
!Documented hysterectomy 
!Documented bilateral salpi[INVESTIGATOR_1656] 
!Documented bilateral oophorectomy.
Documentation can come from the site personnel’s review of the female’s medical records, 
medical examination, or medical history interview. 
For a female with permanent infertility due to an alternate medical cause other than the above, 
(e.g., mullerian agenesis, androgen insensitivity), Investigator discretion applies to determine study entry. 
3. A postmenopausal female 
!A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
oA high follicle-stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in a female not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of [ADDRESS_120023] discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N96/156CONTRACEPTIVES ALLOWED DURING THE STUDY
Highly Effective Methods That Have Low User Dependency 
!Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation* 
!Intrauterine device (IUD) 
!Intrauterine hormone-releasing system (IUS) 
!Bilateral tubal occlusion 
!Vasectomized partner: a highly effective contraceptive method provided that the partner 
is the sole sexual partner of a WOCBP and the absence of sperm has been confirmed. Otherwise, use an additional highly effective method of contraception. The spermatogenesis cycle is approximately 90 days. 
Highly Effective Methods That Are User Dependent 
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation 
!Oral 
!Intravaginal* 
!Transdermal* 
!Injectable* 
!Progestogen-only hormone contraception associated with inhibition of ovulation 
!Oral 
!Injectable* 
!Sexual abstinence: a highly effective method only if defined as refraining from 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study. 
Notes: 
Contraceptive use by [CONTACT_108132]. 
Highly effective methods are those with a failure rate of < 1% per year when used 
consistently and correctly.
Typi[INVESTIGATOR_107921]. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for this study. Male condom and female condom cannot be used together (due to risk of failure with friction). 
*Not approved in Japan
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N97/156Appendix 4 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Definitions
Adverse Event
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, 
regardless of causal relationship with this treatme nt. Therefore, an AE can be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product.
For surgical or diagnostic procedures, the condition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.
The Investigator is required to grade the severity or toxicity of each AE.Investigators will reference the NCI-CTCAE, v5.0 (publication date: 27 November 2017), a 
descriptive terminology that can be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
If the severity for an AE is not specifically grad ed by [CONTACT_12134]-CTCAE, the Investigator is to use the 
general NCI-CTCAE definitions of Grade [ADDRESS_120024] medical judgment.
The 5 general grades are:
Grade [ADDRESS_120025] also be reported as an SAE. However, a 
laboratory abnormality of Grade 4, such as anemia or ne utropenia, is considered serious only if the 
condition meets one of the serious criteria specified below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death will not be recorded as separate event. Only, if no cause of death can be reported (e.g., sudden death, unexplained death), the death per se might then be reported as an SAE.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N98/156Investigators must also systematically assess the causal relationship of AEs to study intervention 
(including any other non-study interventions, radiation therapy, etc.) using the following definitions. Decisive factors for the assessment of causal relationship of an AE to the study intervention include, but may not be limited to, temporal relationship between the AE and the study intervention, known side effects of study intervention, medical history, concomitant medication, course of the underlying disease, and study procedures.
Unrelated: Not reasonably related to the study intervention. AE could not medically 
(pharmacologically/clinically) be attributed to the study intervention under study in this clinical study protocol. A reasonable alternative explanation must be available.
Related: Reasonably related to the study intervention. AE could medically 
(pharmacologically/clinically) be attributed to the study intervention under study in this clinical study protocol.
Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (e.g., on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to study intervention discontinuation or are considered otherwise medically important by [CONTACT_737]. If a laboratory abnormality fulfills these criteria, the identified medical condition (e.g., anemia or increased ALT) must be reported as the AE rather than the abnormal value itself.
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:
!Results in death
!Is life-threatening. Life-threatening refers to an event in which the participant is at risk of 
death at the time of the event, not an event that hypothetically might have caused death if it 
was more severe.
!Requires inpatient hospi[INVESTIGATOR_43928]
!Results in persistent or significant disability or incapacity
!Is a congenital anomaly or birth defect
!Is otherwise considered to be medically important (e.g., new cancer). Important medical 
events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_107922], based upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that 
do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N99/156For the purposes of reporting, any suspected transmission of an infectious agent via a study 
intervention is also considered an SAE, as specified below for reporting SAEs.
Events that Do Not Meet the Definition of an SAE
Elective hospi[INVESTIGATOR_43930], or to simplify study intervention or procedures (e.g., an 
overnight stay to facilitate intravenous therapy) are not considered SAEs. However, all events leading to unplanned hospi[INVESTIGATOR_43931] (i.e., undesirable effects of any administered treatment) must be documented and reported as SAEs.
Events Not to Be Considered as AEs/SAEs
Medical conditions present at the initial study visit that do not worsen in severity or frequency 
during the study are defined as Baseline Medical Conditions and are not to be considered AEs.
AE/SAEs Observed in Association with Disease Progression
Progression of the disease/disorder being studied assessed by [CONTACT_108133] (including laboratory abnormalities) should not be reported as an (S)AE, unless the participant’s general condition is more severe than expected for the participant’s condition and/or unless the outcome is fatal within the adverse event reporting period, as defined in Section  8.3.2.  
Adverse Events of Special Interest
Infusion-related reactions including hypersensitivity, irAEs, TGF- β inhibition mediated skin 
reactions, anemia, and bleeding AEs are all considered as AESIs for bintrafusp alfa.
Other Adverse Events to be Reported Following a Specialized Procedure 
Not applicable.
Recording and Follow-up of AE and/or SAE
It is important that each AE report include a description of the event, its duration (onset and 
resolution dates and also onset and resolution times, when it is important to assess the time of AE onset relative to the recorded study interventi on administration time), its severity, its causal 
relationship with the study intervention, any other potential causal factors, any treatment given or other action taken, including dose modification or discontinuation of the study intervention, and its outcome. In addition, serious cases should be identified, and the appropriate seriousness criteria documented.
Specific guidance is in the eCRF Completion and Monitoring Conventions provided by [CONTACT_429].
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N100/156Reporting Serious Adverse Events
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 HOURS after becoming aware of the event) inform the Sponsor or its designee using the electronic SAE report form in the Electronic Data Capture (EDC) system.
Reporting of SAEs using a paper report form is required as a back-up method only for an EDC 
system failure. Names, addresses, and telephone and fax numbers will be included on the paper form. All information from the paper form must be transcribed into the electronic form as soon as the system becomes available.
In exceptional circumstances, an SAE (or follow-up information) may be reported by [CONTACT_756]; 
in these cases, an electronic SAE report form must be completed immediately thereafter.
Relevant pages from the eCRF may be provided in parallel (e.g., medical history, concomitant 
drugs). Additional documents may be provided by  [CONTACT_737], if available (e.g., laboratory 
results, hospi[INVESTIGATOR_27450], autopsy report). 
The Investigator must respond to any reque st for follow-up information (e.g., additional 
information, outcome, final evaluation, other records where needed) or to any question the Sponsor/designee may have on the AE within the same timelines as those noted above for initial reports. This is necessary to ensure prompt assessment of the event by [CONTACT_43971] (as applicable) to allow the Sponsor to meet strict regulatory timelines associated with expedited safety reporting obligations.
Requests for follow-up will usually be made via the study monitor, although in exceptional 
circumstances the drug safety department may cont act the Investigator directly to obtain further 
information or to discuss the event.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N101/156Appendix 5 The Recommendations for irAE Management
This appendix provides recommendations to the Investigators for the management of irAEs. The 
contents are based on the NCCN irAE management guidelines (in Accordance with the Joint American Society of Clinical Oncology Clinical Practice Guidelines and National Comprehensive Cancer Network, Brahmer JR, 2018) and FDA recommendations to require permanent treatment 
discontinuation for G4 irAEs (unless otherwise indicated in the tables below). Differences with 
ASCO/NCCN irAE management guidelines as recommended by [CONTACT_108134]. Critical instructions include the requirement that treatment must be permanently discontinued for the following Grade 4 irAE toxicities: Rash/inflammatory dermatitis, nephritis, autoimmune hemolytic anemia, hemolytic uremic syndrome, aplastic anemia, immune thrombocytopenia, acquired TTP, and in certain circumstances, lymphopenia.
Table of Tables
Table A1 Management of Skin irAEs in Patients Treated With ICPis.............102
Table A2 Management of GI irAEs in Patients Treated With ICPis................107Table A3 Management of Lung irAEs in Patients Treated With ICPis ...........111Table A4 Management of Endocrine irAEs in Patients Treated With ICPis ...112Table A5 Management of Musculoskeletal irAEs in Patients Treated With 
ICPis .................................................................................................117
Table A6 Management of Renal irAEs in Patients Treated With ICPis...........121Table A7 Management of Nervous System irAEs in Patients Treated With 
ICPis .................................................................................................123
Table A8 Management of Hematologic irAEs in Patients Treated With 
ICPis .................................................................................................128
Table A9 Management of Cardiovascular irAEs in Patients Treated With 
ICPis .................................................................................................135
Table A10 Management of Ocular irAEs in Patients Treated With ICPis.........137
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N102/156Table A1 Management of Skin irAEs in Patients Treated With ICPis
1.0 Skin Toxicities
1.1 Rash/in ﬂammatory dermatitis
Deﬁnition: Erythema multiforme minor (a targetoid reaction in the skin and mucous membranes usually triggered 
by [CONTACT_79422], such as herpes simplex viruses, but can be associated with an immune-related drug eruption and if 
progresses to erythema multiforme major, it and can be a harbinger of SCAR, such as SJS), lichenoid (resembling 
the ﬂat-topped, polygonal, and sometimes scaly or hypertrophic lesions of lichen-planus), eczematous 
(inﬂammatory dermatitis characterized by [CONTACT_108135], erythematous, scaly, or crusted papules or plaques on the skin, 
which is vulnerable to superinfection, psoriasiform [resembling the well-demarcated, erythematous, and scaly 
papules and plaques of psoriasis], morbilliform [a nonpustular, nonbullous measles-like exanthematous rash of the 
skin often referred to as “maculopapular”] and without systemic symptoms or laboratory abnormalities, excluding occasional isolated peripheral eosinophilia, palmoplantar erythrodysesthesia [hand-foot syndrome; redness, numbness, burning, itching, and super ﬁcial desquamation of the palms and soles], neutrophilic dermatoses [e.g., 
Sweet syndrome], and others)
Diagnostic work-up
Pertinent history and physical examination
Rule out any other etiology of the skin problem, such as an infection, an effect of another drug, or a skin condition 
linked to another systemic disease or unrelated primary skin disorder
If needed, a biologic checkup, including a blood cell count and liver and kidney testsDirected serologic studies if an autoimmune condition is suspected, such as lupus or dermatomyositis: a screening 
antinuclear antibody test, SS-A/Anti-Ro, SS-B/Anti-La if predominantly photodistributed/photosensitivity, antihistone, double-stranded DNA, and other relevant serologies. Consider expanding serologic studies or 
diagnostic work-up if other autoimmune conditions are considered based on signs, symptoms Skin biopsy
Consider clinical monitoring with use of serial clinical photographyReview full list of patient medications to rule out other drug-induced cause for photosensitivity
Grading Management
Grading according to CTCAE is a challenge for skin. 
Instead, severity may be based on BSA, tolerability, 
morbidity, and duration
G1: Symptoms do not affect the quality of life or 
controlled with topi[INVESTIGATOR_107923]/or oral antipruriticContinue ICPi
[INVESTIGATOR_107924]/or mild-moderate 
potency topi[INVESTIGATOR_107925]
G2: In ﬂammatory reaction that affects quality of life and 
requires intervention based on diagnosisConsider holding ICPi [INVESTIGATOR_107926]. If not resolved, interrupt treatment until skin AE has reverted to Grade 1
Consider initiating prednisone (or equivalent) at dosing 
1 mg/kg, tapering over at least 4 weeks
In addition, treat with topi[INVESTIGATOR_39669], oral 
antihistamines, and medium- to high-potency topi[INVESTIGATOR_11930]
G3: As G2 but with failure to respond to indicated interventions for a G2 dermatitisHold ICPi [INVESTIGATOR_107927], oral antihistamines, and 
high-potency topi[INVESTIGATOR_107928] (methyl)prednisolone (or equivalent) 1-2 mg/kg, 
tapering over at least 4 weeks
G4: All severe rashes unmanageable with prior 
interventions and intolerablePermanently discontinue ICPi
[INVESTIGATOR_107929]: IV (methyl)prednisolone (or 
equivalent) dosed at 1-2 mg/kg with slow tapering when 
the toxicity resolves
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N103/156Monitor closely for progression to severe cutaneous 
adverse reaction
Should admit patient immediately with direct oncology 
involvement and with an urgent consult by [CONTACT_108136]
1.2 Bullous dermatoses
Deﬁnition: Including bullous pemphigoid or other autoimmune bullous dermatoses, bullous drug reaction
Diagnostic work-up
Physical examinationRule out any other etiology of the skin problem, such as an infection, an effect of another drug, or a skin condition 
linked to another systemic disease
If needed, a biologic checkup, including a blood cell count, liver, and kidney tests; consider serum antibody tests to 
rule out bullous pemphigoid or, under the guidance of dermatology, sending patient serum for indirect 
immuno ﬂuorescent testing to rule out other autoimmune blistering diseases
Referral to dermatology for blisters that are not explained by [CONTACT_108137] (e.g., herpes 
simplex, herpes zoster, bullous impetigo, bullous insect bite, friction or pressure blister)
Consider skin biopsy (both hematoxylin and eosin evaluation of lesional skin and direct immuno ﬂuorescence 
evaluation of perilesional skin)
Grading Management
G1: Asymptomatic, blisters covering < 10% BSA and no associated erythemaIf blisters are < 10% BSA, asymptomatic, and 
nonin ﬂammatory (such as the case with friction blisters 
or pressure blisters), cessation of ICPi [INVESTIGATOR_107930], and only observation and/or local wound care is 
warranted.
When symptomatic bullae or erosions, which are 
deroofed vesicles or bullae, are observed on the skin or 
mucosal surfaces, the cutaneous irAE is by [INVESTIGATOR_5328] ﬁnition 
considered at least G2
See G2 management recommendations
G2: Blistering that affects quality of life and requires 
intervention based on diagnosis not meeting criteria for Grade > 2
Blisters covering 10%-30% BSAHold ICPi [INVESTIGATOR_107931]-up and to determine appropriateness of resuming
Attention given to general local wound care, which 
includes plain petrolatum ointment and bandages or plain petrolatum ointment gauze and bandage over any 
open erosions, which are left over on the skin after the 
blister has popped or if the roof of the blister easily sloughs off
Counsel patients to avoid skin irritants and 
overexposure to sun, wear protective clothing, use 
sunscreens
Work-up for autoimmune bullous disease as 
aboveInitiate Class 1 high-potency topi[INVESTIGATOR_11977] (e.g., clobetasol, betamethasone or equivalent) and reassess every 3 days for progression or improvement
Low threshold to initiate treatment with prednisone (or 
equivalent) at 0.5-1 mg/kg dosing and taper over at 
least 4 weeks
Monitor patients with G2 irAEs closely for progression 
to involvement of greater BSA and/or mucous membrane involvement. Consider following patients closely using serial photography
Primer on monitoring for complicated cutaneous 
adverse drug reactions:
Review of systems: Skin pain (like a sunburn), fevers, malaise, myalgias, arthralgias, abdominal pain, ocular 
discomfort or photophobia, sores or discomfort in the 
nares, sores or discomfort in the oropharynx, 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N104/156odynophagia, hoarseness, dysuria, sores or discomfort 
in the vaginal area for women or involving the meatus of the penis for men, sores in the perianal area, or pain with bowel movements
Physical examination: Include vital signs and a full skin examination speci ﬁcally evaluating all skin surfaces and 
mucous membranes (eyes, nares, oropharynx, genitals, 
and perianal area). Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of DIHS/DRESS). Assess for pustules or blisters or erosions in addition to areas of “dusky erythema,” which 
may feel painful to palpation. To assess for a positive 
Nikolsky sign, place a gloved ﬁnger tangentially over 
erythematous skin and apply friction parallel to the skin surface. Nikolsky sign is positive if this results in 
detached or sloughing epi[INVESTIGATOR_107932], which is the case in some autoimmune disorders (eg, pemphigus) and SJS/TEN
G3: Skin sloughing covering > 30% BSA with associated pain and limiting self-care ADLHold ICPi [INVESTIGATOR_107933] (methyl)prednisolone (or equivalent) 1-2 
mg/kg, tapering over at least [ADDRESS_120026] secondary cellulitis or if patient has other infection 
risk factors, such as neutropenia, etc.
G4: Blisters covering > 30% BSA with associated ﬂuid 
or electrolyte abnormalitiesPermanently discontinue ICPi
[INVESTIGATOR_107934] a dermatologist
Administer IV (methyl)prednisolone (or equivalent) 1-2 
mg/kg with tapering over at least [ADDRESS_120027] secondary cellulitis or if patient has other infection 
risk factors, such as neutropenia, etc.
1.3 SCARs, including SJS, TEN, acute generalized exanthematous pustulosis, and DRESS/DIHS
Deﬁnition: Severe changes in either structure or functions of skin, the appendages or the mucous membranes due 
to a drug
Diagnostic work-up
Total body skin examination with attention to examining all mucous membranes as well as complete review of 
systems
Rule out any other etiology of the skin problem, such as an infection, an effect of another drug, or a skin condition 
linked to another systemic disease.
A biologic checkup, including a CBC with differential test, and liver and kidney function tests, including urinalysis, 
in addition to the blood work; if the patient is febrile, blood cultures should be considered as well.
Skin biopsies to assess for full-thickness epi[INVESTIGATOR_59373], as is seen in SJS/TEN, as well as other possible 
etiologies like paraneoplastic pemphigus or other autoimmune blistering dermatoses or other drug reactions, such as acute generalized exanthematous pustulosis.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N105/156Consider following patients closely using serial clinical photography.
If mucous membrane involvement or blistering is observed on the skin, consider early admission to a burn center 
for further monitoring and management Primer on monitoring for complicated cutaneous adverse drug reactions:
Review of systems: Skin pain (like a sunburn), fevers, malaise, myalgias, arthralgias, abdominal pain, ocular 
discomfort or photophobia, sores or discomfort in the nares, sores or discomfort in the oropharynx, odynophagia, hoarseness, dysuria, sores or discomfort in the vaginal area for women or involving the meatus of the penis for men, sores in the perianal area, or pain with bowel movements.
Physical examination: Include vital signs and a full skin examination speci ﬁcally evaluating all skin surfaces and 
mucous membranes (eyes, nares, oropharynx, genitals, and perianal area). Assess for lymphadenopathy, facial or 
distal extremity swelling (may be signs of DIHS/DRESS). Assess for pustules or blisters or erosions in addition to 
areas of “dusky erythema,” which may feel painful to palpation. To assess for a positive Nikolsky sign, place a gloved ﬁnger tangentially over erythematous skin and apply friction parallel to the skin surface. Nikolsky sign is 
positive if this results in detached or sloughing epi[INVESTIGATOR_107935], which is the case in some autoimmune disorders (e.g., pemphigus) and SJS/TEN.
Grading Management
All Grades In cases of suspected SJS or any mucous membrane 
involvement, discontinue ICPi [INVESTIGATOR_107936], regardless of grade
G1: NA For SCARs, there is no G1 category; if lower BSA is 
involved with bullae or erosions, there should remain a high concern that this reaction will progress to G3 or G4
G2: Morbilliform (“maculopapular”) exanthem covering 10%-30% BSA with systemic symptoms, lymphadenopathy, or facial swellingHold ICPi [INVESTIGATOR_107937] 3 days 
with G2 irAEs for progression to involvement of greater BSA and/or mucous membrane involvement
Consider following patients closely using serial 
photography
Initiate therapy with topi[INVESTIGATOR_39669], oral 
antihistamines, and medium- to high-strength topi[INVESTIGATOR_107938] (or equivalent) 0.5-1 
mg/kg tapered over at least 4 weeks
G3: Skin sloughing covering < 10% BSA with mucosal involvement associated signs (e.g., erythema, purpura, epi[INVESTIGATOR_89152], mucous membrane detachment)Hold ICPi [INVESTIGATOR_107939], oral antihistamines, and high-strength 
topi[INVESTIGATOR_11930]; dimethicone may also be offered as an alternative to petrolatum
Administer IV (methyl)prednisolone (or equivalent) 0.5-1 
mg/kg and convert to oral corticosteroids on response, 
wean over at least 4 weeks
Admit to burn and/or consult wound services with 
attention to supportive care, including ﬂuid and 
electrolyte balance, minimizing insensible water losses, and preventing infection
Given the immune mechanism of action of these 
medicines, use of immune suppression is warranted 
and should be offered
For mucous membrane involvement of SJS or TEN, 
appropriate consulting services should be offered to guide management in preventing sequelae from scarring (e.g., ophthalmology; ear, nose, and throat; 
urology; gynecology; etc., as appropriate)
G4: Skin erythema and blistering/sloughing covering 
≥10% to > 30% BSA with associated signs (e.g., 
erythema, purpura, epi[INVESTIGATOR_89152], mucous membrane detachment) and/or systemic symptoms and concerning associated blood work abnormalities (e.g., Permanently discontinue ICPi
[INVESTIGATOR_107940] a burn unit or ICU with 
consulted dermatology and wound care services
Consider further consultations based on management 
of mucosal surfaces
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N106/156Abbreviations: ADL, activities of daily living; AE, adverse event; BSA, body surface area; CBC, complete blood count; 
CTCAE, Common Terminology Criteria for Adverse Events; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug reaction with eosinophilia and systemic symptoms; G, Grade; ICPi, immune checkpoint inhibitor; ICU, intensive care unit; irAE, immune-related adverse event; IV, intravenous; IVIG, intravenous immunoglobulin; NA, not 
applicable; SCAR, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TENS, toxic epi[INVESTIGATOR_7387].liver function test elevations in the setting of 
DRESS/DIHS)(e.g., ophthalmology; urology; gynecology; ear, nose, 
and throat surgery; etc.) Initiate IV (methyl)prednisolone (or equivalent) 1-2 mg/kg, tapering when toxicity resolves to normal
IVIG or cyclosporine may also be considered in severe 
or corticosteroid-unresponsive cases
Consider pain/palliative consultation and/or admission 
in patients presenting with DRESS manifestations
Additional considerations: The usual prohibition of corticosteroids for SJS is not relevant here, as the underlying 
mechanism is a T-cell immunodirected toxicity
Adequate suppression is necessary with corticosteroids or other agents and may be prolonged in cases of 
DRESS/DIHS
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N107/156Table A2 Management of GI irAEs in Patients Treated With ICPis
2.0 GI Toxicities
2.1 Colitis
Deﬁnition: A disorder characterized by [INVESTIGATOR_2993] ﬂammation of the colon
Diagnostic work-up
G2
Work-up of blood (CBC, comprehensive metabolic panel, TSH, ESR, CRP), stool (culture, Clostridium difficile, 
parasite, CMV or other viral etiology, ova and parasite) should be performed
Consider testing for lactoferrin (for patient strati ﬁcation to determine who needs more urgent endoscopy) and 
calprotectin (to follow-up on disease activity)
Screening laboratories (HIV, hepatitis A and B, and blood quantiferon for TB) to prepare patients to start in ﬂiximab 
should be routinely done in patients at high risk for those infections and appropriately selected patients based oninfectious disease expert’s evaluation
Imaging (e.g., CT scan of abdomen and pelvis and GI endoscopy with biopsy) should be considered as there is 
evidence showing that the presence of ulceration in the colon can predict a corticosteroid refractory course, which may require early in ﬂiximab
Consider repeating endoscopy for patients who do not respond to immunosuppressive agents; repeating 
endoscopy for disease monitoring can be considered when clinically indicated and when planning to resume 
therapy
G3-4
All the work-up listed for G2 (blood, stool, imaging, and scope with biopsy) should be completed immediately
Consider repeating endoscopy for patients who do not respond to immunosuppressive agents; repeating 
endoscopy for disease monitoring should only be considered when clinically indicated and when planning to 
resume ICPi
[INVESTIGATOR_107941] (based on CTCAE for diarrhea, as most often used clinically)Management
All patients Counsel all patients to be aware of and inform their 
health care provider immediately if they experience:
Abdominal pain, nausea, crampi[INVESTIGATOR_007], blood or mucus in 
stool or changes in bowel habits, fever, abdominal distention, obstipation, constipation
For G2 or higher, consider permanently discontinuing 
CTLA-4 agents and may restart PD-1, PD-L1 agents if 
patient can recover to G1 or less; concurrent 
immunosuppressant maintenance therapy should be considered only if clinically indicated in individual cases
G1: Increase of fewer than four stools per day over baseline; mild increase in ostomy output compared with baselineContinue ICPi; alternatively, ICPi [INVESTIGATOR_107942]
G1Monitor for dehydration and recommend dietary 
changes Facilitate expedited phone contact [CONTACT_10974]/caregiver May obtain gastroenterology consult 
for prolonged G1 cases
G2: Increase of four to six stools per day over baseline; 
moderate increase in ostomy output compared with baselineShould hold ICPi [INVESTIGATOR_107943]’s symptoms 
recover to G1; can consider permanently
discontinuing CTLA-4 agents and may restart PD-1, 
PD-L1 agents if patient can recover to G1 or less
Concurrent immunosuppressant maintenance therapy 
(10 mg prednisone equivalent dose) may be offered only if clinically indicated in individual cases
May also include supportive care with medications such 
as Imodium if infection has been ruled out
Should consult with gastroenterology for G2 or higher
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N108/1562.0 GI Toxicities
Administer corticosteroids, unless diarrhea is transient, 
starting with initial dose of 1 mg/kg/day prednisone or
equivalent
When symptoms improve to G1 or less, taper 
corticosteroids over at least 4-6 weeks before resuming treatment, although resuming treatment while on low-dose corticosteroid may also be an option after an 
evaluation of the risks and bene ﬁts
EGD/colonoscopy, endoscopy evaluation should be 
highly recommended for cases Grade ≥2 to stratify 
patients for early treatment with in ﬂiximab based on the 
endoscopic ﬁndings and to determine the safety of 
resuming PD-1, PD-L1 therapy
Stool in ﬂammatory markers can be considered 
(lactoferrin and calprotectin) in cases of G2 or higher to 
differentiate functional versus in ﬂammatory diarrhea, 
and use calprotectin to monitor treatment response if provider prefers
Repeat colonoscopy is optional for cases of G2 or 
higher for disease activity monitoring to achieve 
complete remission, especially if there is a plan to resume ICPi
G3: Increase of seven or more stools per day over baseline, incontinence, hospi[INVESTIGATOR_374], severe increase in ostomy output compared with baseline, 
limiting self-care ADLShould consider permanently discontinuing CTLA-4 
agents and may restart PD-1, PD-L1 agents if patient can recover to G1 or less.
Administer corticosteroids (initial dose of 1-2 mg/kg/d 
prednisone or equivalent)
Consider hospi[INVESTIGATOR_107944] ≥3-5 days or recur after 
improvement, consider administering IV corticosteroid or noncorticosteroid (e.g., in ﬂiximab)
Consider colonoscopy in cases where patients have 
been on immunosuppression and may be at risk for opportunistic infections as an independent cause for 
diarrhea (i.e., CMV colitis) and for those who are anti-
TNF or corticosteroid refractory
G4: Life-threatening consequences; urgent intervention indicatedPermanently discontinue treatment
Should admit patient when clinically indicated; patients 
managed as outpatients should be very closely monitored
Administer 1-2 mg/kg/d methylprednisolone or 
equivalent until symptoms improve to G1, and then start taper over 4-6 weeks
Consider early in ﬂiximab 5-10 mg/kg if symptoms 
refractory to corticosteroid within 2-3 days Consider 
lower GI endoscopy if symptoms are refractory despi[INVESTIGATOR_107945] (not approved in Japan) may be considered in patients refractory to in ﬂiximab and/or 
contraindicated to TNF-a blocker. The decision should be made on an individual basis from gastroenterology and oncology evaluation. This is based on case series showing promising results
Patients with hepatitis and irAE colitis are rare, and management should include permanently discontinuing ICPi 
[INVESTIGATOR_107946], enteritis alone as the cause of diarrhea is uncommon and requires small bowel biopsy as the evaluation 
tool. It may be managed similar as colitis, including corticosteroid and/or in ﬂiximab, etc.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N109/1562.0 GI Toxicities
2.2 Hepatitis
Deﬁnition: A disorder characterized by a viral pathologic process involving the liver parenchyma
Diagnostic work-upMonitor patient for abnormal liver blood tests: AST, ALT, and bilirubin prior to each infusion and/or weekly if G1 
liver function test elevations. No treatment is recommended for G1 liver function test abnormality
For G2 or higher:Work-up for other causes of elevated liver enzymes should be tested, viral hepatitis, alcohol history, iron study, 
thromboembolic event, liver ultrasound, cross-sectional imaging for potential liver metastasis from primary malignancy. If suspi[INVESTIGATOR_107947], can consider ANAs, antismooth muscle antibodies, antineutrophil cytoplasmic antibodies. If patients with elevated alkaline phosphatase alone, g-glutamyl
transferase should be tested. For isolated elevation of transaminases, consider checking CK for other etiologies
Grading Management
All patients Counsel all patients to be aware of and inform their 
health care provider immediately if they experience:
Yellowing of skin or whites of the eyes Severe nausea 
or vomiting
Pain on the right side of the abdomen DrowsinessDark urine (tea colored)Bleeding or bruising more easily than normal Feeling 
less hungry than usual
G1: Asymptomatic (AST or ALT > ULN to 3.[ADDRESS_120028] and/or total bilirubin > ULN to 1.[ADDRESS_120029])Continue ICPi [INVESTIGATOR_107948]; consider alternate 
etiologies
Monitor laboratories one to two times weeklyManage with supportive care for symptom control
G2: Asymptomatic (AST or ALT > 3.0 to ≤[ADDRESS_120030] 
and/or total bilirubin > 1.5 to ≤[ADDRESS_120031])Hold ICPi [INVESTIGATOR_107949] G1 or 
less on prednisone ≤10 mg/d
For Grade 2 hepatic toxicity with symptoms, may 
administer corticosteroid 0.5-1 mg/kg/d prednisone or 
equivalent if the abnormal elevation persists with 
signi ﬁcant clinical symptoms in 3-[ADDRESS_120032] appropriate treatment 
option in the situation of immune-mediated hepatitis given the potential risk of idiosyncratic liver failure 
(Note: No clear evidence shows the liver toxicity from 
inﬂiximab from other studies)
In follow-up, may resume ICPi [INVESTIGATOR_107950] G1 or less and corticosteroid ≤10 mg/d; taper over at least 1 month
Patients should be advised to stop unnecessary 
medications and any known hepatotoxic drugs
G3: Symptomatic liver dysfunction, ﬁbrosis by [CONTACT_9256], 
compensated cirrhosis, reactivation of chronic hepatitis 
(AST or ALT 5-[ADDRESS_120033] and/or total bilirubin 3-10x3 
ULN)Permanently discontinue ICPi
[INVESTIGATOR_107951] 1-2 mg/kg 
methylprednisolone or equivalent
If corticosteroid refractory or no improvement after 3 
days, consider mycophenolate mofetil or azathioprine (if 
using azathioprine should test for thiopurine methyltransferase de ﬁciency)
Laboratories at daily or every other day; consider 
inpatient monitoring for patients with AST/ALT > [ADDRESS_120034] and/or elevated TB [ADDRESS_120035]
Increase frequency of monitoring to every 1-2 days
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N110/1562.[ADDRESS_120036] appropriate treatment 
option in the situation of immune-mediated hepatitis 
given the potential risk of liver failure (Note: No clear evidence shows that the liver toxicity from in ﬂiximab 
from other studies); alternatives include non–TNF-a 
agents as systemic immunosuppressants If no 
improvement is achieved with corticosteroids or for patients on combination therapy with a novel agent, with standard chemotherapy, or with targeted therapy, refer to hepatologist for further pathologic evaluation of 
hepatitis
Corticosteroid taper can be attempted around 4-6 
weeks; re-escalate if needed; optimal duration unclear
G4: Decompensated liver function (e.g., ascites, coagulopathy, encephalopathy, coma; AST or ALT > [ADDRESS_120037] and/or total bilirubin > [ADDRESS_120038])Permanently discontinue ICPi
[INVESTIGATOR_107952] 2 mg/kg/d methylprednisolone equivalents
If corticosteroid refractory or no improvement after 
3 days, consider mycophenolate mofetil
Monitor laboratories daily; consider inpatient monitoringAvoid the use of in ﬂiximab in the situation of 
immune-mediated hepatitis
Hepatology consult if no improvement was achieved 
with corticosteroid
Corticosteroid taper can be attempted around 4-6 
weeks when symptoms improve to G1 or less; re-escalate if needed; optimal duration unclear
Consider transfer to tertiary care facility if necessary
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations is moderate.
*not approved in Japan. 
Abbreviations: ADL, activities of daily living; ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, 
aspartate aminotransferase; CBC, complete blood count, CK, creatine kinase; CMV, cytomegalovirus; CRP, C-reactive protein; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; CTLA-4, 
cytotoxic T-cell lymphocyte-4; EGD, esophagogastroduodenoscopy; ESR, erythrocyte sedimentation rate; G, Grade; 
GI, gastrointestinal; HIV, human immunodeficiency virus; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; IV, intravenous; PD-1; programmed death 1; PD-L1, programmed death ligand 1; TB, tuberculosis; TNF, tumor necrosis factor; TSH, thyroid-stimulating hormone; ULN, upper limit of normal.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N111/156Table A3 Management of Lung irAEs in Patients Treated With ICPis
3.0 Lung Toxicities
3.1 Pneumonitis
Deﬁnition: Focal or diffuse in ﬂammation of the lung parenchyma (typi[INVESTIGATOR_107953] ﬁed on CT imaging)
No symptomatic, pathologic, or radiographic features are pathognomonic for pneumonitisDiagnostic work-up
Should include the following: CXR, CT, pulse oximetry
For G2 or higher, may include the following infectious work-up: nasal swab, sputum culture and sensitivity, blood 
culture and sensitivity, urine culture and sensitivity
Grading Management
G1: Asymptomatic, con ﬁned to one lobe of the lung or 
< 25% of lung parenchyma, clinical or diagnostic 
observations onlyContinue ICPi 
[INVESTIGATOR_107954]. Monitor participants weekly or 
more frequently as needed with history, physical examination and pulse oximetry; may also offer CXR. 
May offer one repeat CT scan in 3-4 weeks; in patients 
who have had baseline testing, may offer a repeat spi[INVESTIGATOR_038]/DLCO in 3-4 weeks 
If symptoms appear and/or changes in the physical 
exam are noted, treat as G2
G2: Symptomatic, involves more than one lobe of the lung or 25%-50% of lung parenchyma, medical 
intervention indicated, limiting instrumental ADLHold ICPi [INVESTIGATOR_107955] G1 or less
Prednisone 1-2 mg/kg/d and taper by 5-10 mg/wk over 
4-6 weeks Consider bronchoscopy with BAL
Consider empi[INVESTIGATOR_107956] 3 days with history and physical 
examination and pulse oximetry, consider CXR; no 
clinical improvement after 48-72 hours of prednisone, 
treat as G3
G3: Severe symptoms, hospi[INVESTIGATOR_91536], involves all lung lobes or 50% of lung parenchyma, limiting self-care
ADL, oxygen indicatedG4: Life-threatening respi[INVESTIGATOR_7798], urgent 
intervention indicated (intubation)Permanently discontinue ICPi
[INVESTIGATOR_107957]; (methyl)prednisolone IV 1-2 
mg/kg/d; no improvement after 48 hours, may add 
inﬂiximab 5 mg/kg or mycophenolate mofetil IV 1 g 
twice a day or IVIG for 5 days or cyclophosphamide; taper corticosteroids over 4-6 weeks
Pulmonary and infectious disease consults if necessaryBronchoscopy with BAL ± transbronchial biopsyPatients should be hospi[INVESTIGATOR_107958] 
(> 12 weeks), according to institutional guidelines
Consider calcium and vitamin D supplementation with prolonged corticosteroid useThe role of prophylactic ﬂuconazole with prolonged corticosteroid use (> 12 weeks) remains unclear, and 
physicians should proceed according to institutional guidelines
Bronchoscopy + biopsy; if clinical pi[INVESTIGATOR_107959], no need for biopsyAll recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: ADL, activities of daily living; BAL, bronchoalveolar lavage; CT, computed tomography; CXR, chest x-ray; DLCO, diffusing capacity of lung for carbon monoxide; G, Grade; GI, gastrointestinal; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; IV, intravenous; IVIG, intravenous immunoglobulin; PPI, proton pump 
inhibitor.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N112/156Table A4 Management of Endocrine irAEs in Patients Treated With ICPis
4.[ADDRESS_120039] visit, especially any of the following:
Headaches that will not go away or unusual headache patterns
Vision changesRapid heartbeatIncreased sweatingExtreme tiredness or weaknessMuscle achesWeight gain or weight lossDizziness or fainting
Feeling more hungry or thirsty than usual
Hair lossChanges in mood or behavior, such as decreased sex 
drive, irritability, or forgetfulness Feeling cold
Constipation
Voice gets deeperUrinating more often than usualNausea or vomitingAbdominal pain
4.1 Thyroid
4.1.1 Primary hypothyroidism
Deﬁnition: Elevated TSH, normal or low FT4
Diagnostic work-up
TSH and FT4 every 4-6 weeks as part of routine clinical monitoring on therapy or for case detection in 
symptomatic patients
Grading Management
G1: TSH < 10 mIU/L and asymptomatic
G2: Moderate symptoms; able to perform ADL; TSH 
persistently > 10 mIU/LShould continue ICPi [INVESTIGATOR_107960]-up and 
monitoring of TSH, FT4 May hold ICPi [INVESTIGATOR_107961] 
> 10 mIU/L (measured 4 weeks apart)
Monitor TSH every 6-8 weeks while titrating hormone 
replacement to normal TSH FT4 can be used in the short-term (2 weeks) to ensure adequacy of therapy in 
those with frank hypothyroidism where the FT4 was 
initially low
Once adequately treated, should monitor thyroid 
function (at least TSH) every 6 weeks while on active ICPi [INVESTIGATOR_107962]; repeat testing annually or as 
indicated by [CONTACT_108138]
G3-4: Severe symptoms, medically signi ﬁcant or life-
threatening consequences, unable to perform ADLHold ICPi [INVESTIGATOR_107963] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N113/1564.0 Endocrine Toxicity
May admit for IV therapy if signs of myxedema 
(bradycardia, hypothermia) Thyroid supplementation 
and reassessment as in G2
Additional considerations
For patients without risk factors, full replacement can be estimated with an ideal body weight–based dose of 
approximately 1.6 μg/kg/d
For elderly or fragile patients with multiple comorbidities, consider titrating up from low dose, starting at 25-50 mg
Extreme elevations of TSH can be seen in the recovery phase of thyroiditis and can be watched in asymptomatic 
patients to determine whether there is recovery to normal within 3-4 weeks
Under guidance of endocrinology, consider tapering hormone replacement and retesting in patients with a history 
of thyroiditis (initial thyrotoxic phase)
Adrenal dysfunction, if present, must always be replaced before thyroid hormone therapy is initiated 
4.1.2 Hyperthyroidism
Deﬁnition: Suppressed TSH and high normal or elevated FT4 and/or triiodothyronine
Diagnostic work-up
Monitor TSH, FT4 every 4-[ADDRESS_120040] disease (e.g., 
ophthalmopathy)
Close monitoring of thyroid function every 2-3 weeks after diagnosis to catch transition to hypothyroidism in 
patients with thyroiditis and hyperthyroidism
Grading Management
G1: Asymptomatic or mild symptoms Can continue ICPi [INVESTIGATOR_107960]-up and monitoring 
of TSH, FT4 every 2-3 weeks until it is clear whether 
there will be persistent hyperthyroidism (see below) or 
hypothyroidism (see 4.1.1)
Consider holding ICPi [INVESTIGATOR_107964]-Blocker (e.g., atenolol, propranolol) for symptomatic 
relief
Hydration and supportive careCorticosteroids are not usually required to shorten 
duration
For persistent hyperthyroidism (> 6 weeks) or clinical 
suspi[INVESTIGATOR_2798], work-up for Graves disease (TSI or TRAb) and consider thionamide (methimazole or PTU) Refer 
to endocrinology for Graves disease
G3-4: Severe symptoms, medically signi ﬁcant or life-
threatening consequences, unable to perform ADLHold ICPi [INVESTIGATOR_107965]
b-Blocker (e.g., atenolol, propranolol) for symptomatic 
relief
For severe symptoms or concern for thyroid storm, 
hospi[INVESTIGATOR_107966] 1-2 mg/kg/d 
or equivalent tapered over 1-2 weeks; consider also use of SSKI or thionamide (methimazole or PTU).
Additional considerations
Thyroiditis is transient and resolves in a couple of weeks to primary hypothyroidism or normal. Hypothyroidism can 
be treated as above. Graves’ disease is generally persistent and is due to increased thyroid hormone production that can be treated with antithyroid medical therapy. Physical examination ﬁndings of ophthalmopathy or thyroid 
bruit are diagnostic of Graves and should prompt early endocrine referral.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N114/1564.0 Endocrine Toxicity
4.2 Adrenal – primary adrenal insuf ﬁciency
Deﬁnition: Adrenal gland failure leading to low morning cortisol, high morning ACTH, as well as hyponatremia and 
hyperkalemia with orthostasis and volume depletion due to loss of aldosterone
Diagnostic work-up for patients in whom adrenal insuf ﬁciency is suspected:
Evaluate ACTH (AM), cortisol level (AM)Basic metabolic panel (Na, K, CO
2, glucose)
Consider ACTH stimulation test for indeterminate 
results
If primary adrenal insuf ﬁciency (high ACTH, low 
cortisol) is found biochemically:
Evaluate for precipi[INVESTIGATOR_107967]/hemorrhage
Grading Management
G1: Asymptomatic or mild symptoms Consider holding ICPi [INVESTIGATOR_107968] (5-10 mg daily) 
or hydrocortisone (10-20 mg orally every morning, 5-10 mg orally in early afternoon)
May require ﬂudrocortisone (0.1 mg/d) for 
mineralocorticoid replacement in primary adrenal 
insuf ﬁciency
Titrate dose up or down as symptoms dictate
G2: Moderate symptoms, able to perform ADL Consider holding ICPi [INVESTIGATOR_107969]
(if prednisone, 20 mg daily; if hydrocortisone, 20-30 mg 
in the morning, and 10-20 mg in the afternoon) to manage acute symptoms.
Taper stress-dose corticosteroids down to maintenance 
doses over 5-10 days
Maintenance therapy as in G1.
G3-4: Severe symptoms, medically signi ﬁcant or life-
threatening consequences, unable to perform ADLHold ICPi [INVESTIGATOR_107970], for after hours, make an emergency 
department referral for normal saline (at least 2 L) and 
IV stress-dose corticosteroids on presentation 
hydrocortisone 100 mg or dexamethasone 4 mg (if the diagnosis is not clear and stimulation testing will be needed)
Taper stress-dose corticosteroids down to maintenance 
doses over 7-14 days after discharge
Maintenance therapy as in G1
Additional considerationsPrimary and secondary adrenal insuf ﬁciency can be distinguished by [CONTACT_108139]. 
If the ACTH is low with low cortisol, then management is as per 4.3.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N115/1564.[ADDRESS_120041] low morning cortisol as a result of 
iatrogenic, secondary adrenal insuf ﬁciency. ACTH will also be low in these patients. A diagnosis of adrenal 
insuf ﬁciency is challenging to make in these situations (see next section on hypophysitis).
Emergent therapy for someone with suspected adrenal insuf ﬁciency is best done with dexamethasone as a 
stimulation test can still be performed. If the diagnosis is already con ﬁrmed, can use hydrocortisone 100 mg.
All patients need education on stress dosing and a medical alert bracelet for adrenal insuf ﬁciency to trigger stress-
dose corticosteroids by [CONTACT_108140].
Endocrine consultation prior to surgery or any procedure for stress-dose planning.
4.3 Pi[INVESTIGATOR_2117] - hypophysitis
Deﬁnition: In ﬂammation of the pi[INVESTIGATOR_107971]. Most commonly presenting with 
central adrenal insuf ﬁciency. May also have central hypothyroidism, diabetes insipi[INVESTIGATOR_27562], and hypogonadism. 
Diagnostic work-up
Diagnosis: Low ACTH with a low cortisol. Low or normal TSH with a low FT4. Hypernatremia and volume depletion 
with diabetes insipi[INVESTIGATOR_27562]. Low testosterone or estradiol with low LH and FSH.
Testing:Evaluate ACTH, cortisol (AM), TSH, FT4, electrolytesConsider evaluating LH, FSH, and testosterone levels in males or estrogen in premenopausal females with fatigue, 
loss of libido, and mood changes Consider MRI of the brain with or without contrast with pi[INVESTIGATOR_2117]/sellar cuts in patients with multiple endocrine abnormalities ± new severe headaches or complaints of vision changes
Grading Management
G1: Asymptomatic or mild symptoms Consider holding ICPi [INVESTIGATOR_107972] G1
G3-4: Severe symptoms, medically signi ﬁcant or life-
threatening consequences, unable to perform ADLHold ICPi [INVESTIGATOR_107973] G1Consider initial pulse dose therapy with prednisone 1-2 
mg/kg oral daily (or equivalent) tapered over at least 1-[ADDRESS_120042] when planning hormone replacement therapy for multiple 
deﬁciencies
All patients need instruction on doubling doses for illness (stress dosing) and a medical alert bracelet for adrenal 
insuf ﬁciency to trigger stress-dose corticosteroids by [CONTACT_108141] ﬁciency
Work-up cannot be done with a simple AM cortisol in a patient on corticosteroids for other conditionsLaboratory con ﬁrmation of adrenal insuf ﬁciency should not be attempted until treatment with corticosteroids for 
other disease is ready to be discontinued. For long-term exposure, consult endocrinology for recovery and weaning protocol using hydrocortisone.
4.4 Diabetes
Deﬁnition: T2DM is a combination of insulin resistance and insuf ﬁciency that may require oral or insulin therapy. It 
may be new onset or exacerbated during therapy for nonimmunologic reasons, such as corticosteroid exposure.
Autoimmune T1DM results from islet cell destruction and is often acute onset, with ketosis and an insulin 
requirement
Diagnostic work-upMonitor patients for hyperglycemia or other signs and symptoms of new or worsening DM, including measuring 
glucose at baseline and with each treatment cycle during induction for 12 weeks, then every 3-6 weeks thereafter. 
To guide the work-up in new-onset hyperglycemia, clinicians should consider a patient’s medical background, 
exposure history, and risk factors for each subtype of DM.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N116/1564.0 Endocrine Toxicity
Laboratory evaluation in suspected T1DM should include testing for ketosis in urine and an assessment of the 
anion gap on a metabolic panel. Anti–glutamic acid decarboxylase, anti–islet cell, or anti–insulin antibodies are 
highly speci ﬁc for autoimmune diabetes. Insulin and C-peptide levels can also assist in the diagnosis.
Grading Management
G1: Asymptomatic or mild symptoms; fasting glucose 
value > ULN (160 mg/dL); fasting glucose value > ULN (8.9 mmol/L); no evidence of ketosis or laboratory evidence of T1DMCan continue ICPi [INVESTIGATOR_107974]-up and 
laboratory evaluation
May initiate oral therapy for those with new-onset T2DM
Screen for T1DM if appropriate, for example, acute 
onset with prior normal values or clinical concern for 
ketosis
G2: Moderate symptoms, able to perform ADL, fasting glucose value > 160-250 mg/dL; fasting glucose value> 8.9-13.9 mmol/L, ketosis or evidence of T1DM at any glucose levelMay hold ICPi [INVESTIGATOR_107975] T2DM Should administer insulin for T1DM (or as 
default therapy if there is confusion about type)
Urgent endocrine consultation for any patient with 
T1DM; in the absence of endocrinology, internalmedicine may suf ﬁce
Consider admission for T1DM if early outpatient 
evaluation is not available or signs of ketoacidosis are 
present
G3-4: Severe symptoms, medically signi ﬁcant or life-
threatening consequences, unable to perform ADL
G3: > 250-500 mg/dL (> 13.9-27.8 mmol/L)G4: > 500 mg/dL (> 27.8 mmol/L)Hold ICPi [INVESTIGATOR_107976] G1 or less
Urgent endocrine consultation for all patientsInitiate insulin therapy for all patients
Admit for inpatient management: Concerns for 
developi[INVESTIGATOR_107977], Symptomatic patients regardless of 
diabetes type, New-onset T1DM unable to see endocrinology
Additional considerations
Insulin therapy can be used as the default in any case with hyperglycemiaLong-acting therapy alone is not usually suf ﬁcient for T1DM, where half of daily requirements are usually given in 
divided doses as prandial coverage and half as long acting.
Insulin doses will be lower in T1DM because of preserved sensitivity (total daily requirement can be estimated at 
0.3-0.4 units/kg/d).
In T2DM, sliding-scale coverage with meals over a few days provides data to estimate a patient’s daily 
requirements and can be used to more rapi[INVESTIGATOR_107978].
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: ACTH, adrenocorticotropic hormone; ADL, activities of daily living; CT, computed tomography; DKA, diabetic ketoacidosis; DM, diabetes mellitus; EMS, emergency medical services; FSH, follicle-stimulating hormone; 
FT4, free thyroxine; G, Grade; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; LH, luteinizing 
hormone; MRI, magnetic resonance imaging; PTU, propylthiouracil; 2L, second-line; SSKI, potassium iodide; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TRAb, thyroid-stimulating hormone receptor antibody; TSH, thyroid-stimulating hormone; TSI, thyroid-stimulating immunoglobulin; ULN, upper limit of normal.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N117/156Table A5 Management of Musculoskeletal irAEs in Patients Treated With ICPis
5.0 Musculoskeletal Toxicities
5.1 In ﬂammatory arthritis
Deﬁnition: A disorder characterized by [INVESTIGATOR_2993] ﬂammation of the joints
Clinical symptoms: Joint pain accompanied by [CONTACT_108142]; in ﬂammatory symptoms, such as stiffness after 
inactivity or in the morning, lasting > 30 minutes to 1 hour; improvement of symptoms with NSAIDs or corticosteroids but not with opi[INVESTIGATOR_107979] ﬂammatory arthritis.
Diagnostic work-up
G1Complete rheumatologic history and examination of all peripheral joints for tenderness, swelling, and range of 
motion; examination of the spi[INVESTIGATOR_107980] x-ray/imaging to exclude metastases and evaluate joint damage (erosions), if appropriate
Consider autoimmune blood panel including ANA, RF, and anti-CCP, and anti-in ﬂammatory markers (ESR and 
CRP) if symptoms persist; if symptoms are suggestive of reactive arthritis or affect the spi[INVESTIGATOR_050], consider HLA B27 
testing
G2
Complete history and examination as above; laboratory tests as aboveConsider US ± MRI of affected joints if clinically indicated (e.g., persistent arthritis unresponsive to treatment, 
suspi[INVESTIGATOR_107981])
Consider early referral to a rheumatologist, if there is joint swelling (synovitis) or if symptoms of arthralgia persist 
> [ADDRESS_120043] advice and reviewMonitoring: Patients with in ﬂammatory arthritis should be monitored with serial rheumatologic examinations, 
including in ﬂammatory markers, every 4-6 weeks after treatment is instituted.
Grading Management
All Grades Clinicians should follow reports of new joint pain to 
determine whether in ﬂammatory arthritis is present; 
question whether symptom new since receiving ICPi
G1: Mild pain with in ﬂammation, erythema, or joint 
swellingContinue ICPi
[INVESTIGATOR_107982]/or NSAIDs
G2: Moderate pain associated with signs of 
inﬂammation, erythema, or joint swelling, limiting 
instrumental ADLHold ICPi [INVESTIGATOR_107983] ≤10 mg/d 
Escalate analgesia and consider higher doses of 
NSAIDS as needed
If inadequately controlled, initiate prednisone or 
prednisolone 10-20 mg/d or equivalent for 4-6 weeks
If improvement, slow taper according to response 
during the next 4-6 weeks; if no improvement after initial 
4-6 weeks, treat as G3
If unable to lower corticosteroid dose to < 10 mg/d after 
[ADDRESS_120044]
Consider intra-articular corticosteroid injections for large 
joints
Referral to rheumatology
G3-4: Severe pain associated with signs of 
inﬂammation, erythema, or joint swelling; irreversible 
joint damage; disabling; limiting self-care ADLFor G3: Hold ICPi [INVESTIGATOR_107984], if recover to G1 or less
For G4: permanently discontinue ICPi[INVESTIGATOR_107985] 0.5-1 mg/kgIf failure of improvement after [ADDRESS_120045]
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N118/1565.0 Musculoskeletal Toxicities
Synthetic: methotrexate, le ﬂunomide
Biologic: consider anticytokine therapy such as TNF-a 
or IL-6 receptor inhibitors. (Note: As caution, IL-6 
inhibition can cause intestinal perforation; while this is 
extremely rare, it should not be used in patients with colitis.) Test for viral hepatitis B, C, and latent/active TB test prior to DMARD treatment
Referral to rheumatology.
Additional considerationsEarly recognition is critical to avoid erosive joint damage.Corticosteroids can be used as part of initial therapy in in ﬂammatory arthritis, but due to likely prolonged treatment 
requirements, physicians should consider starting corticosteroid-sparing agents earlier than one would with other irAEs
Oligoarthritis can be treated early on with intra-articular corticosteroids; consider early referral.Consider PCP prophylaxis for patients treated with high dose of corticosteroids for 12 weeks, as per local 
guidelines.
5.2 Myositis
Deﬁnition: A disorder characterized by [CONTACT_108143] ﬂammation with weakness and elevated muscle enzymes (CK). 
Muscle pain can be present in severe cases. Can be life-threatening if respi[INVESTIGATOR_107986]-upComplete rheumatologic and neurologic history regarding differential diagnosis; rheumatologic and neurologic 
examination, including muscle strength; and examination of the skin for ﬁndings suggestive of dermatomyositis. 
Muscle weakness is more typi[INVESTIGATOR_107987]. Consider pre-existing conditions that can cause similar 
symptoms.
Blood testing to evaluate muscle in ﬂammation
CK, transaminases (AST, ALT), LDH, and aldolase can also be elevatedTroponin to evaluate myocardial involvement and other cardiac testing, such as echocardiogram, as neededInﬂammatory markers (ESR and CRP)
Consider EMG, imaging (MRI), and/or biopsy on an individual basis when diagnosis is uncertain and overlap with 
neurologic syndromes, such as myasthenia gravis, is suspected
Consider paraneoplastic autoantibody testing for myositis and neurologic conditions, such as myasthenia gravis 
Monitoring: CK, ESR, CRP
G1: Complete examination and laboratory work-up as above
G2: Complete history and examination as above; autoimmune myositis blood panel; EMG, MRI of affected joints
Early referral to a rheumatologist or neurologist
G3-4: As for G2Urgent referral to a rheumatologist or neurologist
Grading Management
G1: Mild weakness with or without pain Continue ICPi
[INVESTIGATOR_107988], 
may offer oral corticosteroids, and treat as G2
Offer analgesia with acetaminophen or NSAIDs if there 
are no contraindications
G2: Moderate weakness with or without pain, limiting age-appropriate instrumental ADLHold ICPi [INVESTIGATOR_107989], if CK is normal and prednisone dose 10 mg; if worsens, treat as per G3
NSAIDs as neededReferral to rheumatologist or neurologistIf CK is elevated three times or more), initiate 
prednisone or equivalent at 0.5-1 mg/kg
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N119/1565.[ADDRESS_120046] 
patients with G2 symptoms and objective ﬁndings 
(elevated enzymes, abnormal EMG, abnormal muscle MRI or biopsy)
G3-4: Severe weakness with or without pain, limiting self-care ADLFor G3: Hold ICPi [INVESTIGATOR_107990] G1 or less and permanently 
discontinue if any evidence of myocardial involvement
For G4: permanently discontinue ICPi[INVESTIGATOR_107991] 1 mg/kg or equivalent. Consider 1-2 
mg/kg of methylprednisolone IV or higher-dose bolus if severe compromise (weakness severely limiting mobility, cardiac, respi[INVESTIGATOR_696], dysphagia)
Consider plasmapheresisConsider IVIG therapyConsider other immunosuppressant therapy, such as 
methotrexate, azathioprine, or mycophenolate mofetil, if 
symptoms and CK levels do not improve or worsen 
after 4-6 weeks; rituximab is used in primary myositis but caution is advised given its long biologic duration
In case of management with rituximab, ICPi [INVESTIGATOR_107992]: Caution is advised with rechallenging
5.3 Polymyalgia-like syndrome
Deﬁnition: Characterized by [CONTACT_108144]/or lower extremities and no signs of 
true muscle in ﬂammation such as CK elevation or EMG ﬁndings of myositis. No true muscle weakness, dif ﬁculty in 
active motion related to pain
Diagnostic work-up
G1Complete rheumatologic history regarding differential diagnosis and examination of all joints and skin
Check for symptoms of temporal arteritis, such as headache or visual disturbances; refer to ophthalmologist if 
present, and consider temporal artery biopsy ANA, RF, anti-CCP
CK to evaluate differential diagnosis of myositis
Inﬂammatory markers (ESR, CRP)
Monitoring: ESR, CRP
G2: Complete history and examination as above; autoimmune tests as required for differential diagnosis; early 
referral to a rheumatologist
G3-4: As for G2; see rheumatologist advice and review
Grading Management
G1: Mild stiffness and pain Continue ICPi
[INVESTIGATOR_107982]/or NSAIDs if 
there are no contraindications
G2: Moderate stiffness and pain, limiting age-appropriate instrumental ADLConsider holding ICPi [INVESTIGATOR_107993], prednisolone < 10 mg; if worsens, treat as per G3
Initiate prednisone 20 mg/d or equivalent; if symptoms 
improve, start to taper dose after 3-4 weeks
If no improvement or need for higher dosages after 4 
weeks, escalate to G3 Consider referral to 
rheumatology
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N120/1565.0 Musculoskeletal Toxicities
G3-4: Severe stiffness and pain, limiting self-care ADL For G3: Hold ICPi [INVESTIGATOR_107994], in consultation with 
rheumatology, if recover to G1 or less; however, note that cases of toxicity returning upon rechallenge have 
been reported. ICPi [INVESTIGATOR_107995] G4: permanently discontinue ICPi[INVESTIGATOR_107996] 20 mg/d or equivalent. If no 
improvement or need for higher dosages for prolonged time, may offer a corticosteroid-sparing agent such as methotrexate or IL-6 inhibition with tocilizumab
(Note: As caution, IL-6 inhibition can cause intestinal 
perforation; while this is extremely rare, it should not be 
used in patients with colitis or GI metastases). Consider admission for pain control
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: ADL, activities of daily living; ALT, alanine aminotransferase; ANA, antinuclear antibodies; AST, aspartate aminotransferase; CCP, citrullinated protein antibody; CK, creatine kinase; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; EMG, electromyography; ESR, erythrocyte sedimentation rate; G, Grade; HLA, human leukocyte antigen; ICPi, immune checkpoint inhibitor; IL, interleukin; irAE, immune-related 
adverse event; IV, intravenous; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MRI, magnetic 
resonance imaging, NSAID, nonsteroidal anti-in ﬂammatory drug; PCP, Pneumocystis pneumonia; RF, rheumatoid 
factor; TB, tuberculosis; TNF, tumor necrosis factor.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N121/156Table A6 Management of Renal irAEs in Patients Treated With ICPis
6.0 Renal Toxicities
Nephritis and renal dysfunction: diagnosis and monitoring
For any suspected immune-mediated adverse reactions, exclude other causesMonitor patients for elevated serum creatinine prior to every doseRoutine urinalysis is not necessary, other than to rule out UTIs, etc.; nephrology may consider furtherIf no potential alternative cause of AKI identi ﬁed, then one should forego biopsy and proceed directly with 
immunosuppressive therapy Swift treatment of autoimmune component important
6.1 Nephritis
Deﬁnition: In ﬂammation of the kidney affecting the structure
Grading Management
G1: Creatinine level increase 
> ULN - 1.[ADDRESS_120047] Consider temporarily holding ICPi, pending 
consideration of potential alternative etiologies (recent IV contrast, medications, ﬂuid status) and baseline renal 
function. A change that is still < 1.[ADDRESS_120048] could be 
meaningful
G2: Creatinine 
> 1.5 - 3.0 x baseline; > 1.[ADDRESS_120049] Hold ICPi 
[INVESTIGATOR_107997] (recent IV contrast, 
medications, ﬂuid status, etc.); if other etiologies ruled 
out, administer 0.5-1 mg/kg/d prednisone equivalents
If worsening or no improvement: 1 to 2 mg/kg/d 
prednisone equivalents and permanently discontinuetreatment
If improved to G1 or less, taper corticosteroids over 4-6 
weeks If no recurrence of chronic renal insuf ﬁciency, 
discuss resumption of ICPI [INVESTIGATOR_107998] ﬁts.
G3: Creatinine 
> 3.0 x baseline; > 3.[ADDRESS_120050] Permanently discontinue ICPi
G4: Life-threatening consequences; dialysis indicated; 
> 6.[ADDRESS_120051] Permanently discontinue ICPi
[INVESTIGATOR_107999] (recent IV contrast, 
medications, ﬂuid status, etc.)
Administer corticosteroids (initial dose of 1-2 mg/kg/d 
prednisone or equivalent)
Additional considerations
Monitor creatinine weeklyReﬂex kidney biopsy should be discouraged until corticosteroid treatment has been attempted
6.2 Symptomatic nephritis: follow-up
Grading Management
G1 Improved to baseline, resume routine creatinine 
monitoring
G2 If improved to G1, taper corticosteroids over at least 
[ADDRESS_120052] > [ADDRESS_120053] 
4 weeks 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N122/1566.[ADDRESS_120054] 3-5 days or worsen, consider 
additional immunosuppression (e.g., mycophenolate)
G4 If improved to G1, taper corticosteroids over at least 
[ADDRESS_120055] 2-3 days or worsen, consider 
additional immunosuppression (e.g., mycophenolate)
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: AKI, acute kidney injury; G, Grade; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; IV, intravenous; ULN, upper limit of normal; UTI, urinary tract infection.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N123/156Table A7 Management of Nervous System irAEs in Patients Treated With ICPis
7.0 Nervous System Toxicities
7.1 Myasthenia gravis
Deﬁnition: Fatigable or ﬂuctuating muscle weakness, generally more proximal than distal. Frequently has ocular 
and/or bulbar involvement (ptosis, extraocular movement abnormalities resulting in double vision, dysphagia, dysarthria, facial muscle weakness). May have neck and/or respi[INVESTIGATOR_65208]. (Note: May occur with myositis and/or myocarditis). Respi[INVESTIGATOR_108000], myocarditis. 
Miller Fisher variant of Guillain-Barré syndrome (ophthalmoparesis) and the oculobulbar myositis (ptosis, 
ophthalmoparesis, dysphagia, neck and respi[INVESTIGATOR_108001]) with ICPi [INVESTIGATOR_108002].
Diagnostic work-up
AChR and antistriated muscle antibodies in blood; if AChR antibodies are negative, consider muscle speci ﬁc 
kinase and lipoprotein-related 4 antibodies in blood Pulmonary function assessment with NIF and VC
CPK, aldolase, ESR, CRP for possible concurrent myositisConsider MRI of brain and/or spi[INVESTIGATOR_050], depending on symptoms to rule out CNS involvement by [CONTACT_108145][INVESTIGATOR_108003] ﬁciency or elevated CPK, troponin T, perform cardiac examination with ECG and TTE for 
possible concomitant myocarditis
Neurologic consultationElectrodiagnositic studies, including neuromuscular junction testing with repetitive stimulation and/or jitter studies, 
NCS to exclude neuropathy, and needle EMG to evaluate for myositis
Grading Management
All grades All grades warrant work-up and intervention given 
potential for progressive myasthenia gravis to lead to respi[INVESTIGATOR_108004] G1
G2: Some symptoms interfering with ADL MGFA severity class 1 (ocular symptoms and ﬁndings only) 
and MGFA severity class 2 (mild generalized weakness)Hold ICPi [INVESTIGATOR_108005] G2 patients (MGFA 1 and 
2) only if symptoms resolve 
Should consult neurologyPyridostigmine starting at 30 mg orally three times a 
day and gradually increase to maximum of 120 mg orally four times a day as tolerated and based on symptoms Administer corticosteroids (prednisone, 
1-1.5 mg/kg orally daily) if symptoms G2; wean based 
on symptom improvement
G3-4: Limiting self-care and aids warranted, weakness limiting walking, ANY dysphagia, facial weakness, respi[INVESTIGATOR_65208], or rapi[INVESTIGATOR_108006], or MGFA severity class 3-4 moderate to 
severe generalized weakness to myasthenic crisisPermanently discontinue ICPi
[INVESTIGATOR_108007], may need ICU-level monitoring
Neurology consultContinue corticosteroids and initiate IVIG 2 g/kg IV over 
5 days (0.4 g/kg/d) or plasmapheresis for 5 days
Frequent pulmonary function assessment
Daily neurologic review
Additional considerationsAvoid medications that can worsen myasthenia: β-blockers, IV magnesium, ﬂuoroquinolones, aminoglycosides, 
and macrolides Initially a 5-day course of plasmapheresis or a 2 g/kg course of IVIG over 5 days
1-2 mg/kg methylprednisolone daily, wean based on symptom improvementPyridostigmine, wean based on improvementICPi-associated myasthenia gravis may be monophasic, and additional corticosteroid-sparing agents may not be 
required
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N124/1567.0 Nervous System Toxicities
7.2 Guillain-Barré syndrome
Deﬁnition: Progressive, most often symmetrical muscle weakness with absent or reduced deep tendon re ﬂexes. 
Often starts with sensory symptoms/neuropathic pain localized to lower back and thighs. May involve extremities (typi[INVESTIGATOR_108008]), facial, respi[INVESTIGATOR_696], and bulbar and oculomotor nerves. May have dysregulation of autonomic nerves.
Diagnostic work-up
Neurologic consultation
MRI of spi[INVESTIGATOR_108009] (rule out compressive lesion and evaluate for nerve root 
enhancement/thickening)
Lumbar puncture: CSF typi[INVESTIGATOR_108010]; even though this is not typi[INVESTIGATOR_108011]-Barré syndrome, cytology should be sent with any CSF sample from a patient with cancer.
Serum antibody tests for Guillain-Barré syndrome variants (GQ1b for Miller Fisher variant a/w ataxia and 
ophthalmoplegia) Electrodiagnostic studies to evaluate polyneuropathy
Pulmonary function testing (NIF/VC)
Frequent neurochecks
Grading Management
All grades Warrant work-up and intervention given potential for 
progressive Guillain-Barré syndrome to lead to respi[INVESTIGATOR_108012]: There is no G1 toxicity
G1: Mild, none NA
G2: Moderate, some interference with ADL, symptoms 
concerning to patientDiscontinue ICPi
G3-4: Severe, limiting self-care and aids warranted, 
weakness, limiting walking, ANY dysphagia, facial weakness, respi[INVESTIGATOR_65208], or rapi[INVESTIGATOR_108013]. 
Admission to inpatient unit with capability of rapid 
transfer to ICU-level monitoring Start IVIG (0.4 g/kg/d for 5 days for a total dose of 2 g/kg) or plasmapheresis. Corticosteroids are usually not recommended for 
idiopathic Guillain-Barré syndrome; however, in 
ICPi-related forms, a trial is reasonable (methylprednisolone 2-4 mg/kg/d), followed by [CONTACT_108146] (methylprednisolone 1 g/d 
for 5 days) may also be considered for G3-4 along with 
IVIG or plasmapheresis
Frequent neurochecks and pulmonary function 
monitoring
Monitor for concurrent autonomic dysfunctionNonopi[INVESTIGATOR_108014]/ileus
Additional considerations
Slow prednisone taper after corticosteroid pulse plus IVIG or plasmapheresis May require repeat IVIG courses
Caution with rechallenging for severe cases
7.3 Peripheral neuropathy
Deﬁnition: Can present as asymmetric or symmetric sensory, motor, or sensory motor de ﬁcit. Focal 
mononeuropathies, including cranial neuropathies (e.g., facial neuropathies/Bell palsy) may be present. Numbness and paresthesias may be painful or painless. Hypo- or are ﬂexia or sensory ataxia may be present.
Diagnostic work-up
G1Screen for reversible neuropathy causes: diabetic screen, B12, folate, TSH, HIV, consider serum protein 
electrophoresis, and other vasculitic and autoimmune screen Neurologic consultation
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N125/1567.[ADDRESS_120056]
G2: in addition to aboveMRI spi[INVESTIGATOR_108015]/MRI of brain if cranial nerve Consider EMG/NCSConsider neurology consultationG3-4: go to Guillain-Barré syndrome algorithm
Grading Management
G1: Mild, no interference with function and symptoms 
not concerning to patient. Note: Any cranial nerve problem should be managed as moderateLow threshold to hold ICPi [INVESTIGATOR_108016] a 
week If to continue, monitor very closely for any symptom progression
G2: Moderate, some interference with ADL, symptoms concerning to patient (i.e., pain but no weakness or gait limitation)Hold ICPi [INVESTIGATOR_108017] G1
Initial observation OR initiate prednisone 0.5-1 mg/kg (if 
progressing from mild)
Neurontin, pregabalin, or duloxetine for pain
G3-4: Severe, limiting self-care and aids warranted, 
weakness limiting walking or respi[INVESTIGATOR_66780] (i.e., leg weakness, foot drop, rapi[INVESTIGATOR_108018]) Severe may be Guillain-Barré syndrome and should be managed as suchPermanently discontinue ICPi
[INVESTIGATOR_108019] 2-4 mg/kg and proceed 
as per Guillain-Barré syndrome management
7.4 Autonomic neuropathy
Deﬁnition: Nerves that control involuntary bodily functions are damaged. This may affect blood pressure, 
temperature control, digestion, bladder function, and sexual function. A case of severe enteric neuropathy with ICPi [INVESTIGATOR_108020]. Can present with GI dif ﬁculties such as new severe constipation, nausea, urinary 
problems, sexual dif ﬁculties, sweating abnormalities, sluggish pupil reaction, and orthostatic hypertension.
Diagnostic work-up
An evaluation by [CONTACT_108147], depending on organ system, with testing that may include
Screening for other causes of autonomic dysfunction: diabetic screen, adrenal insuf ﬁciency, HIV, paraproteinemia, 
amyloidosis, botulism; consider chronic diseases such as Parkinson and other autoimmune screening
AM orthostatic vitalsConsider electrodiagnostic studies to evaluate for concurrent polyneuropathyConsider paraneoplastic Lambert-Eaton myasthenic syndrome, antineutrophil cytoplasmic antibodies, and 
ganglionic AChR antibody testing
Grading Management
G1: Mild, no interference with function and symptoms not concerning to patientLow threshold to hold ICPi [INVESTIGATOR_108016] a 
week; if to continue, monitor very closely for any symptom progression
G2: Moderate, some interference with ADL, symptoms concerning to patientHold ICPi [INVESTIGATOR_108017] G1
Initial observation OR initiate prednisone 0.5-1 mg/kg (if 
progressing from mild)
Neurologic consultation
G3-4: Severe, limiting self-care and aids warranted Permanently discontinue ICPi
[INVESTIGATOR_108021] 1 g daily for 3 days followed 
by [CONTACT_108148]
7.5 Aseptic meningitis
Deﬁnition: may present with headache, photophobia, and neck stiffness; often afebrile but may be febrile. There 
may be nausea/vomiting. Mental status should be normal (distinguishes from encephalitis).
Diagnostic work-upMRI of brain with or without contrast + pi[INVESTIGATOR_108022], ACTH to rule out adrenal insuf ﬁciency
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N126/1567.0 Nervous System Toxicities
Consider lumbar puncture: measure opening pressure; check cell count and protein glucose; and perform Gram 
stain, culture, PCR for HSV, and other viral PCRs depending on suspi[INVESTIGATOR_2798], cytology
May see elevated WBC count with normal glucose, normal culture, and Gram stain; may see reactive lymphocytes 
or histiocytes on cytology
Grading Management
G1: Mild, no interference with function and symptoms 
not concerning to patient. Note: Any cranial nerve 
problem should be managed as moderate.
G2: Moderate, some interference with ADL, symptoms 
concerning to patient (i.e., pain but no weakness or gait limitation)
G3-4: Severe, limiting self-care and aids warrantedHold ICPi [INVESTIGATOR_108023] ﬁts, consider 
empi[INVESTIGATOR_108024] (IV acyclovir) and antibacterial 
therapy until CSF results Once bacterial and viral infection are negative, may closely monitor off corticosteroids or consider oral prednisone 0.5-1 mg/kg 
or IV methylprednisolone 1 mg/kg if moderate/severe 
symptoms
7.6 Encephalitis
Deﬁnition: As for aseptic meningitis, need to exclude infectious causes, especially viral (i.e., HSV).
Confusion, altered behavior, headaches, seizures, short-term memory loss, depressed level of consciousness, 
focal weakness, speech abnormality 
Diagnostic work-up
Neurologic consultation
MRI of brain with or without contrast may reveal T2/ ﬂuid-attenuated inversion recovery changes typi[INVESTIGATOR_108025]: check cell count and protein glucose and perform Gram stain, culture, PCR for HSV and other 
viral PCRs depending on suspi[INVESTIGATOR_2798], cytology, oligoclonal bands, autoimmune encephalopathy, and paraneoplastic 
panels.
May see elevated WBC count with lymphocytic predominance and/or elevated proteinEEG to evaluate for subclinical seizures
Blood: metabolic, CBC, ESR, CRP, ANCA (if suspect vasculitic process), thyroid panel including TPO and 
thyroglobulin Rule out concurrent anemia/thrombocytopenia, which can present with severe headaches and 
confusion
Grading Management
G1: Mild, no interference with function and symptoms not concerning to patient. Note: Any cranial nerve problem should be managed as moderate.
G2: Moderate, some interference with ADL, symptoms 
concerning to patient (i.e., pain but no weakness or gait limitation)
G3-4: Severe, limiting self-care and aids warrantedHold ICPi [INVESTIGATOR_108023] ﬁts
As above for aseptic meningitis suggest concurrent IV 
acyclovir until PCR results obtained and negative
Trial of methylprednisolone 1-2 mg/kgIf severe or progressing symptoms or oligoclonal bands 
present, consider pulse corticosteroids methylprednisolone 1 g IV daily for 3-5 days plus IVIG 2 g/kg over 5 days If positive for autoimmune 
encephalopathy antibody and limited or no 
improvement, consider rituximab or plasmapheresis in consultation with neurology.
7.7 Transverse myelitis
Deﬁnition: Acute or subacute weakness or sensory changes bilateral, often with increased deep tendon re ﬂexes
Diagnostic work-up
Neurologic consultation
MRI of spi[INVESTIGATOR_050] (with thin axial cuts through the region of suspected abnormality) and MRI of brainLumbar puncture: cell count, protein, glucose, oligoclonal bands, viral PCRs, cytology, onconeural antibodies 
Blood: B12, HIV, RPR, ANA, Ro/La, TSH, aquaporin-4 IgG
Evaluation for urinary retention, constipation
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N127/1567.0 Nervous System Toxicities
Grading Management
G1: Mild, no interference with function and symptoms 
not concerning to patient. Note: Any cranial nerve problem should be managed as moderate.
G2: Moderate, some interference with ADL, symptoms 
concerning to patient (i.e., pain but no weakness or gait 
limitation)
G3-4: Severe, limiting self-care and aids warrantedPermanently discontinue ICPi
[INVESTIGATOR_108026] 2 mg/kgStrongly consider higher doses of 1 g/d for 3-5 days 
Strongly consider IVIG
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: AChR, acetylcholine receptor; ACTH, adrenocorticotropic hormone; ADL, activities of daily living; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibodies; CBC, complete blood count; CNS, central nervous 
system; CPK, creatine phosphokinase; CRP, C-reactive protein; CSF, cerebrospi[INVESTIGATOR_872]; ECG, electrocardiogram; 
EEG, electroencephalogram; EMG, electromyography; ESR, erythrocyte sedimentation rate; G, Grade; GI, gastrointestinal; HIV, human immunodeficiency virus; HSV, herpes simplex virus; ICPi, immune checkpoint inhibitor; ICU, intensive care unit; IgG, immunoglobulin G; IV, intravenous; IVIG, intravenous immunoglobulin; irAE, immune-
related adverse event; MGFA, Myasthenia Gravis Foundation of America; MRI, magnetic resonance imaging; NA, not 
applicable; NCS, nerve conduction study; NIF, negative inspi[INVESTIGATOR_105864]; PCR, polymerase chain reaction; RPR, rapid plasma reagin, TPO, thyroid peroxidase; TSH, thyroid-stimulating hormone; TTE, transthoracic echocardiogram; VC, vital capacity; WBC, white blood cell count.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N128/156Table A8 Management of Hematologic irAEs in Patients Treated With ICPis
8.0 Hematologic Toxicities
8.1 Autoimmune hemolytic anemia
Deﬁnition: A condition in which RBCs are destroyed and removed from the blood stream before their normal 
lifespan is over. Symptoms include weakness, paleness, jaundice, dark-colored urine, fever, inability to do physical activity, and heart murmur.
Diagnostic work-up
History and physical examination (with special consideration of history of new drugs and insect, spi[INVESTIGATOR_108027], or snake 
bites)
Blood chemistry, CBC with evidence of anemia, macrocytosis, evidence of hemolysis on peripheral smear; LDH, 
haptoglobin, bilirubin, reticulocyte count, free Hgb DIC panel, which could include PTNIR infectious causes
Autoimmune serologyParoxysmal nocturnal hemoglobinuria screeningDirect and indirect bilirubin; LDH; direct agglutinin test; and if no obvious cause, bone marrow analysis, cytogenetic 
analysis to evaluate for myelodysplastic syndromes
Evaluation for viral/bacterial (mycoplasma, etc.) causes of hemolysis studiesProtein electrophoresis, cryoglobulin analysisWork-up for bone marrow failure syndrome if refractory, including B12, folate, copper, parvovirus, FE, thyroid, 
infection
Glucose-6-phosphate dehydrogenaseEvaluation of common drug causes (ribavirin, rifampin, dapsone, interferon, cephalosporins, penicillins, NSAIDs, 
quinine/quinidine, ﬂudarabine, cipro ﬂoxacin, lorazepam, diclofenac, etc.)
Assessment of methemoglobinemia
Grading Management
G1: Hgb < LLN to 10.0 g/dL; < LLN to 6.2 mmol/L; < 
LLN to 100 g/LContinue ICPi [INVESTIGATOR_107974]-up and 
laboratory evaluation
G2: Hgb < 10.0 to 8.0 g/dL; < 6.2to4.9mmol/L; < 100 to 80 g/LHold ICPi [INVESTIGATOR_108028] 0.5-1 mg/kg/d prednisone equivalents
G3: Hgb < 8.0 g/dL; < 4.9 mmol/L; < 80 g/L; transfusion 
indicatedPermanently discontinue ICPi
[INVESTIGATOR_108029] 1-2 mg/kg/d (oral or IV depending on 
symptoms/speed of development)
If worsening or no improvement, 1-2 mg/kg/d 
prednisone equivalents and permanently discontinue ICPi [INVESTIGATOR_108030]; do 
not transfuse more than the minimum number of RBC 
units necessary to relieve symptoms of anemia or to 
return a patient to a safe Hgb range (7-8 g/dL in stable, noncardiac inpatients)
Should offer patients supplementation with folic acid 1 
mg once daily
G4: Life-threatening consequences, urgent intervention indicatedPermanently discontinue ICPi
[INVESTIGATOR_108031] 1-2 mg/kg/d
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N129/1568.0 Hematologic Toxicities
If no improvement or if worsening while on 
corticosteroids or severe symptoms on presentation, 
initiate other immunosuppressive drugs, such as rituximab, IVIG, cyclosporin A, and mycophenolate mofetil
RBC transfusion per existing guidelines; discuss with 
blood bank team prior to transfusions that a patient with 
possible ICPi [INVESTIGATOR_108032].
Additional considerations: Monitor Hgb levels on a weekly basis until the corticosteroid tapering process is 
complete; thereafter, less-frequent testing is needed
8.2 Acquired TTP
Deﬁnition: A disorder characterized by [CONTACT_108149], thrombocytopenic 
purpura, fever, renal abnormalities, and neurologic abnormalities, such as seizures, hemiplegia, and visual 
disturbances. It is an acute or subacute condition. 
Diagnostic work-up
History with speci ﬁc questions related to drug exposure (e.g., chemotherapy, sirolimus, tacrolimus, opana ER 
antibiotics, quinine) Physical examination, peripheral smear
ADAMTS13 activity level and inhibitor titer
LDH, haptoglobin, reticulocyte count, bilirubin, urinalysis to rule out other causesPT, activated PTT, ﬁbrinogen
Blood group and antibody screen, direct antiglobulin test, CMV serologyConsider CT/MRI brain, echocardiogram, ECGViral studiesNote: This disorder is usually associated with a severe drop in platelets and hemolysis/anemia precipi[INVESTIGATOR_108033] ﬁrst step in the management of TTP is a high index 
of suspi[INVESTIGATOR_108034]; hematology consult should immediately be called, as delay in identi ﬁcation is associated with increased 
mortality/morbidity.
Initially, the patient should be stabilized and any critical 
organ dysfunction stabilized
G1: Evidence of RBC destruction (schistocytosis) without anemia, renal insuf ﬁciency, or 
thrombocytopenia clinically
G2: Evidence of RBC destruction (schistocytosis) 
without clinical consequence with G2 anemia and thrombocytopeniaHold ICPi [INVESTIGATOR_108023] ﬁts, noting that 
there are currently no data to recommend restarting 
ICPi [INVESTIGATOR_108035] 0.5-1 mg/kg/d prednisone
G3: Laboratory ﬁndings with clinical consequences (G3 
thrombocytopenia, anemia, renal insuf ﬁciency > 2)
G4: Life-threatening consequences (e.g., CNS 
hemorrhage or thrombosis/embolism or renal failure)For G3: Hold ICPi [INVESTIGATOR_108036] ﬁts, 
noting that there are currently no data to recommend 
restarting ICPi [INVESTIGATOR_108037] G4: permanently discontinue ICPi
[INVESTIGATOR_108038], initiate PEX according 
to existing guidelines with further PEX dependent on 
clinical progress
Administer methylprednisolone [ADDRESS_120057] PEX
May offer rituximabIn case of management with rituximab, ICPi [INVESTIGATOR_108039] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N130/1568.0 Hematologic Toxicities
8.3 Hemolytic uremic syndrome
Deﬁnition: A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, 
and severe thrombocytopenia. Signs and symptoms of hemolytic uremic syndrome can include:
Bloody diarrheaDecreased urination or blood in the urineAbdominal pain, vomiting, and occasionally feverPallor
Small, unexplained bruises or bleeding from the nose and mouth Fatigue and irritability
Confusion or seizuresHigh blood pressureSwelling of the face, hands, feet, or entire body
Diagnostic work-upHistory and physical examination (special consideration for new history of high-risk drugs, hypertension, or cardiac 
causes) CBC with indices
Blood smear morphology. Note that the presence of schistocytes on smear is critical for diagnosis.Serum creatinineADAMTS13 (to rule out TTP)Homocysteine/methylmalonic acidComplement testing C3, C4, CH50 (complement inhibitory antibodies for suspected familial)Evaluate reticulocyte count and mean corpuscular volume
Evaluation of infectious cause, including screening for EBV, CMV, HHV6
Evaluation for nutritional causes of macrocytosis (B12 and folate)Pancreatic enzymesEvaluation for diarrheal causes, shiga toxin, Escherichia coli 0157, etc.Direct antibody test (Coombs test), haptoglobin, LDH, and other etiologies of anemiaEvaluation for common drugs causing hemolysis (tacrolimus, cyclosporine, sirolimus, etc.)Evaluation for concurrent confusion
Grading Management
G1-2: Evidence of RBC destruction (schistocytosis) 
without clinical consequences of anemia, thrombocytopenia Grade 2
G3: Laboratory ﬁndings with clinical consequences 
(e.g., renal insuf ﬁciency, petechiae)
G4: Life-threatening consequences (e.g., CNS 
thrombosis/ embolism or renal failure)For G1 and G2: Continue ICPi [INVESTIGATOR_107974]-
up and laboratory evaluation
Supportive care 
For G3 and G4: Permanently discontinue ICPi
[INVESTIGATOR_108040] 900 mg weekly 
for four doses, 1,200 mg week 5, then 1,200 mg every 2 
weeks
Red blood transfusion according to existing guidelines
8.4 Aplastic anemia
Deﬁnition: Condition in which the body stops producing enough new blood cells 
Diagnostic work-up
History and physical examination (close attention to medications, exposure to radiation, toxins, recent viral 
infections) CBC, smear, reticulocyte count
Viral studies, including CMV, HHV6, EBV, parvovirusNutritional assessments including B12, folate, iron, copper, ceruloplasmin, vitamin DSerum LDH, renal functionWork-up for infectious causesIdentify marrow hypo/aplasiaBone marrow biopsy and aspi[INVESTIGATOR_108041], including neutrophil count, proportion of GPI-negative cells by ﬂow for PNH
Flow cytometry to evaluate loss of GPI-anchored proteins
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N131/1568.0 Hematologic Toxicities
Type and screen patient for transfusions and notify blood bank that all transfusions need to be irradiated and 
ﬁltered
Grading Management
G1: Nonsevere, < 0.5 polymorphonuclear cells x 109/L 
hypocellular marrow, with marrow cellularity < 25%, 
peripheral platelet count > 20,000, reticulocyte count 
< 20,000Hold ICPi [INVESTIGATOR_108042]-up, and laboratory evaluation 
Supportive transfusions as per local guidelines
G2: Severe, hypocellular marrow < 25% and two of the 
following: ANC < 500, peripheral platelet < 20,000, and reticulocyte < 20,000Hold ICPi [INVESTIGATOR_108043] + cyclosporine; HLA typi[INVESTIGATOR_108044]; all blood products should be irradiated and ﬁltered
Supportive care with granulocyte colony-stimulating 
factor may be added in addition
G3-4: Very severe, ANC > 200, platelet count > 20,000, 
reticulocyte count > 20,000, plus hypocellular marrow > 25%For G3: Hold ICPi [INVESTIGATOR_108045]; 
if not resolved, discontinue treatment until AE has reverted to G1
For G4: permanently discontinue ICPi[INVESTIGATOR_108046], growth factor support
Horse ATG plus cyclosporine
If no response, repeat immunosuppression with rabbit 
ATG plus cyclosporine, cyclophosphamide
For refractory patients, consider eltrombopag plus 
supportive care
8.5 Lymphopenia
Deﬁnition: An abnormally low level of lymphocytes in PB; for adults, counts of < 1,500/mm3 
Diagnostic work-up
History and physical examination (special attention for lymphocyte-depleting therapy such as ﬂudarabine, ATG, 
corticosteroids, cytotoxic chemotherapy, radiation exposure, etc., as well as history of autoimmune disease, family history of autoimmune disease) Evaluation of nutritional state as cause
Spleen sizeCBC with differential, peripheral smear and reticulocyte countsCXR for evaluation of presence of thymomaBacterial cultures and evaluation for infection (fungal, viral, bacterial speci ﬁcally CMV/HIV)
Grading Management
G1-2: 500-1,000 PB lymphocyte count
G3: 250-499 PB lymphocyte count
G4: < 250 PB lymphocyte countContinue ICPi [INVESTIGATOR_8178] G1 to G2
For G3 single laboratory values out of normal range 
without any clinical correlates, hold treatment until 
resolution to G1
For G4, for single laboratory values out of normal range 
without any clinical correlates, permanent treatment discontinuation is not required. Treatment should be 
held until the etiology is determined. Permanent 
treatment discontinuation will only be required, if lymphopenia is considered of immune related in nature, no clear alternative explanation exists for the event, and 
grade 4 lymphopenia does not resolve within 14 days. If 
the event is not considered immune related and 
resolves to G ≤1 restarting treatment may be 
considered.
Check CBC weekly for monitoring, initiation of CMV 
screening Consider holding ICPi
[INVESTIGATOR_108047] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N132/1568.0 Hematologic Toxicities
Initiate Mycobacterium avium complex prophylaxis and 
Pneumocystis jirovecii prophylaxis, CMV screening. 
HIV/hepatitis screening if not already done
May consider EBV testing if evidence of 
lymphadenopathy/hepatitis, fevers, hemolysis consistent with lymphoproliferative disease. 
8.6 Immune thrombocytopenia
Deﬁnition: An autoimmune disorder characterized by [CONTACT_108150]-up
History and physical examination (special attention for lymphocyte-depleting therapy, such as ﬂudarabine, ATG, 
corticosteroids, cytotoxic therapy) Family history of autoimmunity or personal history of autoimmune disease
History of viral illness
CBCPeripheral blood smear, reticulocyte countBone marrow evaluation only if abnormalities in the above test results and further investigation is necessary for a 
diagnosis
Patients with newly diagnosed immune thrombocytopenia should undergo testing for HIV, hepatitis C virus, 
hepatitis B virus, and Helicobacter pylori Direct antigen test should be checked to rule out concurrent Evan 
syndrome
Nutritional evaluationBone marrow evaluation if other cell lines affected and concern for aplastic anemia
Grading Management
G1: Platelet count < 100/ μL
G2: Platelet count < 75/ μLContinue ICPi [INVESTIGATOR_107974]-up and 
laboratory evaluation
Hold ICPi [INVESTIGATOR_108048]; if not resolved, 
interrupt treatment until AE has reverted to G1
Administer prednisone 1 mg/kg/d (dosage range, 
0.5-2 mg/kg/d) orally for 2-[ADDRESS_120058] effective dose IVIG may be used in conjunction with corticosteroids if a more-rapid increase in platelet 
count is required.
G3: Platelet count < 50/ μL Hold ICPi [INVESTIGATOR_108048]; if not resolved, 
interrupt treatment until AE has reverted to G1
G4: Platelet count < 25/ μL Permanently discontinue ICPi
[INVESTIGATOR_108049] 1-2 mg/kg/d (oral or IV depending on 
symptoms)
If worsening or no improvement, 1-2 mg/kg/d 
prednisone equivalents and permanently discontinue 
treatment
IVIG used with corticosteroids when a more-rapid 
increase in platelet count is required
If IVIG is used, the dose should initially be 1 g/kg as a 
one-time dose. This dosage may be repeated if necessary
If previous treatment with corticosteroids and/or IVIG 
unsuccessful, subsequent treatment may include 
rituximab, thrombopoietin receptor agonists, or more-potent immunosuppression (From American Society of Hematology guideline on immune thrombocytopenia; 
consult for further details)
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N133/1568.0 Hematologic Toxicities
8.7 Acquired hemophilia
Deﬁnition: Disorder caused by [CONTACT_108151] (inhibitors) directed against plasma coagulation 
factors 
Diagnostic work-up
Full blood count to assess platelet number, ﬁbrinogen, PT, PTT, INR; the typi[INVESTIGATOR_2855] ﬁnding in patients with acquired 
hemophilia A is a prolonged activated PTT with a normal PT
MRI, CT, and ultrasonography may be indicated to localize, quantify, and serially monitor the location and 
response of bleeding Medication review to assess for alternative causes
Determination of Bethesda unit level of inhibitor
Grading Management
G1: Mild, 5%-40% of normal factor activity in blood, 
0.05-0.4 IU/mL of whole bloodHold ICPi [INVESTIGATOR_108023] ﬁts
Administer 0.5-1 mg/kg/d prednisone
Transfusion support as required
Treatment of bleeding disorders with hematology 
consult
G2: Moderate, 1%-5% of normal factor activity in blood, 
0.01- 0.05 IU/mL of whole bloodHematology consult
Administration of factor replacement (choice based on 
Bethesda unit of titer)
Administer 1 mg/kg/d prednisone ± rituximab (dose, 375 
mg/m2weekly for 4 weeks) and/or cyclophosphamide 
(dose, 1-2 mg/kg/d); choice of rituximab v cyclophosphamide is patient speci ﬁc and should be 
done with assistance of hematology consult; 
prednisone, rituximab, and cyclophosphamide should 
be given for at least 5 weeks
Factors should be provided to increase level during 
bleeding epi[INVESTIGATOR_1841], with choice of factor based on presence or absence of inhibitor
G3-4: Severe, < 1% of normal factor activity in blood, < 0.01 IU/mL of whole bloodPermanently discontinue ICPi
[INVESTIGATOR_108050], choice based on 
Bethesda unit level of inhibitor By[CONTACT_108152] (factor VII, factor VIII inhibitor by[CONTACT_108153]); caution should be taken in the elderly and those with 
coronary artery disease
Prednisone 1-2 mg/kg/d (oral or IV depending on 
symptoms) ± rituximab (dose, 375 mg/m
2weekly for 
4 weeks) and/or cyclophosphamide (dose, 1-2 mg/kg/d).
Transfusion support as required for bleedingIf worsening or no improvement add cyclosporine or 
immunosuppression/immunoadsorption
Additional considerations: The American Heart Association requires specialist clinical and laboratory expertise. Consult and/or transfer to a specialist center is often appropriate. If consultation with or transfer to a hemophilia center is not immediately possible, then investigation and treatment should be initiated while a liaison is being 
established.
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N134/156Abbreviations: AE, adverse event; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CBC, complete 
blood count; CMV, cytomegalovirus; CNS, central nervous system; CT, computed tomography; CXR, chest x-ray; DIC, disseminated intravascular coagulation; EBV, Epstein-Barr virus; ECG, electrocardiogram; ER, extended release; FE, ferritin; G, Grade; GPI, glycosylphosphatidylinositol; Hgb, hemoglobin; HHV6, human herpesvirus 6; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; ICPi, immune checkpoint inhibitor; INR, international 
normalized ratio; irAE, immune-related adverse event; IV, intravenous; IVIG, intravenous immunoglobulin; LDH, 
lactate dehydrogenase; LLN, lower limit of normal; MRI, magnetic resonance imaging; NSAID, nonsteroidal anti-inﬂammatory drug; PB, peripheral blood; PEX, plasma ex-change; PNH, paroxysmal nocturnal hemoglobinuria; PT, 
prothrombin time; PTT, partial thromboplastin time; RBC, red blood cell count; TTP, thrombotic thrombocytopenic 
purpura.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N135/156Table A9 Management of Cardiovascular irAEs in Patients Treated With ICPis
9.0 Cardiovascular Toxicities
9.1 Myocarditis, pericarditis, arrhythmias, impaired ventricular function with heart failure and vasculitis
Deﬁnition: Signs and symptoms may include chest pain, arrhythmia, palpi[INVESTIGATOR_814], peripheral edema, progressive or 
acute dyspnea, pleural effusion, fatigue
Diagnostic work-up
At baselineECG
Consider troponin, especially in patient treated with combination immune therapi[INVESTIGATOR_108051]/symptoms 
(consider cardiology consult)
ECG
Troponin
BNP Echocardiogram CXRAdditional testing to be guided by [CONTACT_108154]
G1: Abnormal cardiac biomarker testing, including 
abnormal ECG
G2: Abnormal screening tests with mild symptomsG3: Moderately abnormal testing or symptoms with mild 
activity
G4: Moderate to severe decompensation, IV medication 
or intervention required, life-threatening conditionsAll grades warrant work-up and intervention given 
potential for cardiac compromise
Consider the following:For G1: Hold ICPi[INVESTIGATOR_108052] G2, G3, and G4: Permanently discontinue ICPi
[INVESTIGATOR_108052] G1-G4: High-dose corticosteroids (1-2 mg/kg of 
prednisone) initiated rapi[INVESTIGATOR_375] (oral or IV depending on 
symptoms)
Admit patient, cardiology consultationImmediate transfer to a coronary care unit for patients 
with elevated troponin or conduction abnormalities
In patients without an immediate response to high-dose 
corticosteroids, consider early institution of cardiac transplant rejection doses of corticosteroids 
(methylprednisolone 1 g every day) and the addition of 
either mycophenolate, in ﬂiximab, or antithymocyte 
globulin
Qualifying statement: Treatment recommendations are based on anecdotal evidence and the life-threatening nature of cardiovascular complications. The appropriateness of rechallenging remains unknown. Note that inﬂiximab has been associated with heart failure and is contraindicated at high doses in patients with moderate-
severe heart failure.
9.2 Venous thromboembolism
Deﬁnition: A disorder characterized by [CONTACT_108155] a vessel by a thrombus that has migrated from a distal site via 
the blood stream. Clinical signs and symptoms are variable and may include pain, swelling, increased skin vein 
visibility, erythema, and cyanosis accompanied by [CONTACT_108156], pleuritic pain, cough, 
wheezing, or hemoptysis for PE
Diagnostic work-up
Evaluation of signs and symptoms of PE or DVT may include Clinical prediction rule to stratify patients with 
suspected venous thromboembolism Venous ultrasound for suspected DVT
CTPA for suspected PECan also consider D-dimer for low-risk patients based on risk strati ﬁcation by [CONTACT_108157]/PE 
when CT or Doppler are not available or appropriate Ventilation/perfusion scan is also an option when CTPA is not appropriate
Consider other testing, including ECG, CXR, BNP and troponin levels, and arterial blood gas
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N136/1569.0 Cardiovascular Toxicities
Grading Management
G1: Venous thrombosis (e.g., super ﬁcial thrombosis) Continue ICPi
[INVESTIGATOR_108053]
G2: Venous thrombosis (e.g., uncomplicated DVT), 
medical intervention indicated
G3: Thrombosis (e.g., uncomplicated PE [venous], 
nonembolic cardiac mural [arterial] thrombus), medical 
intervention indicatedHold ICPi [INVESTIGATOR_108054] G1 or less. If reverts 
to G2, use benefit-risk assessment for ICPi [INVESTIGATOR_108055], dabigatran, rivaroxaban 
api[INVESTIGATOR_3822], or edoxaban for initial and long-term treatment
IV heparin is an acceptable alternative for initial use, 
and oral anticoagulants are acceptable for the long term
G4: Life-threatening (e.g., PE, cerebrovascular event, arterial insuf ﬁciency), hemodynamic or neurologic 
instability, urgent intervention indicatedPermanently discontinue ICPi
[INVESTIGATOR_108056], 
ACC, and/or AHA guidelines and with guidance from cardiology 
Respi[INVESTIGATOR_108057], dabigatran, rivaroxaban, 
api[INVESTIGATOR_3822], or edoxaban for initial and long-term 
treatment
IV heparin is an acceptable alternative for initial use, 
and oral anticoagulants are acceptable for the long term
Further clinical management as indicated based on 
symptoms
Additional considerations
While it may be impossible to determine the etiology of thromboembolic disease in patients with advanced cancer 
and the role, if any, that ICPi [INVESTIGATOR_108058], it is reasonable to remove the potential inciting agents given the severity and life-threatening potential of G4 complications. Clinicians are to use clinical judgment and take into account the risks and bene ﬁts when deciding whether to discontinue ICPi [CONTACT_3148].
Anticoagulant therapy duration should continue for a minimum of 9-12 months to inde ﬁnitely in the setting of active 
cancer unless patient is asymptomatic, doing well, or in remission.
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: BNP, brain natriuretic peptide; CT, computed tomography; CTPA, computed tomography pulmonary 
angiography; CXR, chest x-ray; DVT, deep vein thrombosis; ECG, electrocardiogram; G, Grade; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; IV, intravenous; LMWH, low-molecular-weight heparin; MRI, magnetic resonance imaging; PE, pulmonary embolism; VKA, vitamin K agonist.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N137/156Table A10 Management of Ocular irAEs in Patients Treated With ICPis
10.[ADDRESS_120059] eye examination
10.1 Uveitis/iritis
Deﬁnition: In ﬂammation of the middle layer of the eye Diagnostic work-up: as per above
Grading Management
G1: Asymptomatic Continue ICPi
[INVESTIGATOR_108059] 1 week
Artiﬁcial tears
G2: Medical intervention required, anterior uveitis Hold ICPi [INVESTIGATOR_108060], cycloplegic agents, systemic 
corticosteroids
May resume ICPi [INVESTIGATOR_108061], which are purely indicated for ocular adverse effects or once corticosteroids for other 
concurrent systemic irAEs are reduced to ≤10 mg; 
continued topi[INVESTIGATOR_2855]/ocular corticosteroids are permitted when resuming therapy to manage and minimize local toxicity Re-treat after return to G1 or less
G3: Posterior or panuveitis Permanently discontinue ICPi
[INVESTIGATOR_108062].Systemic corticosteroids and 
intravitreal/periocular/topi[INVESTIGATOR_11930]
G4: 20/200 or worse Permanently discontinue ICPi
[INVESTIGATOR_108063] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N138/[ZIP_CODE].0 Ocular Toxicities
Systemic corticosteroids (IV prednisone 1-2 mg/kg or 
methylprednisolone 0.8-1.6 mg/kg) and 
intravitreal/periocular/topi[INVESTIGATOR_108064]: Consider use of in ﬂiximab or other TNF- αblockers in cases that are severe and 
refractory to standard treatment
10.2 Epi[INVESTIGATOR_108065]ﬁnition: In ﬂammatory condition affecting the epi[INVESTIGATOR_108066]-up: As per 10.0
Grading Management
G1: Asymptomatic Continue ICPi
[INVESTIGATOR_108059] 1 week
Artiﬁcial tears
G2: Vision 20/40 or better Hold ICPi [INVESTIGATOR_108067], cycloplegic agents, systemic 
corticosteroids
G3: Symptomatic and vision worse than 20/40 Permanently discontinue ICPi
[INVESTIGATOR_108062].Systemic corticosteroids and topi[INVESTIGATOR_108068]
G4: 20/200 or worse Permanently discontinue ICPi
[INVESTIGATOR_108069].
Systemic corticosteroids and topi[INVESTIGATOR_108070]: Consider use of in ﬂiximab or other TNF- αblockers in cases that are severe and 
refractory to standard treatment
10.3 Blepharitis
Deﬁnition: In ﬂammation of the eyelid that affects the eyelashes or tear production Diagnostic work-up: As per 10.0
Grading Management
No formal grading system Warm compresses and lubrication drops
Continue therapy unless persistent and serious
All recommendations are expert consensus based, with bene ﬁts outweighing harms, and strength of 
recommendations are moderate.
Abbreviations: ICPi, immune checkpoint inhibitor; G, Grade; irAE, immune-related adverse event; IV, intravenous, TNF, tumor necrosis factor.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N139/156Appendix 6 Clinical Laboratory Tests
Laboratory 
AssessmentsParameters
Hematology Platelet countdMean Corpuscular 
Volume (MCV)White blood cell (WBC) 
Count with Differentiald:
!Neutrophils
!Lymphocytes
!Monocytes
!Eosinophils
!BasophilsReticulocytes (%) Mean corpuscular 
hemoglobin concentration (MCHC)
HemoglobindMean corpuscularhemoglobin (MCH)
Hematocrit Activated partial 
thromboplastin time 
(aPTT)a
Red blood cell countdProthrombin timea
Absolute lymphocyte countdInternational normalizedratio (INR)
a
Absolute neutrophil countd
Biochemistry Blood Urea 
Nitrogen/Total ureaPotassium Aspartate 
Aminotransferase
dBilirubin (total, indirect/direct)
d
CreatininedSodium Alanine 
AminotransferasedTotal Protein
Glucose Calcium Alkaline phosphatase Tuberculin skin test, 
QuantiFERON-TB-Gold, or T-SPOT (for patients with active tuberculosis 
[as defined in Exclusion 
Criteria #5, Section  5.2], 
perform at baseline and as clinically indicated) 
Lipase Chloride Albumin
C-reactiveproteinAmylase
Full Urinalysis Dipstick plus microscopic evaluation. Dipstick, including physical appearance, bilirubin, 
blood, color, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, as locally available
Other Tests !FSH and estradiol (as needed if nota WOCBP only)
!Serum or highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test
!Free T4 and TSH
!Hepatitis Screeningb: Hepatitis B surface antigen; Hepatitis B core antibody and 
Hepatitis C antibody
!HIV; HIV virus RNA, quantitative; and CD4 lymphocyte countc
aCoagulation parameters collected at Baseline and as clinically indicated, thereafter (See  Table 1) .
bIf hepatitis B surface antigen positive and hepatitis B core antibody positive, then reflex to quantitative HBV DNA 
(PCR); if hepatitis B core antibody positive alone, then reflex to quantitative hepatitis B DNA (PCR); if hepatitis C 
antibody positive, then reflex to quantitative hepatitis C RNA (PCR).
cNot required for all patients. Testing required for patients with known history of HIV. 
d Results must be reviewed by [CONTACT_13658] 3 days prior to dosing. 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N140/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N141/156 CCI
CCICCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N142/156Appendix 9 Response Evaluation Criteria in Solid Tumors (RECIST) 
Version 1.1
The text below was obtained from the following reference:  Eisenhauer 2009.
Definitions
Response and progression will be evaluated in this study using the international criteria proposed 
by [CONTACT_108158] (Version 1.1). Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Note: Lesions are either 
measurable or non-measurable using the criteria provided below. The term “evaluable” in reference to measurability will not be used because it does not provide additional meaning or accuracy.
Measurable Disease
Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the plane 
of measurement is to be recorded) with a minimum size of: 
![ADDRESS_120060] scan (irrespective of scanner type) and MRI (no less than double the slice 
thickness and a minimum of 10 mm)
!10 mm caliper measurement by [CONTACT_461] (when superficial)
![ADDRESS_120061] X-ray (if clearly defined and surrounded by [CONTACT_6776]).
Malignant lymph nodes : To be considered pathologically enlarged and measurable, a lymph node 
must be ≥[ADDRESS_120062] scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At Baseline and in  Follow-up, only the short axis will be measured 
and followed.
Non-measurable Disease
All other lesions (or sites of disease), including small lesions (longest diameter ≥10 to < 15 mm 
with conventional techniques or < [ADDRESS_120063] scan), are considered non-measurable disease. Leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by [CONTACT_108159]-measurable.
Bone lesions:
!Bone scan, PET scan, or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.
!Lytic bone lesions or mixed lytic-blastic lesi ons, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_12783]-sectional imaging techniques such as CT or MRI can be 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N143/156considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above.
!Blastic bone lesions are non-measurable.
Cystic lesions:
!Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by [CONTACT_108], simple cysts.
!Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same participant, these are preferred for selection as target lesions.
Lesions with prior local treatment:
!Tumor lesions situated in a previously irradiated area, or in an area subjected to other local 
regional therapy, are usually not considered  measurable unless there has been demonstrated 
progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable.
Target Lesions
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, should be 
identified as target lesions and recorded and measured at Baseline. Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by [CONTACT_33490]. Pathological nodes which are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥[ADDRESS_120064] in which the image is obtained (for CT scan this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥10 mm but < 15 mm) should 
be considered non-target lesions. Nodes that have a short axis < 10 mm are considered non-pathological and should not be recorded or followed.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N144/156sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease. 
Non-target Lesions
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at Baseline. Measurements are not required, and these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ (more details to follow). In addition, it is possibl e to record multiple non-target lesions involving 
the same organ as a single item on the case record form (e.g., ‘multiple enlarged pelvic lymph nodes’ or ‘multiple liver metastases’). 
GUIDELINES FOR EVALUATION OF MEASURABLE DISEASE
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
Baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at Baseline and during follow-up. Imaging based evaluation should always be done rather than clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by [CONTACT_12148].
No photographs, no skin lesion measurement by c alipers and no measurements on chest X-ray will 
be done in this study.
CT, MRI: CT is the best currently available and reproducible method to measure lesions selected 
for response assessment. This guideline has defined measurability of lesions on CT scan based on the assumption that CT slice thickness is [ADDRESS_120065] slice thickness greater than 5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g., for body scans). 
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from [ADDRESS_120066] in selected instances.
Endoscopy, laparoscopy: The utilization of these techniques for objective tumor evaluation is not 
advised. However, they can be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in studies where recurrence following CR or surgical resection is an endpoint.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N145/156Tumor markers: Tumor markers alone cannot be used to assess objective tumor response. If 
markers are initially above the upper normal limit; however, they must normalize for a participant to be considered in CR. Because tumor markers are disease specific, instructions for their measurement should be incorporated into protocol s on a disease specific basis. Specific guidelines 
for both CA-125 response (in recurrent ovarian cancer) and prostate-specific antigen response (in recurrent prostate cancer), have been published. In addition, the Gynecologic Cancer Intergroup has developed CA-[ADDRESS_120067]-line studies in ovarian cancer.
Cytology, histology: These techniques can be used to differentiate between PR and CR in rare 
cases if required by [CONTACT_990] (e.g., residual lesions in tumor types such as germ cell tumors, where known residual benign tumors can remain). When effusions are known to be a potential adverse 
event (AE) of treatment (e.g., with certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can be considered if the measurable tumor has met criteria for response or SD in order to differentiate between response (or SD) and PD.
RESPONSE CRITERIA
Evaluation of Target Lesions
CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-
target) must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the 
baseline sum diameters. 
PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the 
smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of 1 or more new lesions is also considered progression). 
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking 
as reference the smallest sum diameters while on study. 
Lymph nodes. Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the Baseline examination), even if the nodes regress to below 10 mm on study. This means that when lymph nodes are included as target lesions, the ‘sum’ of lesions may not be zero even if CR criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm. Case report forms (CRFs) or other data collection methods may therefore be designed to have target nodal lesions recorded in a separate section where, in order to qualify for CR, each node  must achieve a short axis < 10 mm. For PR, 
SD, and PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.
Target lesions that become ‘too small to measure’. While on study, all lesions (nodal and 
non-nodal) recorded at Baseline should have their actual measurements recorded at each 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N146/156subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or lymph 
nodes which are recorded as target lesions at Baseline become so faint on CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being ‘too small to measure’. When this occurs it is important that a value be recorded on the eCRF. If it is the opi[INVESTIGATOR_26191], the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by [CONTACT_108160], such as in the retroperitone um; however, if a lymph node is believed to be 
present and is faintly seen but too small to measure , a default value of 5 mm should be assigned in 
this circumstance as well). This default value is derived from the [ADDRESS_120068] slice thickness (but should not be changed with varying CT slice thickness). The measurement of these lesions is potentially non-reproducible; therefore, providing this default value will prevent false responses 
or progressions based upon measurement error. To reiterate, however, if the radiologist is able to provide an actual measure, that should be recorded, even if it is below 5 mm.
Lesions that split or coalesce on treatment. When non-nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be adde d together to calculate the target lesion sum. 
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the ‘coalesced lesion’.
Evaluation of Non-target Lesions
While some non-target lesions may actually be measurable, they need not be measured and instead 
should be assessed only qualitatively at the time points specified in the protocol. 
CR: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph 
nodes must be non-pathological in size (< 10 mm short axis). 
Non-CR/Non-PD: Persistence of 1 or more non-t arget lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
PD: Unequivocal progression (see comments below) of existing non-target lesions. (Note: the 
appearance of 1 or more new lesions is also considered progression). 
When the participant also has measurable disease. In this setting, to achieve ‘unequivocal 
progression’ on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease such that, even in the presence of SD or partial response in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest ‘increase’ in the size of 1 or more non- target lesions is usually not sufficient to quality for 
unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N147/156When the participant has only non-measurable disease. This circumstance arises in some Phase 
III studies when it is not a criterion of study entry to have measurable disease. The same general 
concept applies here as noted above; however, in this instance there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by [CONTACT_108]: if all lesions are truly non-measurable), a useful test that can be applied when assessing participants for unequivocal progression is to consider if the increase in overall disease burden based on the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease: i.e., an increase in tumor burden representing an additional 73% increase in ‘volume’ (which is equivalent to a 20% increase diameter in a measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, an increase in lymphangitic disease from localized to widesprea d, or may be described in protocols as ‘sufficient 
to require a change in therapy’. If ‘unequivocal progression’ is seen, the participant should be considered to have had overall PD at that point. While it would be ideal to have objective criteria to apply to non-measurable disease, the very na ture of that disease makes it impossible to do so; 
therefore, the increase must be substantial.
New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments 
on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal: i.e., not attributable to differences in scanning technique, change in imaging modality, or findings thought to represent something other than tumor (e.g., some ‘new’ bone lesions may be simply healing or 
flare of pre-existing lesions). This is particularly important when the participant’s Baseline lesions show partial or CR. For example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which it is not. 
A lesion identified on a follow-up study in an anatomical location that was not scanned at Baseline 
is considered a new lesion and will indicate PD. An example of this is the participant who has visceral disease at Baseline and while on study has a brain CT or MRI ordered which reveals metastases. The participant’s brain metastases are considered to be evidence of PD even if he/she did not have brain imaging at Baseline.
If a new lesion is equivocal, e.g., because of its small size, continued therapy and follow-up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.
While fludeoxyglucose positron emission tomography (FDG-PET) response assessments need 
additional studies, it is sometimes reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible ‘new’ disease). New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm:
a. Negative FDG-PET at Baseline, with a positiv e FDG-PET at follow-up is a sign of PD based 
on a new lesion.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N148/156b. No FDG-PET at Baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD. If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up CT scans are needed to determine if there is  truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD.
Evaluation of Best Overall Response
The best overall response (BOR) is the best response recorded from the start of the study 
intervention until the End-of-Treatment taking into account any requirement for confirmation. On occasion, a response may not be documented until after the end of therapy, so protocols should be clear if post-treatment assessments are to be considered in determination of BOR. Protocols must specify how any new therapy introduced before progression will affect best response designation. The participant’s BOR assignment will depend on the findings of both target and non-target disease and will also take into consideration the appearance of new lesions. Furthermore, depending on the nature of the study and the protocol re quirements, it may also require confirmatory 
measurement. Specifically, in non-randomized studies where response is the primary endpoint, confirmation of PR or CR is needed to deem either 1 the ‘BOR’. 
The BOR is determined once all the data for the participant is known. Best response determination 
in studies where confirmation of complete or PR IS NOT required: Best response in these studies is defined as the best response across all time points (for example, a participant who has SD at first assessment, PR at second assessment, and PD on last assessment has a BOR of PR). When SD is believed to be best response, it must also meet the protocol-specified minimum time from baseline. If the minimum time is not met when SD is otherwise the best time point response, the participant’s 
best response depends on the subsequent assessments. For example, a participant who has SD at first assessment, PD at second and does not meet minimum duration for SD, will have a best response of PD. The same participant lost to follow-up after the first SD assessment would be considered inevaluable.
Target Lesions Non-target Lesions New Lesions Overall Response
CR CR No CR
CR
CRNon-CR/non-PD
Not EvaluatedNo
NoPartial response
Partial response
Partial response Non-PD or not all evaluated No Partial response
SD
Not all evaluatedNon-PD or not all evaluated
Non-PDNo
NoSD
NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR=complete response, NE=not evaluable, SD=stable disease, PD=progressive disease.
See text for more details.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N149/156Note:
When nodal disease is included in the sum of target lesions and the nodes decrease to ‘normal’ 
size (< 10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that participants with CR may not have a total sum of ‘zero’ on the eCRF. 
In studies where confirmation of response is required, repeated ‘NE’ time point assessments may 
complicate best response determination. The analysis plan for the study must address how missing data/assessments will be addressed in determination of response and progression. For example, in most studies, it is reasonable to consider a participant with time point responses of PR-NE-PR as a confirmed response.
Participants with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of PD at that time should be reported as ‘symptomatic deterioration’. Every effort should be made to document objective progression even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003]. 
Conditions that define ‘early progression, early death, and inevaluability’ are study-specific and 
should be clearly described in each protocol (depending on treatment duration, and treatment periodicity).
In some circumstances it may be difficult to disti nguish residual disease from normal tissue. When 
the evaluation of CR depends upon this determination, it is recommended that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) before assigning a status of CR. The use of FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring. The use of FDG-PET in this circumstance should be prospectively described in  the protocol and supported by [CONTACT_108161]. However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG-PET and biopsy resolution/sensitivity.
For equivocal findings of progression (e.g., very s mall and uncertain new lesions; cystic changes 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.
CONFIRMATORY MEASUREMENT/DURATION OF RESPONSE
Confirmation
In non-randomized studies where response is the primary endpoint, confirmation of PR and CR is 
required to ensure the responses identified are not the result of measurement error. This will also 
permit appropriate interpretation of results in the context of historical data where response has traditionally required confirmation in such studies. However, in all other circumstances, i.e., in randomized studies (Phase II or III) or studies where SD or progression are the primary endpoints, 
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N150/156confirmation of response is not required since it will not add value to the interpretation of the study 
results. However, elimination of the requirement for response confirmation may increase the importance of central review to protect against bias, in particular in studies which are not blinded.
In the case of SD, measurements must have met the SD criteria at least once after study entry at a 
minimum interval (in general not less than 6 to 8 weeks) that is defined in the study protocol.
Duration of Overall Response
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented (taking as reference for PD the smallest measurements recorded on study).
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease
Stable disease is measured from the start of the treatment (in randomized studies, from date of 
randomization) until the criteria for progression are met, taking as reference the smallest sum on study (if the baseline sum is the smallest, this is the reference for calculation of PD).
The clinical relevance of the duration of SD varies in different studies and diseases. If the 
proportion of participants achieving SD for a minimum period of time is an endpoint of importance in a particular study, the protocol should specify the minimal time interval required between 2 measurements for determination of SD.
Note: The DOR and SD as well as the progression-free survival are influenced by [CONTACT_108162]-up after baseline evaluation. It is not in the scope of this guideline to define a standard follow-up frequency. The frequency should take into account many parameters including disease 
types and stages, treatment periodicity, and standard practice. However, these limitations of the precision of the measured endpoint should be taken into account if comparisons between studies are to be made.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N152/156Section # and Name [CONTACT_23688]
1.3 Schedule of Activities 
and throughout the protocol, as applicable
Updated note for  
) and blood sample for ADA. To update the collection time to within 
4 hours prior to study intervention infusion.
Appendix 2 Study Governance
4.4 End of Study DefinitionDescription of end of study includes 
allowance for further enrollment in China.This allowance for additional enrollment in 
China beyond the end of global enrollment (if needed) is intended to satisfy local 
regulatory requirements.
5.1 Inclusion Criterion #[ADDRESS_120069] disease progression or recurrence 
within 6 months. Also, patients who 
previously only received platinum as a radiosensitizer are not eligible.This change is intended to provide a more 
homogeneous patient population and incorporates regulatory feedback received for this study. 
5.1 Inclusion Criterion #9a Added text as per the FDA guidance 
document & American Gastroenterological Association 
(AGA) guidance for HIV/HBV/HCV.To clarify the treatment of participants 
infected with HBV at study entry.
5.[ADDRESS_120070] ITT with FAS.
CCI
CCICCI
CCI
CCI CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N153/156Section # and Name [CONTACT_23688]
9.4.4 Sequence of 
AnalysesAdjustment for the estimation of the 
timelines for the final analysis and additional analyses for the potential to continue enrollment to achieve the desired 15% of study population 
enrolled in China.This allowance for additional enrollment in 
China beyond the end of global enrollment (if needed) is intended to satisfy local regulatory requirements.
Appendix 2 Study GovernanceAdded additional text or modified the 
previous text.Modifications based on changes to 
protocol template version 14 and updates 
based on regional requirements.  
Appendix 9 Response 
Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Addition of RECIST 1.1 as an 
Appendix.For consistency across the development 
program.
Appendix 12 Coordinating Investigator [INVESTIGATOR_108071].Administrative update.
Throughout the protocol Minor editorial and formatting 
revisions; correction of minor 
typographical errors.To make minor revisions for correctness, 
readability, consistency of language across 
the bintrafusp alfa development program, 
and for compliance with current Sponsor guidelines.
CCI
CCI
Bintrafusp alfa (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N154/156Appendix 11 Sponsor Signature [CONTACT_108168]: A Phase II, Multicenter, Open Label Study of Bintrafusp 
alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing 
Chemotherapy
Regulatory Agency Identifying 
Numbers:, EudraCT: 2019-003583-40
Clinical Study Protocol Version: 22 June 2021/Version 3.0
I approve the design of the clinical study:
____________________________________ ____________________________
Signature [CONTACT_108169] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N155/156Appendix 12 Coordinating Investigator [INVESTIGATOR_108072]: A Phase II, Multicenter, Open Label Study of Bintrafusp 
alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease 
Progression During or After Platinum-Containing 
Chemotherapy
Regulatory Agency Identifying 
Numbers: EudraCT: 2019-003583-40
Clinical Study Protocol Version: 22 June 2021/Version 3.0
Site Number:
I approve the design of the clinical study, am responsible for the conduct of the study at this site 
and understand and will conduct it per the clinical study protocol, any approved protocol amendments, International Council for Harmonisation Good Clinical Practice (Topic E6) and all applicable Health Authority requirements and national laws.
____________________________________ ____________________________
Signature [CONTACT_108169] (M7824) Phase II Bintrafusp alfa Monotherapy
MS200647_0017 in Platinum-Experienced Cervical Cancer
C O N F I D E N T I A L
I N F O R M A T I O N156/156Appendix 13 Principal Investigator [INVESTIGATOR_108072]: A Phase II, Multicenter, Open Label Study of Bintrafusp 
alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing 
Chemotherapy
Regulatory Agency Identifying 
Numbers:, EudraCT: 2019-003583-40
Clinical Study Protocol Version: 22 June 2021/Version 3.0
Site Number:
I am responsible for the conduct of the study at this site and understand and will conduct it per the 
clinical study protocol, any approved protocol amendments, International Council forHarmonisation Good Clinical Practice (Topic E6) and all applicable Health Authority requirements and national laws.
I also understand that Health Authorities may require the Sponsors of clinical studies to obtain and 
supply details about ownership interests in the Sponsor or Investigational Medicinal Product and any other financial ties with the Sponsor. The Sponsor will use any such information solely for complying with the regulatory requirements. Therefore, I agree to supply the Sponsor with any necessary information regarding ownership interest and financial ties including those of my spouse and dependent children, and to provide updates as necessary to meet Health Authority requirements.
____________________________________ ____________________________
Signature [CONTACT_108170], academic degree:
Function/Title:Institution:Address:Telephone number:Fax number:E-mail address:
CCI
CCICCI